var title_f34_10_34976="Ketoconazole: Pediatric drug information";
var content_f34_10_34976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketoconazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/62/20457?source=see_link\">",
"       Ketoconazole (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/26/10659?source=see_link\">",
"       Ketoconazole (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13401 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34976=[""].join("\n");
var outline_f34_10_34976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/62/20457?source=related_link\">",
"      Ketoconazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/26/10659?source=related_link\">",
"      Ketoconazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_10_34977="Constipation in adults";
var content_f34_10_34977=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Constipation in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/10/34977/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34977/contributors\" id=\"au721\">",
"       Arnold Wald, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/10/34977/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34977/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/10/34977/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34977/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/10/34977?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CONSTIPATION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Constipation refers to a change in bowel habits, but it has varied meanings. Stools may be too hard or too small, difficult to pass, or infrequent (less than three times per week). People with constipation may also notice a frequent need to strain and a sense that the bowels are not empty.",
"    </p>",
"    <p>",
"     Constipation is a very common problem. Each year more than 2.5 million Americans visit their healthcare provider for relief from this problem. Many factors can contribute to or cause constipation, although in most people, no single cause can be found. In general, constipation occurs more frequently as you get older. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link\">",
"      \"Etiology and evaluation of chronic constipation in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CONSTIPATION DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Constipation can usually be diagnosed based upon your symptoms and a physical examination. You should also mention any medications you take regularly since some medications can cause constipation.",
"    </p>",
"    <p>",
"     You may need a rectal examination as part of a physical examination. A rectal examination involves inserting a gloved finger inside the rectum to feel for any lumps or abnormalities. This test can also check for blood in the stool.",
"    </p>",
"    <p>",
"     Further testing may be ordered in some situations, for example, if you have had a recent change in bowel habits, blood in the stool, weight loss, or a family history of colon cancer. Testing may include blood tests, x-rays, sigmoidoscopy, colonoscopy, or more specialized testing if needed. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/12/42176?source=see_link\">",
"      \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people can treat constipation at home, without seeing a healthcare provider. However, you should speak with a healthcare provider if the problem:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Is new (ie, represents a change in your normal pattern)",
"      </li>",
"      <li>",
"       Lasts longer than three weeks",
"      </li>",
"      <li>",
"       Is severe",
"      </li>",
"      <li>",
"       Is associated with any other concerning features such as blood on the toilet paper, weight loss, fevers, or weakness",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CONSTIPATION TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment for constipation includes changing some behaviors, eating foods high in fiber, and using laxatives or enemas if needed.",
"    </p>",
"    <p>",
"     You can try these treatments at home, before seeing a healthcare provider. However, if you do not have a bowel movement within a few days, you should call your healthcare provider for further assistance. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link\">",
"      \"Management of chronic constipation in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Behavior changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;The bowels are most active following meals, and this is often the time when stools will pass most readily. If you ignore your body's signals to have a bowel movement, the signals become weaker and weaker over time.",
"    </p>",
"    <p>",
"     By paying close attention to these signals, you may have an easier time moving your bowels. Drinking a caffeine-containing beverage in the morning may also be helpful.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Increase fiber",
"     </span>",
"     &nbsp;&mdash;&nbsp;Increasing fiber in your diet may reduce or eliminate constipation. The recommended amount of dietary fiber is 20 to 35 grams of fiber per day. By reading the product information panel on the side of the package, you can determine the number of grams of fiber per serving (",
"     <a class=\"graphic graphic_figure graphicRef51585 \" href=\"mobipreview.htm?38/31/39413\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Many fruits and vegetables can be particularly helpful in preventing and treating constipation (",
"     <a class=\"graphic graphic_table graphicRef52349 \" href=\"mobipreview.htm?28/61/29661\">",
"      table 1",
"     </a>",
"     ). This is especially true of citrus fruits, prunes, and prune juice. Some breakfast cereals are also an excellent source of dietary fiber. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/39/8817?source=see_link\">",
"      \"Patient information: High-fiber diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Fiber side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Consuming large amounts of fiber can cause abdominal bloating or gas; this can be minimized by starting with a small amount and slowly increasing until stools become softer and more frequent.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      LAXATIVES",
"     </span>",
"    </p>",
"    <p>",
"     If behavior changes and increasing fiber does not relieve your constipation, you may try taking a laxative. A variety of laxatives are available for treating constipation. The choice between them is based upon how they work, how safe the treatment is, and your healthcare provider's preferences.",
"    </p>",
"    <p>",
"     In general, laxatives can be categorized into the following groups:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Bulk forming laxatives",
"     </span>",
"     &nbsp;&mdash;&nbsp;These include natural fiber and commercial fiber preparations such as:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Psyllium (Konsyl&reg;; Metamucil&reg;; Perdiem&reg;)",
"      </li>",
"      <li>",
"       Methylcellulose (Citrucel&reg;)",
"      </li>",
"      <li>",
"       Calcium polycarbophil (FiberCon&reg;; Fiber-Lax&reg;; Mitrolan&reg;)",
"      </li>",
"      <li>",
"       Wheat dextrin (Benefiber&reg;)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You should increase the dose of fiber supplements slowly to prevent gas and cramping, and you should always take the supplement with plenty of fluid.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Hyperosmolar laxatives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hyperosmolar laxatives include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Polyethylene glycol (MiraLax&reg;, Glycolax&reg;)",
"      </li>",
"      <li>",
"       Lactulose",
"      </li>",
"      <li>",
"       Sorbitol",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Polyethylene glycol is generally preferred since it does not cause gas or bloating and is available in the United States without a prescription. Lactulose and sorbitol can produce gas and bloating. Sorbitol works as well as lactulose and is much less expensive.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Saline laxatives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Saline laxatives such as magnesium hydroxide (Milk of Magnesia&reg;) and magnesium citrate (Evac-Q-Mag&reg;) act similarly to the hyperosmolar laxatives.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Stimulant laxatives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stimulant laxatives include senna (eg, Black Draught, ex-lax&reg;, Fletcher's&reg;, Castoria&reg;, Senokot&reg;) and bisacodyl (eg, Correctol&reg;, Doxidan&reg;, Dulcolax&reg;).",
"    </p>",
"    <p>",
"     Some people overuse stimulant laxatives. Taking stimulant laxatives regularly or in large amounts can cause side effects, including low potassium levels. Thus, you should take these drugs carefully if you must use them regularly.",
"    </p>",
"    <p>",
"     However, there is no convincing evidence that using stimulant laxatives regularly damages the colon, and they do not increase the risk for colorectal cancer or other tumors.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      New treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lubiprostone (Amitiza&reg;) is a prescription medication that treats severe constipation. It is expensive compared to other agents. However, it may be recommended if you do not respond to other treatments.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Pills, suppositories, or enemas?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Laxatives are available as pills that you take by mouth or as suppositories or enemas that you insert into the rectum. In general, suppositories and enemas work more quickly compared to pills, but many people do not like using them.",
"    </p>",
"    <p>",
"     Healthcare providers occasionally recommend prepackaged enema kits containing",
"     <span class=\"nowrap\">",
"      sodium phosphate/biphosphate",
"     </span>",
"     (Fleet&reg;) if you have not responded to other treatments. These are not recommended if you have problems with your heart or kidneys, and should not be used more than once unless directed by your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Constipation treatments to avoid",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Emollients &ndash; Emollient laxatives, principally mineral oil, soften stools by moisturizing them. However, other treatments have fewer risks and equal benefit.",
"      </li>",
"      <li>",
"       Natural products &ndash; A wide variety of natural products are advertised for constipation. Some of them contain the active ingredients found in commercially available laxatives. However, their dose and purity may not be carefully controlled. Thus, these products are not generally recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A variety of home-made enema preparations have been used throughout the years, such as soapsuds, hydrogen peroxide, and household detergents. These can be extremely irritating to the lining of the intestine and should be avoided.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      BIOFEEDBACK FOR CONSTIPATION",
"     </span>",
"    </p>",
"    <p>",
"     Biofeedback is a behavioral approach that may help some people with severe chronic constipation who involuntarily squeeze (rather than relax) their muscles while having a bowel movement [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/10/34977/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498670292\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11480990\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=see_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/51/35634?source=see_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/18/20770?source=see_link\">",
"      Patient information: Hirschsprung disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/60/27586?source=see_link\">",
"      Patient information: Rectal prolapse in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/55/23411?source=see_link\">",
"      Patient information: Pregnancy symptoms (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11480998\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/12/42176?source=see_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=see_link\">",
"      Motility testing: When does it help?",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40169?source=see_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/constipation.html\">",
"      www.nlm.nih.gov/medlineplus/constipation.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute on Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/constipation/\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/constipation/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/patient-center/digestive-conditions/constipation\">",
"      file://www.gastro.org/patient-center/digestive-conditions/constipation",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Gastroenterology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acg.gi.org/patients/gihealth/constipation.asp\">",
"      www.acg.gi.org/patients/gihealth/constipation.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/10/34977/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/10/34977?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34977/abstract/1\">",
"      Chiarioni G, Whitehead WE, Pezza V, et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006; 130:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34977/abstract/2\">",
"      M&uuml;ller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34977/abstract/3\">",
"      Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005; 100 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34977/abstract/4\">",
"      Wald A. Appropriate use of laxatives in the management of constipation. Curr Gastroenterol Rep 2007; 9:410.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f34_10_34977=[""].join("\n");
var outline_f34_10_34977=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CONSTIPATION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CONSTIPATION DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CONSTIPATION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           LAXATIVES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           BIOFEEDBACK FOR CONSTIPATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/31/39413\" title=\"figure 1\">",
"           Nutrition label fiber PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/61/29661\" title=\"table 1\">",
"           Fiber in foods PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f34_10_34978="Anatomy of the visceral pleura";
var content_f34_10_34978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the visceral pleura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The visceral pleura (VP) of the sheep, an animal with similar pleural anatomy to humans. The visceral pleura lies between the pleural space (PS) and the alveoli (Alv). It is approximately 20 to 80 &micro;m thick and consists of a single mesothelial layer (M) and a subpleural connective tissue layer. The subpleural connective tissue layer contains both collagen and elastin as well as the bronchial arteries (A, which drain into pulmonary veins) and subpleural lymphatics (which do not connect to the pleural space). The bronchial microvessels and lymphatics are relatively far from the pleural space (20 to 50 &micro;m versus 10 to 12 &micro;m in the parietal pleura).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Staub, NC, Wiener-Kronish, JP, Albertine, KH, in: The Pleural in Health and Disease, Chretien, J, Bignon, J, Hirsch, A (Eds), Marcel Dekker, New York, 1985, by courtesy of Marcel Dekker, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34978=[""].join("\n");
var outline_f34_10_34978=null;
var title_f34_10_34979="Peritoneal closure";
var content_f34_10_34979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peritoneal closure during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A continuous synthetic absorbable suture is used, making sure that no viscera are included.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34979=[""].join("\n");
var outline_f34_10_34979=null;
var title_f34_10_34980="Magnesium gluconate: Drug information";
var content_f34_10_34980=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium gluconate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/36/41540?source=see_link\">",
"    see \"Magnesium gluconate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/52/36676?source=see_link\">",
"    see \"Magnesium gluconate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Magonate&reg; [OTC];",
"     </li>",
"     <li>",
"      Magtrate&reg; [OTC];",
"     </li>",
"     <li>",
"      Mag&reg;-G [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Oral;",
"     </li>",
"     <li>",
"      Magnesium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      RDA (elemental magnesium):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     19-30 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 310 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnant females: 350 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;31 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 320 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnant females: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 420 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F190878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/52/36676?source=see_link\">",
"      see \"Magnesium gluconate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      RDA (elemental magnesium):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1-3 years: 80 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     4-8 years: 130 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     9-13 years: 240 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     14-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnant females: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 410 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use with caution; monitor for hypermagnesemia",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magonate&reg;: 1000 mg/5 mL (355 mL) [contains sodium benzoate; melon flavor; equivalent to elemental magnesium 54 mg /5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg [equivalent to elemental magnesium 27 mg], 550 mg [equivalent to elemental magnesium 30 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magonate&reg;: 500 mg [scored; equivalent to elemental magnesium 27 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magtrate&reg;: 500 mg [equivalent to elemental magnesium 27 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag&reg;-G: 500 mg [equivalent to elemental magnesium 27 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3012949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer on an empty stomach",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Diarrhea (excessive oral doses)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3012940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation (self-medication, OTC use): Appropriate use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a healthcare provider in patients with kidney dysfunction, or with a sudden change in bowel habits which persist for &gt;2 weeks. Do not use if abdominal pain, nausea, or vomiting are present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3012936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama, 1998; Osada, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3012938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Enters breast milk/compatible",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3012939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium requirements are the same in lactating and nonlactating females (IOM, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3012948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Whole grains, legumes, and dark-green leafy vegetables are dietary sources of magnesium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Magonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 (54 Mg) mg/5 mL (355 mL): $9.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Magnesium Gluconate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $2.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (90): $5.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     550 mg (100): $6.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Magonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (30): $44.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Manganese Gluconate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $5.58",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F190858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum magnesium: 1.5-2.5 mg/dL; slightly different ranges are reported by different laboratories",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biogam Mg (BE, CH);",
"     </li>",
"     <li>",
"      Gammadyn Mg (BE);",
"     </li>",
"     <li>",
"      Magnerot[inj.] (DE);",
"     </li>",
"     <li>",
"      Magnesio (AR);",
"     </li>",
"     <li>",
"      Magnesium Gluconicum (AT);",
"     </li>",
"     <li>",
"      Magnesium Oligosol (FR);",
"     </li>",
"     <li>",
"      Mikroplex Magnesium (DE);",
"     </li>",
"     <li>",
"      Oligogranul Magnesium (FR);",
"     </li>",
"     <li>",
"      Oligosol Mg (BE, CH, FR);",
"     </li>",
"     <li>",
"      Oligostim Magnesium (FR);",
"     </li>",
"     <li>",
"      Oligostim Mg (BE);",
"     </li>",
"     <li>",
"      Provitina Magnesium (PL);",
"     </li>",
"     <li>",
"      Ultra Mg (LU);",
"     </li>",
"     <li>",
"      Ultra-Mag (AT);",
"     </li>",
"     <li>",
"      Ultra-Mg (BE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F190851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body involving protein synthesis and carbohydrate metabolism (at least 300 enzymatic reactions require magnesium). Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol and on sodium/potassium ATPase in promoting polarization (eg, neuromuscular functioning).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Inversely proportional to amount ingested; 40% to 60% under controlled dietary conditions; 15% to 36% at higher doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Bone (50% to 60%); extracellular fluid (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 30%, to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as magnesium)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bashuk RG and Krendel DA, &ldquo;Myasthenia Gravis Presenting as Weakness After Magnesium Administration,&rdquo;",
"      <i>",
"       Muscle Nerve",
"      </i>",
"      , 1990, 13(8):708-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/10/34980/abstract-text/2385256/pubmed\" id=\"2385256\" target=\"_blank\">",
"        2385256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gams JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(3):240-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/10/34980/abstract-text/3552543/pubmed\" id=\"3552543\" target=\"_blank\">",
"        3552543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, \"Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,\"",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/10/34980/abstract-text/9532984/pubmed\" id=\"9532984\" target=\"_blank\">",
"        9532984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine (IOM),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/10/34980/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9581 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34980=[""].join("\n");
var outline_f34_10_34980=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190884\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190869\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190878\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190870\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190871\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190857\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190848\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3012949\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190859\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190882\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190862\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3012940\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299633\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190855\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3012936\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3012938\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3012939\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3012948\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323351\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190858\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038669\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190851\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190861\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9581\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9581|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/36/41540?source=related_link\">",
"      Magnesium gluconate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/52/36676?source=related_link\">",
"      Magnesium gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_10_34981="Mediastinal benign schwannoma 2";
var content_f34_10_34981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal benign schwannoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The spindle cells may demonstrate nuclear atypia, but mitotic figures are rare. (Hematoxylin and eosin, magnification 100x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34981=[""].join("\n");
var outline_f34_10_34981=null;
var title_f34_10_34982="Chylothorax PA";
var content_f34_10_34982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chylothorax post right pneumonectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 334px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFOAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxeTR5o48tC+AM5K8fWqb6awkT5Dhu/b869DsUW3MTBWCcbsNg465OK57W0NpetOigQliyr/d54B9qAOYFiu1gRjnb+VQeUCCssIkQt0J24+jdv85rYkuEClnaN3I/j9T2qFS7uC1qZcMTvZgPpjHHTd274oAx2sVk5t5N3ONsmFb8+lQPbujbZFZGzyHXBFbRWLJyTEw/56DA/P8Az0q0jKkSGWJbiHBBDYyv04oA5xYeCACc+3WrESLkk8Y6/wCAHatwaQl2XbTpYye8THJB9x1/nVC8sp7NXF1GYm5GCB69jQBWijNzIFUAjtg96V4hESDgDPpnPB/pSW0hMu0SZG3pmo0UFvmO8ocnacYzQAsToXCkFWPTB6/X86a8io7oT5merMOn0xVa1AaUbRuGTlc1K8scfESFwDhmIxk56UAWdNhMssk5G1E5yx71p2eozLv8vCSOcAj+Fe/HrUVo0hiV5lRAeQxXHvz+NS3UZsUEwYNLL8q4XAA/DpQASuLi5aVtyxQEMfr2X+fFSQW41fWBEW2XEmQvAGenXsB7fiOlQW8LiJppH3xx8hM5LMScDA/Gug07SAbae4d3Fwke5g4+6Rg/4UAX7HSzB5LSJJ529okUpgnAxn12981fNsILW3m+QScqW25AOR0rpfsVzqGmWd6eZGiWN42yCBx27f8A2XtWRPCdq27AuyPkYHyD/dPQ84/LrQB1+mXBbw5EbMxxzYwSW2yAf7J6ism68S3VhcC2upHniIw7QnP0GD0571f0qFjaWTIpcgZdScAeuCO+ararpItpHmuYyjuu5GRVG09znHGTnpQBq288mppDIrRZBEakP6njcPzq81tZO13aW73Cz26k/amlOJ2BwwI6KvTb9PcVi6Fp9xcWG9omWKRjslwASR0yPT6Y4xVS+M1lezoZlVgQSvPOen5Y/WgC/FHcNdfIsDSsNuRhpdgIO3PYcZ/CifVGnuBG7NAUOwRbsYYeo+mfeotGmDjziuRuwjY4DZAB+mTj6kVYUxXVwlq1v5spfjzF5Dc8Bhzj6UAbOtGSfw9YzDzC65USYwCM4HHf0rg73zbq0QoquxQ74wep+o7fWuv1YFLFo4YmhAUqqnJChf8APfrXDaPcrPeTCM5XLYVR19eKAOI8SxL9mjZD5nkyYUjuMn9OlJb/ACw7ZAEMihicZCqeN35j8a37+y3Wk9wUkEbHHIHyk8gZ9G65rKsPMurJHuUAuQzIGA/hwOD7EdPoKAOO1u0MLs+OX98g+49c1mWr7WBccIec9xXa39sk8flwqQByVxyF6Y+ormtS04WcuC5YSDcPfHrQBSd4ZQWVSWJyTnn8cf0pFB4IGMcYNRvvBAPPO3gdPapoNjq2/KcZH+elADdvJGeo4IqRSCCrDBPf/GmnGxcqu7gH39KcPm53AL9BxzQA54h1I98//WqJ4sHtnr1q7CNwIByfQ9qZKuenP+e9AGcUIGABjHFRlB26f55q8YxuAALN2XHJq1/Y9yqq86iBGHG85Y/Rf8aAMUoeMYPPQjj869K+E3xa174dadf2Wkabpt3bXcqzSG6ibcpA2kblIJGAODkDnHU1ysOnxp91PMJ/ikPT6DofxzTntJJGAlYsFxgE8AfTpQB7IP2lNSA/e+D9Bkf+8rMB+oNFePLYgAYyR6gUUAe8P4eNzHHJbBkuQvHRVkx24x+dYsukW9+rrNFsuQCCrDHOec+/+ea9J0h1+yJv4VlAIb/9X/1/as7xHo7TuLqziZmcYnEaHkf3iD0P0PbtQB4L4g0R7O42twueCR+nWskwyq6g8EdhwVr2jWtCe7hKFFWQjAJdSSPXj8celcRB4U1GTU1s2tyGbnezLggZOevYZ/SgDjRlm5wzD+GT/Ef560+AiMliJbV+QEPzK3qf8/nXpqeB9KtG26hHNdTkqQIpgijJ45I5PsBx61FqXgvS30+e40tpUe3Y+aj/ADeX2z7r6kdKAOLsrdpFiMQSO5BJRcZ80esbnp9Ovua0VwJSuqws0RwjLKu4r7Zxkd/WqbpcWKHA8tY5DmMfNhgex/qK6/RvFmnzL9j1+KZlAKrcMgYDjvjk/wCeaAObk8FpfzpP4Zma8jAzJASFZeOmT2+gPSuUv7F7S7khubd7SYAl4364/r25969avNGkt4v7S0S5t7uzxkyW7klRgfeA5U9Pb37UWlzb+JbGdPFVukyRD/RrxAEO8YwCRnIA9zzjg80AeRC1jhBTIimYfcfjaD701IxCVXfv255GCCxHU16B4r+G9/Y28WphhfaeU803AP7zHuvp7/yrlrS0tEML4f7OuchiPn9+DjH40AZCSzSy7ZCWK8HB9ParDkvsGTyeh4Le3tUrwOTG0OXMjYwF5Ofaul0bQJLZDPebIXCnYknLMcYzjrQBW0G3SaXyZIhtRi4kPG70HHX2+prqp1uJVCJEq5X94ir8seCCBzwSeP14qpolv/Z9wqMQshjOxDjk9Mn0GRx+PtWtBFcbJpZBI5kwJmK/KW6blHp2yPrQB1NncLdJKWZ4mkAOxjg7lA4yOvODwOOPwyftCoEVsNtzuUqCMnn+nbFalhdxwS28YAdNnzknODjtx6daxLyNFlu1CgIJmG1Tg49ME/1oAkt9SjdHSLckztlUDsV+pzyOP8jpVueZWePy5TIjJ88SgsfwHT/63WsiDT8zndLsnZwdkw27vbPQZ98VsW9vNb5WZVjCAOCjZKfiPbn8aAOg0e0vJmZFcWtsi7mDMP3agAnKj+XvXLfEG3trrUrfUtIunYTosXlSfKwcZzznp0OPw7VsWl9FHY3SyP5YljGxt3Vsnj1Oe/0rlvFF/FeRWsccZDrJl2Ugd+3Hr+PX1oA1tGvJrVI7Oa0lkUcs4+Xnvnt+nbvW4ksRuTKCw8wkejdD0Pr/ACOKytJuVmVHjdlcYGGOevHGasarM7+ZGm9dowCOOT6fWgB+rzuYQLi4Zw8ZJUn5iOmAMEdKwbSBLeS5S2UoXIYyMcsO/J/w/GnpBcTajKVysaLjfIwx9Pp+dKAYLp45pVKyDhkBIP1z0/AfjQBVupIWJdXC2rRGOTj+HoOvfj/PSsJ9Ie4tjeW04LIqq0WNu70789Ovr1HSulNlJfAW1lFJNbZ4jBDEjnOR35+n+NS50m+soFj+yT/ZXUhZRG2VPvxnBP8ASgDlLN4xFJeS4LM+0rjJ47n1PJz7ViaxaqGlO7zFcg4XkofUe2P/ANVdSNKuRvkkt5IXcZ2uhAPGM9OvHX3rAvrVLWdpGkAikyGizznHf0/zzQBz72YuYQlnIu9RzjAb6e/41R+ySyjY4IYDAG3HPt/n8q2L3T5LaTz7U4hl5T1I7jI71JNvm8uIOAy5IYHH1FAHLSwOhAJBLckDtnn/ACKuwQN5RfadwP8AF3qaSSYSbZDDsxgEd/fNbGnaBPd5uLhza26qC5kAyfoM0AYkSK7YRm80nGF5yf8AP8q37Tw3OwMuov8AY4MZKjDSMPYcc/Wut0zSdPtljj0+2cyseZpGGfr049OnatI6DLJb/aZ1WK3jfBklyoPXkk0AcWlkUzDpdt5A/ilPzzOfr0X/AIDj61L/AGVDbL5t1IJLjr1yAfckjp+NaerXttbGSG0dSrHjyvvMf948Y9/0rmLkSXF2DcSKoYnait0+g/i/WgCy95a78rC0oXkKvCgdgT3qF9VZtoijgt1J6qgcn6ls/wAqlTS2ckMzoOxKFeD35xU0WgxPIh3vycAqevfn0/n/ACABky3l6znE8gUcALtXj6CiuptdGgWMhYg4B+9sJz+lFAHvXhr/AImFisrsFmjAE4x1Pt2/HpV/VJidOmhjbaifMEU/dIPf8+fXNZGiSCzniQSAQuMA46tnhv8A61beoLutJAzL8ybSo5IJ/u+/0oA4m/TEgeIEBz0PHTg49exp2l+Q9zH9pCqAcRyHkq2DnI9OR/Wp9SUKwhhJLuCTuPVvY9zjt71gWM8kV3GEkKoCCB2HXoPqcf8A66ANjxPaS3Dx7YojMibGiicOWXna6gfjn8K5rSJljlmedXRIYnDDBAI2kbWH8RPp1rotb232mxpkeZGxKy91PdPoa87uVlmuzFcTFZWPyxHPCnv6H6igCp4xCPcI0HmRyvArurkH5sdT/n3rmYlmDKsuTH0BHNa+sXciX08wXcpckhxuKqOg9c4rOgvBISCGTgMDxkH3FAG34fkl0zUlvNIvzaXmMbwcL9GXo36V6LYarpuuZttQt4NO1VRuVoSFt7o9zgfdbP16+1eawzXE2RboIzkFpCeW/wDr/wAuKvTwOkckcYO0HczL2bsf8+lAHpmi6rJbTzGW3+0BMQvE74DMPTHHSvP/ABh4IknE13pB+8TILFl2vt/vKPr+Faej6vGbmGG/IEvEaTBeJcdN3uPWuqGjMsovnieN4xv8tG3Mx+o7d80AeW6Ppc9pH9lSGY3jNhlEZMhYdtuM4H4V11nof2VBNf3cjSKMhQN7fTjODXeactpdxbJ7f/SpAcOBtlVT0GetZ2s6NaadsaW9W4jwSYY+bhh3yvb0oAzbe2gSITWGnxy3IwPMlG5jnHX/AOt9adrV9cvYssj7ZiQjRqvRexx9R1+tczqnxFnTzbfQbC3sYlG0yzLvmJxjPPTPT8PrXPW/iy6FwyzPBmRdrsIwOueR+NAHcaJfDUwkc8RcWz8kYVsf3s9fXtVa9hhGr3n2cPcJkSDa2SpPXA6nj8RWRpurxzTQiOFI53IB8tyN3IA2n15HHvWqbqNtQf7K6MwCllY8vj0I4PPp9aAIrq9SeKFLyJ5oeq4OHT3U+n51qRiaSxSGJY5GC43E7WK9Rke9J9jGo3hVWj80DfuY8sAM/Tp2rTFukMBViuUOeDhiO4x6ehoAy0ivXSUXcsFvHGEYsRlwzEqoUd+nI9K4fVP7QF3OJYluHilZWltxjcQSPuHntXT6tL5kjrGjklkYknvnOR+Vc7qwVtQupLdpg7zMxBwODjge/XNAGx4UuZHZ0EL7j13HA455B5rs/tEkcKyi4EczNsyrb3xgnH93oOckcVyXh05nhZ3L+YCue68YPPUdv1rYurOd8QWu4mR+nXcMfpjrQBDfTRyZZGGIjnzXjwR64wTnisrU2QXsUl6kpiUZEaNsBY9ASeRgYrRghhgDSyyq0itjaMHH0Hf6mqYtf7SukluFc24zIDg7zzgAAc4oA0bDxBMbUL5H2fco3GJsNxxx+A7Vo2F699KyKZnibIABK+h6HvnriuK1HWDb3kzR26wsowBOdxA9+wrGufEk53+XdncV6KQpz3z7f/WoA9N/s67gdvNiuypHPlqTt5yOMEg8dO4qG8tbHUrY295bxXQBJGFywOOCMcjGT+tec6B4r1OG4WGTUJWQ/KAX6D2z/P8Axr0jS9WvruEfulvIxnJljzsXjkHr+IoA5Kfw9ZgG3juXCKQVEhIVjnP3sZFNh8LT3Uht/sIigJ5uHyq89MN716nZxaDcJ5hfF0OcuxkVD9eox+VWri3nIjj+RbfIYBDmM+v1xQBwWj+ENF0honngW9vUzjzFxGM+3bv9c1oaroC6pp7TziGytoPm8+VtqQdeB+nHP4ZroLu0tNMiZ5kLXSg+Vbgjn691H14rh9Zv73UZnXVH2xowKW4GEjGOAPXuc9ecUAc7ceJbfQbgx6NZi+dmBW8v12Rhh/cQcke7YzWPqup6hrc/m6vdS3Mh42DiNB6Ko6CtW/sUuU5izu45HH/1un+cVhJatbySWxfKJyATkp1/TrQBY06wm1DUrW0tIt01y4iRf4c+p9h/SvT7JdL0ADTtFi8xlO26vpEBmuHHcH+FR0C46VwPhO/h0vxJZTagQkKSnfIF3bVYY3YHbnP4Gu0lt4bW6Je8RizAAQguz8dc9B+JwaANm+01NS0iV7xVmkjby1dlw5PXA7fjXL2Phw312kNtPJy3znZnYP6n2xXQQL/aIVIB9lsFT5mPXHt6++K1Unt4IFjtcRxgckdW+vY9f5UAXtJ0nS7GySFJ5h3OI15PcnnrxRVZJ92XlZSWORuZRgegyeR70UAKPnj8tcoMZXHJIx69fpXQaY4u9OHnyD5PvYI5I6/nz+VYcgW3s0LISQvyoWJLH2JP5moNMupLa2m5VpJW3Hk4Bxjr7ADp/iSAaWoWkd4jfZZf33VRIB82M4AJrk4bAzzS3EcPMYxNG/Hltu6n8en/AOqtSGO4WUEsZpByfm+6Pb0/zmibX4NNLlnRb4pgzFN+FyeGH8Y4+vT0oA5/XLw6ayRMwuJpMkRKSAoxgbiK5e10y41yV3nZfNjAYopI2A8jcO4Pp6Vsz2MFwbm7sJkuHLBp4t2XTd/EueoP6flie1RtsUcihkTcIiw5RiMEof4Tg4OMZHByKAOH1HTJpBcRSgEoCWjJ5jB4yM+/6Vl29ljyZWdooR935SWPPTHpXoV9psbxGOMSm7fO5ppWcuD2ZmJY+3PH6Vi6Jp+pveybrSbYmSoePuevXsPagCtHE0TGSCUKzdY88Aevt/8ArpYY5JpAsrE88CIkKp7En/PNdDbaGYZRLfOCsrDKoDnB7D09/TFdLa6dHhdiQxwwckuNsa9849cfjQBzmm6UwkUlWAUAeY46Z7IOg78+vWu+028i0G3V9Xk8sOMRRAneR6n0+vvXI6x4oit3CaUFViwxdTLkn/dXnA4/lWTq97/bhM00pgkHyuJX4YDsPUD8KAO217VQoQ6OUt4m+V2j4Oc9c9v5V5v4l1C6FzFamL55x8xTliuf0rNk1aLTt9u0klxF/AAdqgf7I6/kah1zxILgRTxkAhRGVT5Tt7A4oAlubYai6w348qFQEyCfMj55AH1pU8GBbrFtdpfwR/MYyvluU9AB1OR0FYkN/HbTrISE2kNjPU+mO3/6q0R4hlnf94Qu3JGxsbc9higC3d38em3ccVrCY3iI3K//ACz9B9fX2q3/AG2txraiYgRsoY4GCSAfXqPpWKdUklicM6tCRu2y4fPPv0HrU9xa2VzNBLDFcxSjBUxPwceoOcZoA7C3u5Zbi3kh/f24fdyN2B1we+KvXGpZWR0UnHUAcj/a9Mis7SraOCaA+fKNwy5J27fpjvWh9pjeeSR4wzhgXBJwwz976+w4oAwtZuVhkknfmWVAQAOnrk9B2rJgInkAVZJGP3h3PAPT2rrbptOu9TH2qzTy5F8vqV2n+9wR0PaqEwFjdyWsiwFkbG7Gcjsc+/8AWgCbQQyXkCpbyBVILPIdm78a6qby5SWeRXfmMhWDA54C/l/KuNnbbKkKqW+dWkYrk8dBj+6Mjnp7VsafZG7ulW6ZyGcYTeVVj2578frigCpcThCVh2OQwUMOQhz/AA5/rxWNrmuQWEJgjk+1agcrKSPkQ9+ep9PStbWI7SK4EayXBCKcwxlcKfr3/GuJk+wwyzSSwTXcqNsQbsYI7Erj8aAMzU9YupovIDnOdoEWckDtx1pLH7Xt23ki26H5v3g3Nj6fpimzXk6MUgC22e0I2nHu3U/nVQvO6s4nmViccuef8/1oA3I7i2s8/ZY/tEincWlHAPrt7jr1ruItSmvrNIboAIPuoECAgjjGOleZabBcXcu5jiBTud2bCgf5/rXR6h4mWGFINP8A3rou0SkYVfcDv/8AqNAHXxRRWpE7zeRF/D5jZz/XFai+MZLWcR6ao8qUfPO6BvMP/XM9vQ15Dcay8smdQ/eAH74PKn6dMfhWrFfRzRx7ZgCTykh2/r/WgD1+1uYb1Ayu0FxKf9XIxaOQ9cq56H2P4VHdxxPGYL22IVDkFfvKenA/PiuH0fUJIU2TBnjbGYpRkH6D+owa9D0qay1CBEmkcgDajOOY/QH1X0zyKAOYutNhjbmTMbDKSjKq3bnsD/noa57UtJS6kDI53xjORg8fh1HtXo13ZSwM8EiO8fRlLZ2n+8PQ88H+lcnqVnPaT7WBkjb5o5AoyV/LqD1FAHNxaNNHGxWNn3HBUDcSPr1Fb2lQTWyJDqqMsKqBGB0UE5G70+lS2WnzWYZ5vkZ0O1WHKjryDwCf0ou75441KbjySpBI3dsAUAdI0UktsGiU/ZwA0ZQZXGBx7e1VYXYOHKsoPB3L17D2FGiXt2GP2KGRoiMlCuVkz65xj+vvXY2dnYPmaGQLKCN6KwxGcc4B6n9B6UAQW0ccUeLq3E0x5bd1Tj7p/DB/Giuitbu0ghEXlx/Jx843H15Prz370UAcVtR4lXawlwCctwBjrnH6Y4qK3gWWVVORjjA4yew9hUu4mDcwYuwAGPf2/wA/hVqwJe6TekYVvlG0dv6dKAM7xDd/YbdLYSLHxubbgOT6D/PPP48HfvDJtUb2Dks2XJ/l+H4fnWr4jvUur27mmYurPtBxkH0I6c8VzcTtIPl/dqSRt9PTPf8AL6UAWWvxaIGt2CBWBQ4yWODyT/n9aJtVjcKVYxMg4ccK2eMkDgf5zmqk8kMZMbjBK8lRknjk/wCRWNJP50saNuMZ4baDlx6H/P5UAdpYX9zHbCSWUJ5vKMQpLD2P/wBet5dTmEMf2iR2QJkI7cbexI6Zx2rl9KnUKfPAlhjUL5ZAAJP3VGf16VvWyx3O8yDzQ5OUcALk/wB7/I/pQBphoXt4riTzCZCTEoHzSDjn1A9z+Xeuf8QaxO0Do0ioirgogwW5Pf29Tk9enSo9SN1mY6fvluNxHHVscLgeg5HHt715l4lj1JJGXUY7mNx0QxsoHt6fqaALt1q9vFMZEcuwPQN/nFUb3VI5J2mEqu/TZHnOPr/9euSnMuMFSqntgjP6VXV5VBAyAO2OlAHV32qG7iRZAFKLtRf/AK/rWS9yXzxhf8579aqIWlDqoycfN6j/AApI1ZBtbavOGz1FAFpJ/LyUQEn72eeKlt1jl+aJtowM44x+NRwfZ48birZPA3/5x3oij8mfBGEzyAe30oA04GlVsRux3HPzfnnmtyznkX7PIrbQp2lskj1PX1/SspYCsUcmWZWHynb29z/Sr9uHSCTzWRtnIBIB68/jQB3r3ywx288flmfG8Er8pI9QD+FS29w1xHteWPy2JdmEeCD6DiuY02eNiEjmWIgZMUg3Zx15H8gOtaJe4aVQrow2kgrnGPT/APXigDangLtHK7K6kYIzg/8A16S/iCrbEkEtCScnPcgH24H6DiqbS3L28f2aBiEfnjP5kfzq1LHe3MbzbY42OCV6gAD07UAOD3Swo8XLt+7EmBgfjitgXUcEDibKBEAPy8E4OCM/7WOe1Y+mMsTRpdTszb1YxqeRyOOn+PUVLrDG81K9VhGIlTaMnOw4J/UD3oA5/e0wnnkR3aXOVzgH6+tYd9Ad8axo0aruB8s8Kf8A9VdJHbbrO2HO5AGct0Hofeor+Pz4Yl85IkAeVyeAPmOTx27daAOWsNBub6YxWLCSTGQjLtBx6knAqO909rXfEWiuLpflaOOTIXp19emMdqmvdTLRmzsmljt5cbnK8yHH5gH86S00e5ayZrdYzKh3EK4L9vmIPJ9zz19MZAKKR3bZWRJHB4ZNwCj0wO/0omiud7CWFiRwRtA/Qc1ZeCeKXzmifuQyjKkHg/j3/wA4qtLLOjbA7BvvfeyR+PagCldBonPBKrwwApiP5suAQRnGF+6P8f0qw9zKF2Pzk5JI5x7mokhiZifKCv2KjGKANrStSubZCqSnZ1CuNw/Xp+GK63R9UDSoYm8iU/wSPlG9gevPv+ZrhoI8cRyFXA79MelXo1lQ9BsXglTkfh60Ae/aTdrqGnI7g+fGpXlsMuOMA+nP609p5YY2TeBGTkOUDbD25I4z047d68x8K+IJraOJS5eLLYGeVPHT25Hr+FejWtxFc24ukZpYmGHH90ntj/630oAw9UneeTbNBFK3Jwc/eHrjFU5JYUiLSMqORuVYhkk47k5x6d/qK0dVVoZFMZOxvuSL1zjpnpnGfwrmWXy7ySMhjFMN65Gec8jA55oAt2usTSIYYpZViXICevsxPX+X0rVtLqZJxNG48xOhYDJHp9Op6965R1+zN5pVjyUD5zz78enfvWnYTh5BuK7AAAA2fw/DrQB6lp9xYahb+dKbe3lB2uso2kn1GOowRyeePaiuSs2jeHLZPOAcDn86KALUwC7QZGVsZAB+bp+lW7BlEjShdr+U3OeB159z1/yKqXUThyOABlTjsQOD/wDXqxHMItPu3TdGEt2z/tEnH6dKAPPL2JpCFkUIGXKqcqM/j/nis2ULaOJmOR0xgYzjv+laeqKwOE2qEA6HGCfX8B/Osm+IESmIqueg4xnqce5wP8mgDOlZHnmkmDF06IhwPYGpI4gPnz85GeBkA+wqCK3dpdwU/MRx1475Pp/Otu2gRl3MOQvy7u5x1Oeh+tAFrTIcWsc4b5SSQFzyfU8enGK1oJiyhsiONCQCwwOf5n2rNYx2Lf6QoeVgMR9/qfQVXlvJrqXcQgj6Y+7jPPH580Aad/fmE7rX91GT8zDG/nucdAcUlvfybg+4MCOrncD+lQxPJtGCUA6kjJ/L/P6U0iJcAFg2c9fXvQBqxXhuMeZBFKOSd0Snt9OnaieKxlx9osbR9x4AjB46Y45qgztCuHAjUD7xGP8AP0/GnJP/ABjnAzknGO+f/r0Abtk9hDapG2nW4TcMsECkew45q1J/Zk0gK6dbbQDuZtuM/l1rmXuCqckENjg+/b3qsW8wl94ZFHQn+VAHXkaLE6f6Dakj729Rtz7cVWlttDlZM2FsF3bwSmMgH9eTWDBdKTjLRv3LHjPqTSySNjacY/8Arf4UAbTwaUVJTT7TLtkrjdk/T1+lV4otIE5U6baozjaQw4A7/pXPNM/mFRuCL3B/zk1E9zMU3NIevCbfvH6UAbd1bWG5GWxtgQ4GFXnB7inCCNUcJFAm0gLtHHvWM0zDYxO3OHDsM8VYivHDhuSrE/xfLjHX60AaVxdyrabUIBLgjAx25/EkVhahcyvfrH84DEOY1PX0/rVuabdt/uk4wvPtReWcE8odyYpEYIwzuB44J9+D+VAFazZIr7cki5Mqg5IB69x/nP41Z1ORYbq9knP7uRyA2OW4J7dsZ/rWfDHC1yoyWUPkehIIqn4gvJ7uC5kLfLA+3bn759f6GgDXF9G1sBtRox8wLEHYOo5JH/1qwtYmt5k2xZ2omSobg46DHcCp9Khnn8sHdNswBuPAx2Bqg9ncXBKmJxIFxgDIAAzigDnZplhdlOd2MknqMntSpfy5yXJbnDd/p7//AFqq38Uxu5OVjjTj5/8ADrU1lZNcCMpJCf4ehUD/AB6dqAB7qWSCUPJJnOQytgH2I9cd6zJrqUPxIckHODnA/wAa0b6IRExrtkbJzIG2huPT2/WseRJC+GUDIxjPP5UASxXUqqSXLZPO8VfgvVVm86AOf9k7e/b3rLUFcl1IOM8e3vTlbJ42qWPY8UAbcTwTMqxS+Weyy8Dp13dj7nFXE86PauD8x+UqpIY8dO3FYKANGpCsSDyByfpitTSrmW0kIjc7W6o2Cv4igDr7dF8tBIdxVfmkB4BHr0/z9BnqvDI1G0VroKz2MmVf92xRl9TxxXGxXttdb4wBaTOm05yUJ+v8OfevXvDt0NRtrSDRPMttRt4drQ3EBkQEDlht4K4zjPrQBTukSSGOaKRLjT5MsJI2zsPTOB0I9PwrD1KzIDLIuyUYbzFzgcZUg13mpyrJbTzXaQBrpgFeJlcLIeRhh1GAeP8ACuXlhM0JiPNzFkJ2PHVOf0oAwY7bfHKDwMEMD936eoqG2s1t3GIxjBIReNx6davTSLDiRZMoc5Pv7D1pmnyq14Z8gKFACgcj3+vpQBqQI6QoknlswHO88jvjj60VLbqpjyT8xYltxGc5ooA3Lg/u4CFccDdz145BqGd9mmXiTMUVkCsu734/L1qe7JEUHH7lEyTnJHHQ/wBKo6wzf2XMI1XcFQFskbcnp79PegDi9ZiZ7xgsRKkHBft+P+eMVmy2wdgkwC+X2BHPTgVuaoyzm5VwGCtv78D/AB6ViRl7mQDhQTsVTz/+vAGaAFgt40Vri46FtqJjBOOpPsBVqe7j0/BB23suHQ7d/wBnT++w7n0Bp5tQga5cGeC3U7YmOQ2ASAfbPasGFHuJJJXaQu5LPI/O5j/h0oAmjRpZA0hZpc5Ynv7mrcBELqn3hnrjP5f49xUhQJFgOAOuWblvxpjmBWVVx5mOBnjHXmgC7EAzuS6qCclycHOP1IpA6xsQpJzzknr+H+e9UkZnJLNgr0HQdvyp4cjIZjwDzjFAEzTAADkcHcSOP/rfhTgsakFGALDdg8g+hqpHIjg7gQxOADyT7n/PepUIAbbxySNvTP50AS3M3lBieFH3j/LNZMV2VuTJ1fPI/nithGDsquu9f4QecCkGlWzDLmQA9AmDg/jQBQbVGU/NtbPqPYfjU0eqxudskXHYr2/yf6VbOmWqR4idtwOAB+lQTWYTlpSD0wEA9e3agBqywzyks5XA+mD/AEFRzR+W5UbCjd8ZPv8A5NSm1QNkbt3HBx9c/lUwlXawBP8AdzzxQBWigmSLdGZVVDjDDAB/wqNhJkhSWBzxjOwfU9qmSdvMbzMb9vTd8ufpVyK3PmH5uQMk5xk/3qAMZnVQmWBcZJXpj/69WTAbi3kAydzKd+08AD/E/pUuoAeUAMMueRuxj6ehpqzeRwdqoAMkgkj3zQBAYyJELf6xiCGbjp6/pTLi1RvMiBDSNMJDxhSoH5nk1qSwx3NxDIhTkAEk9D/WqwgCuHVyeo3E8n/H/wDXQBLp8LxKXyCGHy9xj1FXIk86CRydsz52qvzYP1/rUHmwhMuy44LAZB+nH9aSO6UOp3A4JA5xjnnPrQB5v4rt3ttTRyuxXGzOeM/04qlPLFFEFikQTk8Bh90e/vXoPjCMajpc8SY8xiGWfaBhh0AHWvI1DsWEm5ZDwVY46H/9dAGk/nOyYIZXBJAII+n+f6VGQVMYcYbqVIwfzqoVaPLsrgA7c59fSrTytb8eaJF/h3c/zoAniiZX2ZIzyB0Hpz+dNEPmlQY95bj5Rg+/NVY5WJwB97txV6GeOJWwp3txx3/+tQA+GJEO4uFx3YcCpPLcP5gGVBzuHrj19KfG0UzA+aB14zy1Wk82BD5se2ORsqSoOPfNAAj453DJGe3J/GvQ/hdrB0zSNfuWurPElq9kqSuwmjRx87Q9iSQoAPcjtmvPSFYZmj+8M5X731z3q/awBNJLwAsxk2DAyScHt/hQB1dvdSI6SmXzI5BmOQEAOOn5/XkV3cbNc2VveR7hMQUcf3iOMjtkCvH9JvxCDHMBJAx+dccj3HuP/rV6t4UbfpMq7y8YIKyL/EuOw/XHrQBV8QwBUE6k7XYSYHVc/e49M9qhtrWCRyQSvzBto4xx/Lr/AJxWzq9sstoMDCh/mHJznv7ZxWShmVxHGg2AfOzHgA9j/nNAGlptpvty1tKnllj60Uunj7PAY4pQAGOd3BzRQBsart8qLY+Y5FUsijBB698/lUepKJNKBT93MXBK9OOeTkn/AD+dX7lUk+cBQsS7fpWVqETx2UQYh1clyexPoc85HtmgDi9T875oYsqjPzIpz9ev+eahtUSKdwASqLwSeMn0444qxLG0N15hI2KMZDZBHJ/yareSk7SCHdtcB3cHpjPHHqD/AJOKAEUSXJkRXKQkFNo/iyDVZIGjkEUkIKqeAh+99M9a0rRCkeSE2EHZg/KF6f16/wAqiaMx24IDKGyvmdUb2U/zIoAoXYgc7Uclx0/z61RWII6y7yy57DGB/wDrq1Pb9ShBB9sHH+NRJAT84AOV6dx+FAFhSVH3eRkk54+maTcrrz3HBIPB44P+fWhhiIosnGOCOnbjOP6VHAQhOWYZHr/+v1FAEuU3kHv1J9P8ilLFX6992Rgjjv0qNnGdrLxnoec0gcAElsZ54Ax+f9KALsVwFXj88f5/WrCyNt6qTjpnvWU7jqhbceMLn8unNNaTCqWbk9QT0+nvQBpi6WIfJlie/r+HYf54qNpJNvTkdQTnP+f6VRidxyN5Hr6/nUhbBHPK8/Ke/t+v6UAWXmLAD5AOvHamm4K7TsyQBww5/wA+lQ+YdvXnpjGMfzpo+8WySMY56/40AK0jygbUAK/3Rn9KtxSyRxRsSAMc7jkH/P8An1quE2F95LOnDBCCPwIP6irEZ3JnO4ZzkHJH07c0ARXABhwx2qw71VlJaAB+WU4ye/pWn5ZuDFHHtZmzjcwAyRkc1nNC6RN8vRuVzyp5H6elAE9oQHjVm5P93/P51cliCyEDJA4UD+n+fyrNiBMqFvvKMcdj9K1ZvMaNWRQSeu3A/mePWgClBEZQNx2g/XB7Yz/+r8KI1kZ923eSMfQeg9KtoS8e3HQ4Hbtz9frSpEVbBAwP50AV7iIyW0gl2qcZGTlSf8K8f11Ht9alznLneCAcEHjivc/synapVfMfIUYyMjrz/hmvOvG9pIrw3cQVhAzLKqoflzzj6DmgDmbK9mtLlwUZ0C7drpuwD1IyMf8A6qzpstLIQRtJPB9PStJrhvmIyRtxzkc9qhjbzHO4noCygA5/z/jQAz93HaqVXMxf5hjgDHGPf3pE3NL3bjOcHpV9LOKaASyuiM2T97HHt2/Wo5LSN7bMN0CchTC2Qx/2s9MUAQL/ABEqoPQKecc1btriWCR9rZJwp3HIx9D/AExVYxOrbnXaP4dwB4pwBbPIGOck9/x/GgDdims7gMx3W83DIw5Q+3qPzPStq5R4NGtBIoVZJHbcpOG4wMenX2rjYnXABACqeQep9a3kvHttL05UxIjmQlH5GcgZH4Z6ZoAtxoj7ZHAVuCpH8PsfX86774dSyQyS6bcAYeMsCG53f3Rx0x/kVx+lxR3a77YfvIwG8psblJ/9C9f510fhe5WK+QOzbUkzzxigDuFBkjlgLqI2jIVgP4u2PXpWNK3zxmQ7A2DnOAD6k9O9bV7HJFcSIvRmDpjuOv8AnFUb2P8A0iUKoxu8wqV7E5Ax+P5igDQgsIpolaRTvHykscE4oq1p4Z7YMC3J6lck/rRQAs9wsaBAOZOW3EDAP+elVdcgS4srZndQuCQ3cj0x3NT3dwkQjfaWZvlUHqPyqvfMxt4GKfu23ZXv1/zigDib4s37td3kgliSM59M/l+FQzxtDaho32zsC7r0z/s/l/6FWjJEzXbRjLsWwBjtn+lPu4Y5bghk/cqcsBycKPX6A0Aakf8AolhDNbWgnnaLd5jJkLkdx0Ue/selQa4FSyeO4IW8HzLEoyEPqT0wexrirzUbwCUNNK8cjH5N/Cg8Y/lXSajfSaxpNjqUpjS6toRbzNv+a5K9GI7YHb8aAMR2JYiXKcff7/QDvT4t2AAFPGcY5we30prXGcK+1HJ544qV/LxmMfPxzkHA9qAElEaFQQA5BAXrk9RzVfylK/K4PZscUjxtJhI3O7r15Jx/WmxxzoOQBxng9BQAGJuMqfvdcdzx+P8A9akVCoBCA4A4OR/TrSt5m9SUUnOMjr9MD+VODYJA3D9fr+AoAYAc7cEkDp1wPpVWWMhuhAbvWhuByBxgYJYetATP3VU7gAOeR/8AXoAqRJtQEg4x64/Kp0jP8JbHUEdhx/X+VWY4GJJbg55Jp5gjCjKkgEd8Yzn8s0AVGRgSoOMfiaFjfPCrk84Az+VWl4TqRnpj2NRvIVLY4HTCjnFAAkahlPm4+g6j1p9vkHjG0cZPIP8AhVV5G3YQjH9aktnXswGMNwDn8/5UAWpsxnAUO6EHa6jB+vPpip55YLh1lG0OyneCRkMMdfXjHNVbghyCjdTwQM/5+tJF8hXBKjkjPHOP07f5JoAjkiSRC23DKwIHcj/9eOKsRyE2ewJtcdF9ce/6VUWRljk2Ngfzpr7mZAGx6ZGQM+lAFyGVFPBxuwOTx07VYjuIipyQGxwAaxPMIzngg/NzkD2HtT2GxstkE5wfWgDXv9ZSK1ZUti07HCkN834emPWsmWSPWLR4Z4YlJHVTjjsT+NFxAsiebyc8DJyAP/r0WSFHXDt7huO/86APLr1bnTL54JNx2kgAjrz05pFnha42lWjyrcx8kkjgYNd5470lNSgNxBEBPGMbx39j2z/9evN41Ky5bcuOCMUAab4ZEETbzjAU8EfgaYwYbJGXG75d3bOMkf8A6qpNO2/airsHRewp0chMgDcEYHznjNAGlExYLjPygDg9Kc0DFThD5Y45PA/z/nvUSs0JUvgse44I9fpVyF7ecFJH2MvADDoPTI6DOTQBXhjHckL7c5PvW+bVhYab5BDOUbcwz1yPyqgA0RBdQsbD73VWx0wehH+Nb7ws9rYKSqxGHIYYxyf8/rQBn2zvBIvzNGwPLLwQfcdetdfoFwt2UZQyXKYJXGRJj+JffHUVgSIjYVlXA6E8Zz7dvwqaAPBMssRJCYIyPmU0AexlheWlo+QS0Y2sBkjAwSKgmjZZ1XYQSmNvfIJHSo9FnFxp0UwGGjID8ZAOOv061pTxLugkIG3aVbPT8fQ44/AUAWNOjYWq5IB68pmikj2sud4PPZgPccUUAZUVwklmJFQ/cQhQCBn/AA+tN1KTfpbSOSWbooJwue4PasbTNRjW2+yDyxs+QIvaPPB+lbd1IPsvkSEGVyM4GR0/nQBz0UbGRZcbZF+bAGMDpz69TTQ5dZA2EwjqCD1JGB/Kp5JxHd+WTzgjZycn2/I1TnlMe+Rz/Hxj9OO3T15oAw5LfySm9VyFwOTgf/X9+1WbCNVYiUeWWAycfd9CT7das3Vs85aTbnf8zDgbfrjt3qhdTM0aQ20qBQ6lyylt49ByMZGeaAGXcoTKbARnnA+99O1VoUKv8pKkHJwOBVqVHBWRNrKwxgnq3+NROigA4MbfT8/8nigB0cjJ/rFV+PXsfT9PyqRZkZcH73v39we3aoSMEkfMpP8AD/PFIATvJAZOAcEg/jQAOd2cFXHY9/ypx5JAHBGODUSuu4Ekq2ep/wA/h+P1pzPngMTnOTnI/X/69AD13cAbvXDc/p/hVhVwo5zkclueRUMYbgcMw5P/AOqp93G4sDwOd3P0FACoWLYU/hkj6c/hTWm2jZuGM43Y785xSEhhgkEEZ7fnSFBHw3UjjaeQPegCJiWyQx5PAJz+v+elMIG3btz/ABDI6ep/nUrYCYypI6Y6UJ94EKOe47UAQMpXg56euCo61IBtyyqAW6DOPwp+0OuCoIFIG5w5JJ5wRgg+v+TQAws2CshBCc846f09KVB+84HoxyOg7fWpMR+aNmWZxwF6fjUcUhV1xEeCcMRyPr/L8qAFTLuw+9z1Bxk9RTwpjj7kAggZ6e5qXbMHyRgggjA6de/+etTEBxsIRQPugjue+etAFGUASxk9+WJPv/KmbGeMjGecrnr+NTXNqDwxC/Lz2GQOv5U6MJHON+RuJHqeeQcmgCuzCKMeTGTjnCsTj1P/ANarcEIlHmRLJlhuAJ6+1RzwzRZdeRnPuf8A69WdOkV08t1fP3gdx7/40ASz2U11aFAwCnoSRzxyeewBPWvL/EuiSQzPdReWFbh9p+6ezY9zj9K9gt4WDjcrMpPzccEen+f61k6hZ+fdKURXgPySAjBK5xkn6Z/KgDw8qzOAcgA559acqkFXIAjzwR0rd8W6Q+naq1qVO1hvjJBO9f72e/Ws6HTHdG2yorYyexPb86AGxFdzF2AA5/AdKtQlSAyhWyduPQen+fUUR6c6KpYbwegAyDnpnFX7nSLi009bp5omY5OAACo9x3PtxQBCrCGUnzjG7Y+SJv8AOeg61tNqKSQWbTwhmWDbvhUKSuf4h0J9e9ckrl8nPYkZ71rFMC0CgjECliBjgk5zjr0oA6e0Buh5kTCXGCxBK7frznPNa1lCzSJvTZFHgnt16D/PSuQ06eSK4QwYEgO0uo+bB9/TGeO/Su00SeKaFAcLKx4wMBmPcen0/KgDsPB0p+2SwKBiZeh4OfXPY10yBg6xkkkhsjHf1z1HSuK8PyGDU4WyfkbIxgD+XH0FdvdYiu0kCnbJtcD8B+lAEsEbzxho5JUA+UhSRzRUsbMC+1Xf5iS2FGc8+nvRQB5vpdqItUhmuAWk6KozjZjn9P8AOa2reT52QjJQ5Qc85JwOh/OppYkaxjnhCliuFLHg+px2B+tQqUihcmVlkVQWZePwH8qAObv7hjqmEyDuzyc4Axxn/wCtVidzICy/LGB8pGD1P+Ofes6zmhfV55oVJ+VmIkXIB4GP1JxUtq5hMsr7vs0eW6g88D/P+cgE95KYYhGhAaTlzuyVX0/Gs0W+AWU/Mp5BOe1Tli/70kM7DOQMj8KjDBWyq8H9P/r0ALHuW1wV+WNuR7evvRIAwVshiByD1zUtsVAYAsN44PXPof8A61VzkgsAN/Yj/PFAC+UQ/Hy8ZAFMIDZ3LuYDsMf5+tSh/mYMMZOcZ/zilAYg55AGAQe3vQBTALsVXhj17Uptwi/IOPu+mParG0gZGck8Lims5UHcpA6HHNAEIDpjn69Qc0Oz/KSCQRzn0/x96d5hZiwIL5LAYpWYYIwdo5Jznj1oAiLEqdince/HNSp75GBnjn9fzqZdpChsKT0OM9en+fenKyqeCCR1/D1/WgCIlcYDAehI6e31pVVSpJOFAPABNPDx7fmkUuewI/X8KCwJJBOzPfoPx7igB3ylu+AMcnnNG5UYfJtTO7Ibj6Z9ahdjg9ODnjBx9f8AP51Gzs4XcfmPpgdfqaALe7CudqrtwSM/z96ZLIDIOeDyD6/4U13Zl2rnAOe2fx/z3+lMLZCkhcqSMZ6D/JNAFgjDA5IXbjBP+f0//Woz5isOmfz/APrVExbaNnBU8fX0/IUyMsSu0ksf4f8APJoAmupACXAy6jO7r/n/ADxVOd2YEMRtHIBPX6GraDfD8nzLjIx1P49KoSxEHoNmcAA8DFAFqPJDfPk43dcVd2ElPmcnqAMnPvn0/wDr1zbxlXOMjbypBIqaCeTco85uxXkn/I/z60AdZ9qniYREuRtwQGzj/OamtZ9gQyyruXnZtH4fiOawizxy43tz2zjt0P61JBG+/fsPln07H60AV/iFDaXlpbb3QTwoWh8sn8QeuAfrwenpXlzXKuyRwOMsdw45PH9Pwr1KWK3uUaK8Cmdc7d+RhD64GQfciuC8RR29jcs1jGF81fv4BIP+zzx+PagDNt7g2riSG5zKvJdTwD+XNTRyG4G2dxuk5DA9/p39P/1VnozoGdkBA5BHFWrW6iOf3flv2YcA/j2/z+IA2W08l5FdtzDgDG0j/OK0pVd5LSMIyL5AAVuPXJoaCOSJ23+ZLjc2ehP9evXtWhqCNth8okwiFflx82eTnnnj8P1oAjtiIXKiIIcYPP3j656jnH0rXtWZlRQ2xc/w5BHvz1+tVbeCMqrmJ12jjcCwz7jt+H5U/wAl4yGO+VD0ZQev+fSgDstFuvtKeRIcXK5Kt0LgdeexH059q9It3SW2ticDfCMAZ4Pr/WvF7OV22ujFXBBVk42/5/zmvY7CVZrGzljB3YEbjqQy9c+vrx60AW2RmkchS3Izgj0Ht+P40UXtvdSShrYxspHJb5eaKAObjumksYkiVhHDGAjbeTxzWI8xFvdOInDbeDuB3kita2cytHGHLMV5AXqPX2rH1nCSSqgAVD3HJ/L86AOf063MD3TNlEaNV6+pJzWg0aDRrmMgHcyKxHHBOeP++etU4y1yZgzfOFDHbwcZParFswNjNaDncu4erFTmgCkheD93Kx2DoegP/wBf0qwih/mPylgcjoahLbkVGIb6HOD7+n40quYSN/3OoJ7/AFoAmkG2ZSqs2GByD3/xokBjlbcMKDjHpUezygN4z/snnj6+lWXYuUcEjcmfy4IzQBAAmSuwjPX1p8YdFPzFuOOP1I/GkC7cMm0Ejj0NBcgblx09efwz9KAGOwJwuzd06ccVEc7ssCcccnFOYE/7JJJ47jH+eaVBjrySDgdNo/z3oAYqrIMHaSDhsdvxp4AC7QcEH15HapQ24cKQi87RyBUeUH3WO4ZwQc8/Q96AFbaiDqrjgBTgkDt9KzriRpZXVeB129M+/v8ASrVycxg7gSAcc+9VNwbjJoAhKZbC55/MVNG0sbZIJHQ5HFXdMhikEkjlsIQMccn0J6gfStBIYyNyW3lKOjOM5HruP/66AM9HMgAcKH7E4GT6YqTYFIyMAHGCOv8ASqQLRbgrEYJBC8/r/Wrkc2Su7g4xkg9f8KAJHQmP58EjOSePz/z6VKqCWMI27djAO3BBHv0PfrjpTQzD5VZQc4yowfrUW0hlctkbsYBJYEYySOuDng9OD6GgCQREZD4xnA3f0/w9acEUhQzKN3BKtg//AFjSbFVsAtnOVBA54z3oVgrZYEA9DxigCZyQSwC5bP3Rxz1/DFQyISMbRgjoecfWpMA4+UqSDznrTmUBQXYKB2xn8KAKBtVcHrwO3B/CqDhIpU8xSR94lgR37VuhImkbaT6ruGDj1/lVOe3kuFk2bcoPmUkdP6n/AOvQBZCxzHKYV8AgMcD296fuYKqD5dhBBPG0/wCf0rPjeWKeMquU4GBySPert1I7Y2BnZjggqflz/n9aAMq8bMhl+7k/Nu+6T359fasrXtO+2wN5RJeQHDcZz6YH8q3pY3jIMirsKg8HLDnoBTGt2xIEUgj5lYclfegDy0W81tNJBOCpX5GXBxnrnPf1z6YqWIpvxJEWXjnHJ9CRXb6/o0t5DFdbTHMoAilGCJF9CPX3rlysiP5csZjm/jQ4BB9x/UUASREoZTEyZVeM8gk1tXWqPBqEZC+Q6RIpJ5U4749x6ZrmxKF+bOxBkn5v8+tX9VZm1KTeh24Ta2AGHHt/OgDaS5V2DO25XYgMpBKEjvjpU5iVWVZXkk3fdIHAHbj/AArl4ZBE/wC7Y+Zn7ynHuB+db1nPvIDB0JOVwOVPbHsaAN7TYFknD4VTH825R1PbP1r0vwdI7aVcxnG5HD/N3yAOvXtXnunQGK3YEAyE7mwf09vSu98Av5kt1FnnbkAZyDjgA9hzQB2tjKqRMGLkbsghtvGB7frRWZbsTGA8bFhwecY9qKAOJ0pZBIzmWMMR1xjiq2rW+Z1DbRlfQdOf1q1FCyIwY7VYcKMfp71Q1kK9qWTJZSACeRQBiCJFuQXDcr2/h9OfXrz71Ja5SbPdzlDjvj/9VRlw0smSJGbB5xyfpjpVpFBXkruH3SBzk+nt/hQBBdRceYu1s5wuOh7j1xT0QLGQ2BLjO5RkirYjCKfkYFuobkAVBJAV3bR8p6YPQn3/AM/1oAjYbCEblc9T6U2U7YIyMM3fA5PvQ74ygwQRxz27YqJMlD82QMHGMY/x9P8AOaAGhmbkgjPVR0/+t2pVBOcj5zg4z/nFT+UpOWycc4HcelKAFDHphc+vPv8AnQBEqDG7AYn1PAP+RSlcgZBAxxx/Q0853DJ3YI+6MY/wqJpCxPPHUkdDQAhw4wMMD2zn8KaVyc8sD3z+VNZ2VUVgO427c8e9Seac8Ngd8r1oAa8DugydrY6t3/H/AD1qBdPuSeFUgcHDdBV8Mw9Bgegz0qQSlkOW78c+g9KAM5ba8tpGaJwrkAEh8cf5NaKLLdac0TFTcJJ5iuP7pBzu9fpTCwOQeBjB7H8/8/nS28gV8lm5GDxkn+nFAGZPpkwJPmAE84B70tpbuuSDuVgCB14x71psQxYhsMT1PYfWopMNnK85GcHJPr9P89KAAKCgA6KeeRj8TQEXcRkbOpGBxx/+qhARHtA3H06evFBwFHHBHpQBJy0IYqBuUAkfxGkCq0ZOdoxn5T1/yaAR5Y3cdRk9qYTyDgFwc8nr7igBWHlRkZAU8cDAHvj1pUzJ0PPXnsKfjzN/Jxg4/r7f54qvExWcbTwB0K5B46HNAE2fKPJ25OQCM49aqeazTBQFj6qHI6jrU/n/ALwb1LOeCCcY/D/IqrNIqzOThWJz83PGOv4UAVpbd7Vsqcx5JBU+x5/p+NXIppltSQCQpwEfkEe3tV2Axy2yox/dOMkjB+YZx+eaqyfZo2Ksxj3dSeSPx/SgCVZPtVoHKKhTlgOvXis8TyF/LZZCVOQFwdvritG2jgOxYJmDID/D94e9F9bW88paOQb5PuqxPH1xgUAQDZIpUHDLycryB1J5yPz9q57xBppKLd2w8qQDgnlWHuP4evbGM10j2zoVMTiORR0ByHPqfeomsXTmONCsmG25xkc8D8s4oA8tuA89w8U6ss4O0oeufY981Leq6apMMkFSAeMc7en17V2Op6bHdGJ51CgPkZXoOP8APrXPapbMmp3ALDcHwFc/MeOOewxQBXQyTHLKWdjkHGM10em2pggiZjuU4CsMfKe4Pr7isyy82EhnC8kEgAfz9K0Y40Vw0ROeCQy7cHP5YoA6G2lMYUyYCkBTnBAxxz+X6V3Xg1vJ1mKEjHmj+LryDj2/zmvMx5kSklvlU7WJ+7n/ADx711nw+uTNqcEPR4mzGcHJXHzL17Z/X2oA9PCSsMx4x0IXIAI4/pRUkDnYfKfCZ44z/M0UAee+aqLuSMuT0ZuCfp1/pVe4cuoSZvlOSV4yv41oJiKBQYcPtGFHTn69az7hSodSBkkbtwwT3xQBkCExsREN5Y53Hrz29un61PZfOBIeVQEc55PpUrRJv3SllJzIR69Bkds/571KImFsjPtUt8xB689sD2GaALB6buGIOOTnn0/z+tVrmZlbZCctjnA4B/u9fzz+tPMn2W08xiGdiMKB/n881TWLai9d4xkfjx9aAITEGUnZtHrnH6dqcke0Mvy/MOv+f8+wqxuIHHfuB19M0wEFgGKghcAd/egCJR8rbdqn0Bz9ce3+fWjcOe/Ye39KTcNxJyB7dvahR8ucg+nNAEbcbSeOzd+KjMqAKzMCB6DpUcySL7gtwAaqgOGAI5B5H+e1AFsMjZXd+Q60jOQqja3+yOvFV0G0YB4HOSOPpV2FuCOuD29/WgBr7mLAYwec55p8b7NwcAjp04H6f4U6RMrnKgdd2eg/zimAbBn+9z0NABndwwJHvwP64x6Ug+XbywOdy4GKfkdBn/eA6/5/pTQwAX5iRknnnPsKAJC26STgjq2Aep9B705iolcHg9M98fh0qJwSVGflKjrn9B/n8aduXJJJGSBx6Dgj/wCtQBLtTkMQuPfNNGME7ue/Pb/P0p0JCjcxGO2B0pSQVJIKsfbn/PSgCJXOAApBPcc+vamhwOQMc54zz+lScEb1RQcZ4yR1700sdwHGMHAxQBMrjBG3B/T+uTUTPmcNxjABBP6+9OViw4Iz0AA9qjlIEpyNxb16f5/SgBfLXLYAGThdwz68D/Cql3bHDlTuyAcHtjt0+tXWDFiTg9z6f/rpLncisygkkAY6Y/z+NAFSCJ0tlcLgFiQV9cDqKgvlZ3Tn5zyMdCR/WtmBswBHUngtwBkD65qCe0jurRZI3zhs8nGB/wDroAyY5iiIsRO0tghv8eKurhoSFiA3Hls9P/r/AOeKa2nlH3ITjG3BGe3t0q5HbeRs+0OW3c7P4ce5oAgEwUmOQ+YoHJzg4HQ59fpUsEu2MshYqMEHjAPfjt9eaf5cQ+dVU5PG4fd478dKiSIrIcjAOFLJ1Hvj04oAlCW73P73Cs0i7uMjrwOvGfWszxpoJFxcXlrGZATuZT1ZehJHrg9fSrcZdruMgs2ZACMYXIP9cCtk3AMl2twuAZCW+XOOMDnsOvGOlAHmcLHy40jVVBByhGSfUe316+laMLicDzVXLEAux6A+/cf5zWpr+kwHzJLHzGkZi6x8ZI7gH19u/wClcoJHV/KdZNgyuw9z7/54FAG1E0zB1kXMZ6jocj1610HhImHXbeaPJ+zjzACRlsDG0Hvxn/Oa5iyZztSQMqk8HoUx7/4//XrsNHsJoIhKxXEh2B0xjaBx9Dknj/8AUAD1eQqNjKrMjqrqQOMEfWil0Epd6NaGdlLxp5ecnsT6L70UAcjLGzRhowSzDJIHT1+lV2iWPKMoJ6cdc+mPyrWiG9SVGMD5VOc59fpVS7RUTK9eCzsvb29KAMK9QR7wzHeQM8bdo54x+NN1FNlykeDkKvuc47f5479RS3OfPVWB5dR0ySSf6Z/WpUj87X1aQAoJQCPXb9PpQBnakpS8csRsjXaQB0b0+vSorS5WUbQpUY5BH51PJb+c86sN25j8o4x83emCIWvyxkbjhnc8nj+tADpCMnjLgHPHJqsGbzYn3NtJ64xnPantwjg4xnLfMQQfQ5pI1JkRvuyYyT6+9AEasXI5ySMgjr+HrT1wFOSCR0x3NOZWbAOTt56ZGeg4oERPGB8wwDjnPt+v60ARv8wON2QccN39P1qMx7jkYC56kdTR9mlbIGDnPOfw+v4UeU6sExwAfm/z3oADCw5ZUXnHp+NK52nBPOc7icZ96eFZWGfvDORz69DTHULg4wAf1+tABuLAbhx25/p/SlU/KcN2yQD1pVUk8KAcYFKiEj73X3zj/HnvQBEQzspL4xnkd+On0p5yRn8AOOfYU8xDkYxkfiBj/wCv+uO9IcgMeMgdehzQA6UhFDFieOOQCeOpNQKcYwOM8+/pUsgb5ctghegFNZRkDcRk9e2fQUALG5MZxwMHBI6/WnvnOQBkDjA6D1z/AJ60gHAAGFXgGnFQX+XAJz6D/P8A+qgBVKlSSB0z+frUfCkN82PUevsKAc5HI4xk9/rRnjJI+9+nrQA9QCR0Cfl+OKa6+ZnGFwc9MAelCYVjuOT24zT5GCSgsPmPUg8/nQBAMhSWY7xjYR396RZHRvmOPXHJP+c1aXn2GT0PX3x9aqNDkggfKDkYPP8A+ugCWS5HksenJQMp5yf6/wCFL5vyFYz8gGC2MY/DvzUNz8qJuyF3d/5VBtxEzbyNxwAewzQBPcBmOPmHfaePyp2+QxDcrnH3SO3FMhd2jjCjeR0B64/zxVlJo1Qs0jFG6kD7o9SewoARIt8SEKp4wScmonR4jiVdhZfmy3B/zxx9K2VeKS3VEHluCW3dc8dBVd4TOCszBiPmwRjPPb0oAykdvtkIXcCxBJY9OR/n8qtzXMgvJCGYksQcDBHsfy/pUa2jm7jaHJIf7m7nr2J4IGenvSXCBLybzGIkDHcD2/CgCvqkZvrXK7oZxgqYxgA9iPcnrXNGQzlluVRZgSCAfzyfWutnwEBj5JJIOO/1/wA5rmdYiZLgXcb5MjYKbsqcDrntQAW0QuJhtjOA26RUboBXVQu0yoJCuzAXp/CBwPbHY/X1rl7O5FujQmKM5I3gn5WHYj36V0dkA0ZGGDB2U7sfL65/qPcHvQB3fhe9NrpSxShXIc4Zs5I7UVSsZEFrHsZlGOdmOT6n3ooA2VUrD3yF5GM7vYCsyYOFG/DEjLMo4I6gfritJCq5XBZsc/Px06/hVW6bLOqMQd2WyAO3t0xQBzt6GF5Cq9Q46djzkf59auwKUvVZhjGSoxzn/P8AnioSd17GeWCNk9OTnA7deamRcXJP8Kkk9hx1/n/OgCrfOtsPlOC5Plg8kfTHXr/nFZjgN8zYbnuMhfbH86t3rNczPJgdMJkcj2/WqJT5c7iv+71Pt/n8KAArkt1JUH0606FFMy/PGH35AbjBP8/wpVBbhhjHO1h/nipIyrSg5JBJ59R6YoAHjIJVgVJ+bkdc980xFUI6FcKR6+/r+GfzqQ5GYwQEBJCZ4HuKYdwjYZbp0HT2/GgBrDccBiRn0H0qMbVxuG5sdv5UwR/Ofmw3pnn0+v4+9SBQp2lh7gjP6f5zQAud20/eKnqep5/SoSCowAAMjrx74/8A1VKUJkQscHseuc8cVOIyQpdsuOAexP8AiaAK+wEkNtYZ5zwBinr/ABbsAnv1zUzKA2FAAHqenfj86iBYAhiAfQ+nrQBG7EgrxnGcgfl/Wm8biCB9Qe3rmnuDgdfXPX8qRV3MoIz9en4UAKVYqikkEjH04/nUZXb3YHbk44/CrZyuScBenXOKidcycg4PzEHsc+tACLwVPPXBGB/nFDnjLZJ69c04OMOuBkH5twx2H5//AFqaGY45yec8dR6/y5oAgkBfHHHI6/l9eTQGKuy5OD6Z5+tSnrxyM98GjpgfeJ9h/npQAu4qu5g3Q59v8imMclhgnPTA/PNSRsRtAyV7DHzY7Z/H0xTsAtkg5+n8sUARnAXngHsMnpTtuGLcZwOVGB37/wCfyqUgqzKPnUE4YjBIHQkduOcdunPWl2Ku75vm6jLYwD9OKAILxBJBHglDnhhjI9f5n61XaFprbzIgrHhSOMde/wBf8a0LiJvLII+YA89e1UgqtakKW3ryGJ5PPT+VAEUCeXISWAXJORxtNLcgySFWyMHKDjpmnOuZBvDMw4Uk4we4z/nNS/uxgyqGBztYL83/ANagBtt8iJg5jDY9Of6VLM7KSc4DdW/E9xURZY1ZAhCtgqfvYPr9K0PLS4tI9vyPjOCc/p2oAq2pL3MCZPLAHP145qW7YGeWKTOd3DKec/16VXjEiTRjeSAy8E8jkdsc1YuLkSXc4JUsHIVueh9f5/hQBUvkuFRS0Ksp+VSF4X6jt9axdRgZldi37wKOcfd44+lbkgeN8GVlfJOQDgex54pLsvKHd1LMcqjjAIyO2Bz9DQBwpf5l+bCqxBPp6gf55roNE1MRzHzMmOT5cKefYD8MfrWRe2hinnbysw/eyDyB6bfSqNpch2wMYGNqnn8frQB6sJGX5ZHQuAM/xAZAIwT2wRRWRousGPT0jlja42EqreaFwOuOnPXrRQB6KgxEGVCMKfnYY3HH+eOKpXZKIWyC3qBjr1/z/KtKIgRjJJcjGc9KzdTYrE5VSWJPynrj1oAyQhEZcA/Ocgken09ST19KdfkxWwwf3spxj0A5NWLkBIIIlGAUUD15yR/OsbUJy2oyQqnyxgIMj8Sc/n+VAAYVMbSbsp0C8jPt7fhSPFl8lcsg53YHH/1+lTxrsiXZgjswOf500EKQzFQAey8Edxj+lAFEY2BVBGONuc5+n+FNDEzR8EbjjOO/p2/OnXG0ybSpGU3A4+XjjBPrTI/MNzGj/M2epPWgBCqljj5u3HQd8D/69Pj4JyQx45Xk01QT1AILFuuT/n/PtTlyFOz5lP8ACKAFYKzeYAm4DBJHzY/nj2pGDNgZyo78ZGTk5P8A+vHapDGTnIxzwTgE/wCc9aco2geg6cj86ABV8s9Nx6c5/GkLHAOcnGM4/wA/5/KpSc5ycHsD1J/CopFA2Y5P8hQBHIBjP58DFNXheAc5x0PHvU7Lu9ecHGOv+en4VGE+Vhg5J6EYx/nn9KAIljDHtz6E89v609Ey2TkEcHvUqx5IOBgg9T7Hv6U4cHIwcDvxn/61AERG7PGMnv0yfTP9aayDHUhScnByf8/55p7AkDP0GOv09KYFy/y5Hrx/L04oAbLk45x3HGffFIVJb5sgD359eKlGAy5U47H1phB6hRsPIHX8aAE2DcMYOeB/n8uaZsAOR34Oep/+tUgRsnu3v1I98UoRsHALDJGG/wA/oKAIwGGxsEY45xmpY3wWBORnIxwTSrhFUfw9OxyOwP8AjT2ILhicA9ccfjQArqMBhkZ+YcdqiVcvtHLDkjjip41bBVQNnU98H/Cjyc449sA4/WgCWUFYVBJ4BIwMfj796ovCuDnA+XhlHUe9XrkyR7dqfKBnBPGKrllYq6BUUnbnnGD14/z9aAKMsflqv3sHkD+lS2uWR02guOAvTGR37VZ+VWJyqtjuCR+H+NMEYfsNzDoG/XNAEXkRyx5VSEIHHTnt+fXFCsyTyLtOG6Z4zj0+n+RThbShm2bmEbbxzxUJtpzKS5kDD5jkEZ9/6celAErMks8LyMFYuNrg8cHBB9KS5BM87BJNzMUJAHHv+P45qNY2hnjYxgxswBjPfkf/AFq1FsBNdStE5GXzg8E+vP8AnpQBnWyyMgBKsrccnkevHf6561fkt41gYEBkIOQO5zx/nj602WDDMjYJT7pXkn0/L1NVrhzGpZZAkgXoQSD6AjHFAHL6+ESUN8wQjIIOc+xNc20Uczu5dUmVuAUwrfUg/r/jXQ30iTTSpP8AJIzZPdW564/pWPHb7Lhw6qTgt8pB3Ad/pQBoW07R28a7GYgckMBRTdOlK2ww6qCcgbQeKKAPdVkAgCbhls9B/nt2rKvSZJlXGGzjGcgc1dSVZF2YDsoIOOOvTI/lVZEL3aMCm3eAe35Z7cUAJMSurxADIVwhAI+UKjfMSevKjgc89OtYEUeA8g2iRmLgj1PJOPxP61qTXLJrDwEKN27Bz93PH58mqhtdoRB8ix5XcTgj6flmgCuuQPlDMo6r0AHr/n6VHI24fKT5QJIO04zjnj0q3cxARcDlcb8HseP5kc1WSIqOdvBA5HPX+VAEQTaOG68kAc/jSxxLvTaqnH3D2zTwgAxzuz071PAm+TLA4AyccCgCoY/LYqQcHk5A/WnpEGTc3JxznkY/rV7ysJwFwTxz+lL5KqvAIPoR3oAoiIA+ufQcfX2qMgljjAJPQjGB9KtlO569flB4/H0/rUWwZwMc+n64FADFADZViCT2/wAajcEbQox7cHH9fwNWghOMj6gjPFRtGSU+XgD9B/OgCMID1GAOcHGPx/z/ACoijHlc4Kls88/nVjyuuR8x7jpRzsUkg5PHOfx+n9aAISOCTnJOORnP+HembRhnyzEnHy/5/SpWTJyc+nynnP17daHXIzwx7j19vrQBB5Z3DAyxOffimxBA/wC8GF6EjjaPX8KtCMHhslfbn+VNMeWJ79Md6AIPult3XPJByD2/pSEEZ4z9Bn1/z/8AqqwANx4UDvgdPekdDkDHOfy/zigCsOvqp54GcU5Vw+OTz1Az0/l+NSqAflZcA5OM8g/j60qIFI7AAd6AIOQVLHj/ADx/9apEd+QCN44z6GpUQkKSq+xXnn0x/SnJG2CrIVBY/d9fXigBEQYYqOh4ww59fx/wqVACVyVY9cE5z+X6VKEJcgYBBzz1xUiREun3mOfrn6+hoAbeQ7rZN2T/AMBPP4VnNaN5XyAMUbOO5H0rXvEcIqr25weg/P0qpauCjiRDg5z3z9KAKQB5GOV9ecD+mKlU8llY8Hd8o6elXHgVwW3fKD17j3/+vUL25PKbV+bHz8c+hoAmkUiNTsOFGQ3r9fzpFcqfvId5AIHp9P5+vFPdXjiXcr5Ug8DOfx/zxUrqvnIiIBLjIVOQc/yoAoXcCSOqgkNuGCRnOD1H+e9EheK6kXzFEhJ+VudwI/nxWj/Z+oMFZLdz83RwBg5Hr/npU2paVem/kkjhSMAhtplGd3qP88UAZd2yRILq4wocYIB3AH39657VikgaQSFY1+VZFOWGexHet270TUzcvNBaq6OOU80cfQ/41y2pRXtlIWvLK4WJRhmMRGPrigDCuHVmAmiUEk/vVfIP1Ht+mayGk2XUW1yuTgOrZ28Dv6YrXvo1bMsD70b5snkr9axrmMbmI4JAzn0z1/8Ar0AXTLJGAqoXA6FckfpRWeL1UASVFZl4yaKAPeo7t5YRHEhY7iBv6fgOtNvJUtJ4kfeXdgG6HAI6/j1/GkS6t0t2dHjzkqc8de/uayfElxby2MUkbR7pCPmXJJIAPT15oAuW1sx1FmKeWyn7w/iPb8KuzQlQ0qjr1UDJPsfxAp2nTefawlDEN5y2RgjOAAce4J5zjNWL+Nj+6BTKHLcn8PoOv50AY5jJAZsfMcjPUH0qKRCzEYyQcA5IPTn6irwG751PJz35+nP86Tyy+HPJHIA4HrmgCpFFlgBlsjhV/TIqe3hIduoZQeoGR7f/AKqvWQURTqv+sYjqMk/4ZpAVMj7cDA9e1AFIRkYywUpnnk4z/n9aeQFjO/gYyR/nvUpBA54xjr0PH8+v6UvlHBHJ7HPTPagCo65PLcY47Y/yKbImOc8Ht9farUoI2hhnaeBjp9KRUbJxnjjGR1/woAr+UVG07gfXHX/D6UFBuGSAB0q3EqjOOh7gU1gNyduOTQBVZDv5G71HTPr+NN270GMHLZxyRxVp0OTnnt14x70Bfl5wMnJGKAKflAkbjjPXP9Ke6MW4yCMDB6/55qyseWwBn1wcU7bnIbHGcAUAVfK43YyM556UwxEtkYzyOuM/561fCDI9jwTzg+vNMMSKeFK59Tn/AD+NAFQhsAr1Jz979aiaLJKqAMDaPY9fwrSZP976dfwphQYycnsMck0AZ4jwwPHGMEf56Uqx5K7B8uc8d/8APNXjHgk9COpz/hSeXwflB4PU9qAKgViBhiGPpkEfjUsSBeoHLcY5xUwjwqhsYHPPFTxpkgnrk4zn/GgBqJn1xjPBx7f0q5a25kb7q8DjoMf4UQRLkEdQSBjGf5VpRstsqh+VA3MAOAP6nj/OaAIr6xVSWlXCkBQO4PX6VgSOIrlx5ZVcHaSOM+nsTVfxZ4vijtpBb7seYDuPQg8cDt+Oep5riLG5vr28/ezyRK54Z2JZvwzgj0zQB173hicFyu4ZJDLjI9c1r6ahv4sLmOMgZeY7VHqPc+1ZIi03R7JLu/u4nuOClvNJwT7DsPqCfpXO6n43s55B597BEoGAE7H0x6UAejLBZ29rGFQTFDwT8qjnnAqnf6vIV2Q7bcdVCLjcfQHvXH2fi+Ga0Aa4hm+bgoAcDt2GKsQ6tFd/KkpPGCHGcDPY9+3agC++qziZRLIzoSFbDE5544+uKW/v0+3XCNIRtYNyOq4647GsS9cSyAxxgLkYkHGT71JrFvJ9tmcuDhgMjnt+h9v5HmgBw1OW3bcH5U5yvHPWtqy8VyJujuo/PQc5Ynfj0DdcCuXim3phgME5yO+P5Z/z61eihilQspLZHQHH4YoA6aW20fxGHkSNXlIyUxsmUexH3gPWuM8WeBLqyga50lvtVuPnkgAy0Y9vUCr8ERFzE8TtHJEcrIGJ247g9ee9eg2V0L/T0ulZUuN2yREOPmxnIAGACD0579KAPma7CmXKb8YwQMDBHHeivQfGvh+xm1x5VTy/MUMQEPXJooArXPieOBrpRFvkmTARTkKzHkfn7ZrXjIvNKsZSrqyIQykckDgHtjoa86uFluJxJhlT7w2j36+9emeDEj1HTFVJDMLd9hO0gNk8YY9cdfxoA6rRbUW94kLjhowck5wMb+OnUH6/rWtMTKpZFjVc5AVh0PTPf9T0qZ7RhLcHGdkbqMADoRnv6HpUFtGmEUJlsZJ7YHr+n6UAUpbcmbdgNgcqR1Jo8tlPIx3P+f8AP41tywRtEm0qB1GO3vVDyBHkKCoC5CA5/n60AURD5chYZ568dB/n6+1OSPajnKn6d/zqyRlehOMDKjgAdKdbQfJLkcrx6g+1AFJY2BAB9zntU8UYC5B+XPUj8gf8+vSrCQnjKgjrnGMmpI4iUIP3RjI6mgCgY8A5Bxzgjn2ppjy4wQSD25+vHetIoOm3GefQjFQSxMcZHy5PAGMfl1oAqBfnG7rySeoz+FRmMblwuflzz3q8UzyOmcg449sUwRfMhRRgD8B2z9ePpQBUEXJGO2D05p6pmNNpYqCeB/8AX/GrPlMT90hcYXufepVBKplWxk9O/agCmsfJAI4X0HWjy8AqN35c/wCFXhEQCGGM/Lx6/wCf8+oYwu0kcA5GTigCiUwMjrgck9f04ppj+cBlxz0x79K0PK2g5BG3kn0P+NI0XzAEHnqSRnHpQBQkRtgbGcHscfhShPlHPPfA6f5Of/r1eELFVyvOfr3PFIYeOx3dR2NAGeyjg5J/D8+cUrIShzgZyeR3+v8A9atEQ8nKZBGCMnNNEQZGIBJIJA7/AOf88UAZvl/M4TOSRn/9RqWFMlR/Hk44yc+/+FWzCc8+n+c/5+malghAcEDKHk+9ACxLtGRjc3ABH6j/AOvUV7uitNobh8kn1B9/1rSihDMpA4z2PXuf51T8WgQQRQwndLKdgXPK+ox2PTr2oA5vUtIXUtGK2yoY2BIcqASwK98e5xmuJ1hIPC8Zmm2zXrf6iIEnJHc+w+n+NesxeXbeHjC0RChfuoCN2OSM9PT8vz+efFt3PeahPdTOWllYog/uqOMAf57GgDndTnl1C8lup5GuJn+Z3cZP0+n0qhLAo9MDr7etbFtbMIg+CuAefTimC2DMM8N1wPWgDMg8yItJE7I2eqnH510Wh6rMXWSZcyocLIDx9StUPsO1Rx3wcjp9K2bTSWWNOCr9R9fT60Adlp+qx3ar5mwOSGwM4f3x+ddFeyJ9vuxhWjfbwCOOnU8+ledWkE8E6OBk7wxyOnOf8/8A667i+aX7fOGEe5iMsBgfdzyP8/T0AKU8SxykELs7kcfrU9qBuXyySduA5XIJ9MZp3nN5UkUoOcgg9lPr06VHbrsHBYKMHC9B/jQB0thboLcbzumbBCIAB06k1v6BC268wq/6gMM8DIP/AOv+XvWP4YUXE4RyBtGSNwDZ9R6+ldva28aee8Q3Fl24AP1/z7DpQB5N4ymCaxtTKjywT8+MkknPFFZ/j+ZY/ETj5MGNSABkDrxRQBi/2VNDaxzwxN52CSSRhmzyFP0re8ESSadfm2UkR8Ex7du09cHPb3qC21CNbWIopR4ZeCEGFA54Ge/NSWUUNjq1nfxZEVw/Hy/OOMnvjv8AhQB6vpXmTrNLJuZptxBfqMjp+ZotbTCK7uEPQ54HHr9fSszQ9Qgt7dUkMrlCCpCDgMRjv1rSvtQVdTSGNB87hSWTOMAlj164GPxNAF4Rqg4J4HG4Hg9/0qpKpZgAOh7jB5+nakGpQOpdXuAEZkAKL1BAz1/2qLe78whFUBiNgyDgP+f3cfjQA1rYD5tw3L1A9/605IyIZMJjccEkHn3J7VHBfQyQRyR+agaIOAQCcemc/r3qwk0So7/Me2NvocetADVi/egYOAOcKOvv7e9SiIhckADnqfxz/wDrpFlSRygLDGMgoCMZ2+vtQtzEy7v3mMsCMehI459jQBG0ZOMr7+hxnr/OozEVHCkD25P5/Sknu1tdplQFGJCFByxAy28HjH3cY9DmknuY4yineC7Yyo5Bxng9un50AHll3yo46D25/Wl8gMUYLkY6kbs8UCeIwQy7WUShFwAMgsOOe4H61LE6TMrLkBgAQe59znpQBG0GW6FuOhPP5U9YRsUAndg8HsPT/PWrClBGQFBAAxkfT/GlV1YlUGEjB5PXPHH0oArtENmBkKBxjJHX86TygOwBB59xU6P8wZQnln/YwfX6etEMinzsgghmXg9uMfzoAjEOQSoyRxn1poiw23dgEZB5wffNPN0jifG9WQ7d3XkHGef6055BHceTjaJBuj2e3HJPOc+nbHegCIRrsXBAB5ORjn/I6U8oCee3JGMY96JJRGEDlscbtvc/1p7ugLnB3KccevHT8xQBXMYwpPPJ4x9OP8+1DoNhJB4Bbg9ff09qmuJEhDs4Ztg5xxnt/X9KY0kaq21SNoyCOD1FAEZi/eZO0gY5Ix3qaFdvoXwWw3Az2zUJlRmkEIYOSQpJ6H6U+C4ZIZpVUMkZKKrE54P8sfrQBrWtv+9CnPA5HYjp+XFP1zTo5ryB5BuCx4Py5B68Z9eB9OKW3IEqoehb5ABjb/n+tTXkTi4abcGjVckkkPkEDA7Ae319aAKviBbP/hGxFKpWVkO3aRyDwRjv0/WvnDXdDT+1HSBXkAbbE+3Of8T+or6J1gGV084rIgB+V0B4BX8utc5cLbW7S2sdrGtzIciQD5QP59OPxoA8bfSPsNqqTRlZH+Y9sgfyPeqB0sGQHacqCRgcivRtY2PNMgRWKjfhwMMOmCetWoLCw+wiQRuDJIseeCVJ7igDzu00lpriJGTLE8HsQPWunXS4iCYikhiby3VCG2sAPlOOnBBx71p6HHb3MaXdtHwY1ceZwwJ+n1rbtrZYiSUhy5Z12pt5HGWHc9OaAOUt9L8hgJEypYE5PbI4rodettl88sQYwna0bKpJ5wCOOce/bBzxUd0plKu5zltv9fy6/nXQ3Vn5kTYIG3DE85OR/wDWP6UAcLdWjpIFwwIOOece3+etOWJo03Ajp94jpz/OtGVVi3o5YrH6f3cZ/Pg1RuZ9pK43IiF2B68cde/HrQB0vg6EyG4eSTCowBTqFb8OhxgfhXYzvttXJyuThATjcOvfp/gKwvCFqsNhbCH/AJb/ADMSTz/+oDH4Vs6u+22dVYhAF2nuAc8dcdv84oA8J+INyT4mnA3HaqjKng8UVjeOLpW8UX24chgPug9AKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple gas-liquid levels in the postpneumonectomy space, with cardiomediastinal shift to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34982=[""].join("\n");
var outline_f34_10_34982=null;
var title_f34_10_34983="Anal squamous intraep neoplasia";
var content_f34_10_34983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Anal squamous intraepithelia neoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Bowenoid anal intraepithelia neoplasia.",
"    <br>",
"     (B) Erythroplakic anal intraepithelial neoplasia.",
"     <br>",
"      (C) Leukoplakic anal intraepithelial neoplasia.",
"      <br>",
"       (D) Verrucous anal intraepithelial neoplasia.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Kreuter A, Brockmeyer NH, Hochdorfer B, et al. Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV. J Am Acad Dermatol 2005; 52: 603. Copyright &copy; 2005 The American Academy of Dermatology.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34983=[""].join("\n");
var outline_f34_10_34983=null;
var title_f34_10_34984="Traumatic neuroma";
var content_f34_10_34984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traumatic neuroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 497px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Low-power micrograph of a traumatic neuroma of the superficial branch of the right median nerve. The white arrow shows the parent nerve giving rise to the disorganized proliferation of axons, Schwann cells, and perineural cells within a collagenous stroma that makes up the neuroma. H&amp;E stain, 40x. B) Higher-power micrograph demonstrating the haphazard arrangement of the nerve fiber bundles, both cut longitudinally (white arrow) and in cross-section (black arrow). As noted previously, the neuroma is collagen-rich (blue arrow). H&amp;E stain, 200x.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John E Donahue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34984=[""].join("\n");
var outline_f34_10_34984=null;
var title_f34_10_34985="Sexual dysfunction in women: Management";
var content_f34_10_34985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"66\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sexual dysfunction in women: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/10/34985/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34985/contributors\">",
"     Jan L Shifren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/10/34985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34985/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/10/34985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34985/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/10/34985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual problems are highly prevalent in women. In the United States, approximately 40 percent of women have sexual concerns and 12 percent report distressing sexual problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/1\">",
"     1",
"    </a>",
"    ]. Female sexual dysfunction takes different forms, including lack of sexual desire, impaired arousal, inability to achieve orgasm, pain with sexual activity, or a combination of these issues. Treatment must be tailored to the sexual dysfunction diagnosis or diagnoses and to underlying physical and psychological factors.",
"   </p>",
"   <p>",
"    The management of female sexual dysfunction will be reviewed here. The epidemiology, risk factors, and evaluation of female sexual dysfunction and evaluation and treatment of sexual pain disorders are discussed separately. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of female orgasmic disorder are also described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43032?source=see_link\">",
"     \"Approach to the woman with sexual pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23128?source=see_link\">",
"     \"Differential diagnosis of sexual pain in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36600?source=see_link\">",
"     \"Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2824?source=see_link\">",
"     \"Treatment of female orgasmic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female sexual dysfunction is multifactorial, often with several different etiologies contributing to the problem. Nonetheless, careful evaluation and use of available therapies can improve sexual function for many women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Complete the evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluate the patient for all sexual issues and associated physical or psychological factors before starting treatment. Most women with sexual complaints have issues that impact more than one phase of the normal sexual response cycle (desire, arousal, orgasm) or may complain of a general decrease in sexual satisfaction. As an example, if a woman complains of decreased libido, a full evaluation may also reveal issues with arousal or pain. We restrict use of pharmacologic therapy to women who meet diagnostic criteria for a sexual disorder, a sexual problem associated with personal distress, and for whom non-pharmacologic interventions have proven ineffective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H20#H20\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, sexual complaints usually arise in the context of other physical, psychological, and relationship issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Assess patient goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assess patient goals prior to starting treatment and use her goals to evaluate progress. This also gives the clinician the opportunity to set realistic patient expectations. While some women may desire modest improvements in their sexual life, others may expect that treatment will allow them to achieve an ideal based upon past experience or cultural images of sexuality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treat associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assess for and treat associated conditions before or during sexual dysfunction therapy. Many physical and psychological conditions are associated with sexual dysfunction. Sometimes a sexual problem can be ameliorated by diagnosing and treating an underlying problem or by adjusting therapy to minimize sexual side effects. As an example, women with depression who are experiencing sexual side effects on a selective serotonin reuptake inhibitor (SSRI) can sometimes be treated with a different class of antidepressant. In addition, identification and treatment of substance abuse, as well as the underlying factors that precipitated it, often result in improved sexuality and overall quality of life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H7#H7\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Use a team approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual disorders can be complex and their treatment can be time intensive and require special expertise. With the patient's consent, communication and management decisions should be shared between the patient's clinician and other health care providers who treat the patient (eg, cardiologist, psychiatrist). Also, referrals to psychotherapists, sex therapists, or pelvic physical therapists are often needed to address specific aspects of treatment.",
"   </p>",
"   <p>",
"    In addition, for women with partners, the partner must be involved in the treatment. This may include treatment of the partner's sexual dysfunction, if present,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    involvement of the partner in working with continuing relationship issues (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Sex and couples therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CHALLENGES TO EVALUATING TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inconsistent measures to assess efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion uses the best measures available for evaluation of treatment. One measure that can be quantified and compared among studies is an event log, which is the frequency of sexually satisfying events. However, an event log does not typically assess qualitative changes in sexual function, such as sexual interest or level of distress.",
"   </p>",
"   <p>",
"    Most studies of sexual dysfunction treatment use validated questionnaire scores as an outcome measure. There are multiple questionnaires, which use different questions and scales. This makes it difficult to compare data between studies and treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnoses and therapies are multi-faceted",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female sexual dysfunction typically affects more than one aspect of sexuality (eg, desire, arousal) and most therapies also impact several aspects. Thus, it is not generally possible to identify an isolated sexual issue and select a therapy that specifically targets that concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MAKING A TREATMENT PLAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;As all currently available pharmacologic therapies for female sexual dysfunction are of limited efficacy and associated with side effects and potential risks, non-pharmacologic options should comprise the initial treatment for most women. The principal predictors of sexual satisfaction are physical and mental health, and the quality of the relationship with the partner, so the focus of therapy should be on interventions that optimize health, well-being and the partner relationship. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NON-PHARMACOLOGIC THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychological and relationship issues often underlie, exacerbate, or are amplified by, sexual dysfunction in one or both partners. As an example, a major cause of decreased sexual desire and response is a relationship with limited communication or underlying conflict.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sex and couples therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with sexual dysfunction will often benefit from referral to a sex",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    couples therapist. Couple's counseling is effective when there is relationship conflict or limited communication. Sex therapists often are highly trained counselors, with special expertise in human sexuality. They may be physicians, psychologists or social workers with additional training and experience. Certified sex therapists may be located through the website of the American Association of Sex Educators, Counselors, and Therapists:",
"    <a class=\"external\" href=\"file://www.aasect.org/\">",
"     www.aasect.org",
"    </a>",
"    . Their services are often covered by insurers.",
"   </p>",
"   <p>",
"    Sex therapists educate women and men about the normal sexual response cycle and effectively deal with cultural or religious concerns regarding sexuality. Therapists assign specific exercises, which aid many women and couples with sexual dysfunction. In one study, 65 percent of 365 couples undergoing sex therapy for a range of sexual dysfunctions described their treatment as successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of sex therapy exercise include instruction in the appropriate use of vaginal dilators, which is highly effective in treating most cases of vaginismus and dyspareunia. Another approach is sensate focus exercises to help couples increase mutual sexual pleasure, minimizing the importance of orgasm as the principal goal of sexual encounters.",
"   </p>",
"   <p>",
"    Sex therapists work to improve communication between couples and often help negotiate a mutually acceptable frequency of sexual activity when varying levels of sexual interest are present and causing discord. They may direct patients to a wide range of helpful resources, including book lists, visual aids and devices.",
"   </p>",
"   <p>",
"    Given the efficacy and high degree of safety of sex therapy, consultation with a sex therapist generally should be considered a prerequisite to a trial of pharmacologic therapy for most women with sexual dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pelvic physical therapists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical therapists with subspecialty training in pelvic anatomy and function are very helpful for patients with dyspareunia, vaginismus, and pelvic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although relationship counselors and sex therapists are very helpful for psychologically healthy individuals, women with psychiatric disorders will benefit from appropriate referral. Psychiatric disorders, especially depression and anxiety, are associated with an increased likelihood of sexual dysfunction. Treatment of the underlying psychiatric problem, with appropriate pharmacology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychotherapy can lead to an improved sexual life. Prior physical, emotional or sexual abuse or substance abuse disorders also affect sexual function and may be addressed effectively in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H9#H9\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Psychiatric and neurologic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As pharmacologic treatment of psychiatric illness, particularly with SSRIs, is associated with sexual dysfunction, the expertise of a psychopharmacologist may be required when sexual problems precede, or are exacerbated by psychiatric medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lifestyle changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue, stress and lack of privacy contribute significantly to low libido and sexual problems for women. Often reducing stress with support groups, yoga or other relaxation techniques or exercise, or assistance with childcare responsibilities and housework results in improved sexual interest and satisfaction. Encouraging couples to establish a regular \"date night\" and to spend an occasional night or two away from family responsibilities can lead to significant improvements in sexual interest.",
"   </p>",
"   <p>",
"    Research on sexual function consistently demonstrates increased libido and pleasure in new relationships. Although women should not be advised to improve their sex lives simply by seeking out new partners, they should be encouraged to bring novelty to their current relationships. Reading books about sexuality, visiting a store with items designed to increase sexual pleasure and expanding the typical sexual repertoire effectively increase libido and response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Improving body image",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman's view of her own body affects her sexual interest and satisfaction. Overweight women with sexual dysfunction should be assisted with weight loss. In addition, many women note improvements in their sex lives when they initiate a regular exercise program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lubricants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lubricants during intercourse and non-hormonal vaginal moisturizers can be useful for both pre- and postmenopausal women with vaginal dryness and dyspareunia. A full discussion of vaginal lubricants can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of vaginal atrophy\", section on 'Moisturizers and lubricants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clitoral suction vacuum device, EROS CTDT, is approved by the United States Food and Drug Association (FDA) for female sexual dysfunction. Its design is similar to vacuum devices used for male erectile dysfunction. It may improve local arousal and response by improving clitoral blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/3\">",
"     3",
"    </a>",
"    ]. The device is expensive and likely no more effective than less costly devices available without a prescription, such as vibrators.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     HORMONE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of endogenous androgens do not predict sexual function; however, androgen therapy that increases serum concentrations to the upper limit of normal has been shown to improve female sexual function in selected populations of postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H5#H5\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Role of androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discussion of androgen therapy with a patient must include a full explanation of the potential benefits and risks. Women should understand that data on safety and efficacy are limited, including data on long-term use, or use without concomitant estrogen therapy. In addition, they must be informed that none of the commonly used androgen therapies are approved by the FDA for treating female sexual dysfunction because of limited clinical trial data or concerns about long-term safety (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Adverse effects and contraindications'",
"    </a>",
"    below). The physician is advised to document this discussion in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Effectiveness",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmenopausal women &mdash; Testosterone therapy is the most commonly studied androgen treatment for female sexual dysfunction. The addition of testosterone to postmenopausal estrogen (with or without progestin) therapy in women who undergo menopause naturally or as a result of oophorectomy (surgical menopause) has been shown to improve sexual function in systematic reviews of randomized trials and in most, but not all, subsequent randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/5-15\">",
"       5-15",
"      </a>",
"      ]. Testosterone is primarily used to treat issues with sexual desire or responsiveness, although all aspects of sexual function generally improve, including arousal and orgasmic response.",
"      <br/>",
"      <br/>",
"      Formulations (testosterone,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/36/3652?source=see_link\">",
"       methyltestosterone",
"      </a>",
"      ) and delivery methods (oral, transdermal patch, topical gel) vary across studies. The largest randomized trials utilized a transdermal testosterone patch delivering 300",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      testosterone in postmenopausal women with hypoactive sexual desire disorder (HSDD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/7,9,13\">",
"       7,9,13",
"      </a>",
"      ]. Regarding dosing, in general, trials indicate that a dose of 300",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      for six months is safe and effective in women who are receiving concomitant estrogen therapy. Benefits were reported for many aspects of sexuality, including desire, responsiveness, orgasm, and satisfaction. Pooled data from trials in surgically and naturally menopausal women found that, compared to women who received placebo, women who were treated with testosterone reported a small increase in sexually satisfying events per four weeks (an increase of 1.9 versus 0.9 events over a baseline of approximately three events) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/16\">",
"       16",
"      </a>",
"      ]. In contrast, results of two randomized trials reported by the manufacturer of a topical testosterone gel (LibiGel&reg;) showed no significant increase in sexual desire or the number of sexually satisfying events compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These data do not address use in women who are not taking postmenopausal hormone therapy. This is clinically important, since postmenopausal estrogen (with or without progestin) therapy is no longer universally recommended. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"       \"Postmenopausal hormone therapy: Benefits and risks\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although the majority of studies have assessed the risks and benefits of androgen therapy in postmenopausal women using concurrent estrogen therapy, one large controlled trial reports similar results in menopausal women who are not taking",
"      <span class=\"nowrap\">",
"       estrogen/progestin",
"      </span>",
"      therapy. In this trial, 814 natural or surgically postmenopausal women with HSDD were randomly assigned to receive testosterone (daily dose of 150 or 300 mcg) or a placebo patch [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/11\">",
"       11",
"      </a>",
"      ]. The testosterone 300 mcg group reported significantly more sexual satisfying events than the placebo group (an increase of 2.1 versus 0.7 episodes per four weeks); this was not true for the 150 mcg dose (increase of 1.2 episodes). However, both testosterone doses were associated with significant improvements in desire and reduction in distress about sexual dysfunction.",
"      <br/>",
"      <br/>",
"      There were no differences in treatment efficacy between women with natural versus surgical menopause. Regarding safety, breast cancer was diagnosed in four women who received testosterone, as compared with none who received placebo. Although two of the cases likely were present prior to testosterone administration, the authors concluded that long-term effects of testosterone, including effects on the breast, remain uncertain.",
"      <br/>",
"      <br/>",
"      Another androgen, dehydroepiandrosterone (DHEA), has been shown to improve sexual interest and satisfaction in some studies of women with adrenal insufficiency, but was ineffective in women who were perimenopausal or naturally postmenopausal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. DHEA has not been studied for treatment of sexual dysfunction in women with surgical menopause. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=see_link&amp;anchor=H3#H3\">",
"       \"Dehydroepiandrosterone and its sulfate\", section on 'Use in adrenal insufficiency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premenopausal women &mdash; Testosterone levels in women decline with age, and do not change abruptly at the time of natural menopause. Thus, women in their late 30s and 40s have low androgen levels compared with younger women.",
"      <br/>",
"      <br/>",
"      However, data regarding androgen treatment of premenopausal women are few and inconclusive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. As an example, in the best designed trial, 261 women aged 35 to 46 who complained of decreased sexual satisfaction were randomized to testosterone (180, 90, or 45 microL) versus placebo transdermal metered spray [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/19\">",
"       19",
"      </a>",
"      ]. Improvements in satisfying sexual events compared with placebo were found only in women treated with 90 microL, but not with other testosterone doses. There were no significant improvements in any other measure of sexuality, including desire, pleasure or orgasm. Despite repeated warnings to use contraception, one woman was found to be pregnant at week 20 of the study. When considering androgen therapy in women of reproductive age, inadvertent exposure of a developing fetus must be considered a significant potential risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Available androgen preparations and limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two preparations of testosterone that are convenient and are most likely to achieve therapeutic levels are: (1) topical compounded 1 percent testosterone cream (0.5 grams daily) applied to the skin of the arms, legs or abdomen or (2) Intrinsa&trade; 300 mcg testosterone patch applied twice weekly (available in Europe).",
"   </p>",
"   <p>",
"    No androgen therapies for female sexual dysfunction are approved by the FDA, which declined approval of the testosterone patch for women pending additional long-term safety data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various products in use include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/36/3652?source=see_link\">",
"       methyltestosterone",
"      </a>",
"      , micronized testosterone (must be compounded; prescription only), DHEA",
"     </li>",
"     <li>",
"      Transdermal &mdash; testosterone patches and gels formulated for hypogonadal men; Intrinsa 300 mcg testosterone patch for postmenopausal women (available in Europe), testosterone ointment or cream (compounded topical 1 percent or 2 percent by prescription)",
"     </li>",
"     <li>",
"      Injectable or implants &mdash; intramuscular testosterone injections, testosterone implants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of oral formulations is limited by the potential for adverse changes in lipids and liver function tests following first-pass hepatic metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/36/3652?source=see_link\">",
"     Methyltestosterone",
"    </a>",
"    in combination with estrogen (Estratest) was taken off the United States market in 2009. DHEA is available without a prescription; doses of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    raise circulating androgen levels into the physiologic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/17\">",
"     17",
"    </a>",
"    ]. As this product is subject to minimal regulatory oversight, hormone content is highly variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women should not be given transdermal products formulated for men, such as skin patches (eg, Androderm&trade;) and gels (eg, Androgel&trade;). If they are used, careful dose adjustment is required, as excessive dosing will result from standard doses prescribed for men. Cutting patches is not advised, as no data are available on product stability or resulting testosterone levels.",
"   </p>",
"   <p>",
"    Gels would need to be applied in approximately",
"    <span class=\"nowrap\">",
"     1/10th",
"    </span>",
"    the male prescribed dose, as testosterone levels in women are approximately 10 percent those of men. This is very difficult to do accurately with available gels dosed for men in pumps and packets. In addition, the FDA has issued a warning regarding testosterone gels due to reports of adverse effects in children due to secondary exposure to the skin of an adult who had recently applied the medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the majority of controlled data on the efficacy and safety of testosterone therapy for postmenopausal women with HSDD was obtained using a testosterone transdermal patch (Intrinsa&trade; 300 mcg), these patches may be the preferred product for women electing testosterone therapy. Testosterone patches, currently approved and available in Europe, also have the advantage of governmental oversight of production, twice weekly dosing, and consistent blood levels within the physiologic range.",
"   </p>",
"   <p>",
"    Custom-compounded topical formulations containing testosterone are available by prescription, but often have inconsistent content and bioavailability. A commonly-used treatment is 1 percent testosterone ointment or cream, approximately 0.5 grams daily applied to the skin of the arms, legs or abdomen. Compounding pharmacies typically supply these products in a marked needleless syringe to allow for more accurate dosing, although these controlled administration methods do not overcome the significant inconsistency in delivered dose between pharmacies, or even between separate lots of product from the same pharmacy. Clinical trials have not evaluated the safety or efficacy of this product for any indication, including improvement of female sexual function.",
"   </p>",
"   <p>",
"    Injectable or implantable preparations of testosterone are available, but administration is uncomfortable and inconvenient, and supraphysiologic dosing is likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Adverse effects and contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen therapy in women can potentially result in androgenic, metabolic, or endocrine adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/26\">",
"     26",
"    </a>",
"    ]. Androgens should be used with caution in women at risk for, or who currently have, cardiovascular disease, hepatic disease, endometrial hyperplasia or cancer, or breast cancer. For reproductive age women, androgen therapy should rarely be used, given a low likelihood that decreased testosterone levels are a principal etiologic factor, limited data on efficacy, and potential for inadvertent exposure of a developing fetus.",
"   </p>",
"   <p>",
"    Major issues regarding side effects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cosmetic androgenic side effects, such as hirsutism and acne, are usually mild; irreversible virilizing changes (eg, voice deepening, clitoromegaly) are rare and occur only with excessive dosing.",
"     </li>",
"     <li>",
"      Serum high density lipoprotein cholesterol concentrations decline slightly in postmenopausal women receiving oral testosterone therapy, but it is not known if the change substantially affects overall cardiovascular risk. Non-oral administration is lipid neutral.",
"     </li>",
"     <li>",
"      Most androgens are aromatized to estrogens, thus risks of estrogen therapy are also possible with androgen treatment. A possible association between testosterone administration and breast cancer risk has been reported (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Effectiveness'",
"      </a>",
"      above)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/11\">",
"       11",
"      </a>",
"      ]. Also, some women on testosterone develop abnormal uterine bleeding. Although there is no evidence of an increased risk of endometrial hyperplasia or cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/11,27-29\">",
"       11,27-29",
"      </a>",
"      ], data on long-term use and use in naturally menopausal women not receiving concurrent progestin therapy are very limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of the adverse effects of androgens are limited by the lack of data on women taking testosterone alone (without estrogen). Also, the duration of studies is generally from 3 to 12 months; therefore, the long-term safety of testosterone therapy cannot be assured.",
"   </p>",
"   <p>",
"    Risks of androgen therapy in women are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link&amp;anchor=H15#H15\">",
"     \"Androgen production and therapy in women\", section on 'Risks and side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link&amp;anchor=H150020386#H150020386\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Effect of testosterone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Monitoring androgen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women on androgen therapy should be monitored for potential adverse effects. Some effects are cosmetic (eg, hirsutism, acne), and so are easily detected by the patient. Given potential effects on lipids and liver function, normal values should be confirmed prior to initiating androgen therapy, reassessed approximately six months after starting treatment, and then annually thereafter.",
"   </p>",
"   <p>",
"    Testosterone is metabolized to estrogen, and thus abnormal uterine bleeding or breast symptoms (eg, lump, nipple discharge) may result and require appropriate evaluation. Annual mammograms should be performed in women receiving androgen therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measuring a free testosterone level or free androgen index (total",
"    <span class=\"nowrap\">",
"     testosterone/sex",
"    </span>",
"    hormone binding globulin) in women using topical testosterone therapies may be used as a safety measure, with the goal of keeping the value within the normal range for reproductive aged women provided by the testing laboratory.",
"   </p>",
"   <p>",
"    Testosterone levels should not be used in determining the etiology of a sexual problem or in assessing efficacy of treatment, as several large, well-designed studies confirm the absence of a significant association between androgen levels and sexual function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H5#H5\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Role of androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Women's Health Initiative, a set of clinical trials in over 27,000 postmenopausal women, found that systemic estrogen with or without progestin therapy did not improve sexual satisfaction and may be harmful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link&amp;anchor=H30#H30\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Health-related quality of life'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although evidence does not support a role for systemic postmenopausal hormone therapy in the treatment of sexual problems, if a woman with a previously satisfying sex life presents with sexual problems concurrent with the onset of hot flashes, night sweats, sleep disruption and resulting fatigue, treatment of menopausal symptoms with systemic postmenopausal hormone therapy may lead to improvement in the sexual problem.",
"   </p>",
"   <p>",
"    The majority of postmenopausal women will develop urogenital atrophy in the absence of estrogen therapy. In a double-blind study, 285 postmenopausal women without specific sexual complaints were randomized to low dose oral postmenopausal hormone therapy with vaginal estrogen cream versus placebo for six months. Compared with placebo, treatment with postmenopausal hormone therapy resulted in a significant decrease in dyspareunia and increases in sexual interest, orgasmic response and relationship satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If vasomotor symptoms are not present and there is no indication for systemic estrogen therapy, low dose vaginal estrogen therapy alone is highly effective in treating atrophic changes and dyspareunia. Sexual interest, arousal, and response often improve subsequent to improved vaginal health and comfort during sexual activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vaginal atrophy\", section on 'Vaginal estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Tibolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibolone is a synthetic steroid whose metabolites have estrogenic, progestagenic, and androgenic properties. It was not approved by the FDA due to concerns about risk of breast cancer and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/16\">",
"     16",
"    </a>",
"    ], but is used by postmenopausal women in Europe and other areas.",
"   </p>",
"   <p>",
"    In randomized trials, tibolone appears more effective than",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    therapy for treatment of sexual dysfunction in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. However, the beneficial effects of either of these treatments on sexuality are modest and may not outweigh the risks. Comparative trials of tibolone versus testosterone have not been performed.",
"   </p>",
"   <p>",
"    Adverse effects associated with tibolone are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link&amp;anchor=H533432775#H533432775\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Tibolone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OTHER PHARMACOLOGIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Phosphodiesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphodiesterase (PDE-5) inhibitors effectively treat male erectile dysfunction, but generally have not proven successful in women.",
"   </p>",
"   <p>",
"    Studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    for treatment of women with sexual dysfunction have reported inconsistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. The best available evidence is a randomized trial of nearly 800 pre- and post-menopausal women with disorders of desire, arousal, orgasm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dyspareunia treated with 10 to 100 mg sildenafil for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/35\">",
"     35",
"    </a>",
"    ]. Sildenafil was no more effective than placebo in increasing the frequency of enjoyable sexual events or improving any aspect of sexual function.",
"   </p>",
"   <p>",
"    However, positive effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    on sexual arousal and orgasm have been demonstrated in premenopausal women with selective serotonin reuptake inhibitor (SSRI)-associated sexual dysfunction. A randomized trial of sildenafil 50 or 100 mg in 98 women with major depression in remission on SSRIs found that sildenafil for eight weeks, compared with placebo, significantly improved scores for global sexual function and orgasmic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/40\">",
"     40",
"    </a>",
"    ]. Sildenafil use did not impact sexual desire and had no effect on hormone levels or measures of depression.",
"   </p>",
"   <p>",
"    Although there have been no studies on the use of other PDE-5 inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , on SSRI-induced sexual dysfunction, it is likely that they have similar effectiveness due to their shared mechanism of action.",
"   </p>",
"   <p>",
"    Sexual dysfunction in people taking SSRIs is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link&amp;anchor=H6#H6\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\", section on 'Use of a second drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trial data also suggest that PDE-5 inhibitors may be helpful in treating sexual dysfunction in women with diabetes, multiple sclerosis, or spinal cord injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Further study is needed in these populations.",
"   </p>",
"   <p>",
"    Potential side effects of PDE-5 inhibitors include headache, flushing and nausea. These drugs are contraindicated in patients taking nitrates. Patients must be informed that PDE-5 use for women has not been approved by the FDA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erectile dysfunction is very common in aging men, and women may experience reduced sexual interest and pleasure secondary to a partner&rsquo;s sexual dysfunction. In this setting, PDE-5 inhibitors may result in improved sexual satisfaction for both members of the couple.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Psychotropic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible benefit from dopamine agonists was suggested by sexual effects reported in women with Parkinson's disease treated with these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"     Apomorphine",
"    </a>",
"    is a dopamine agonist used off-label for the treatment of male erectile dysfunction. A two-week randomized cross-over trial of 50 premenopausal women reported treatment with apomorphine improved orgasm, sexual enjoyment and satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/45\">",
"     45",
"    </a>",
"    ]. Notably, only 47 percent of subjects completed the study, possibly due to side effects, which include nausea, vomiting, dizziness, and hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Bupropion",
"    </span>",
"    &nbsp;&mdash;&nbsp;One randomized trial of 75 premenopausal women with HSDD and without underlying depression reported increased sexual pleasure, arousal and orgasm with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    (sustained release 300",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from uncontrolled trials suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    treatment of patients with SSRI-associated sexual dysfunction is beneficial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link&amp;anchor=H8#H8\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\", section on 'Bupropion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Buspirone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    for treatment of SSRI-induced sexual dysfunction have yielded conflicting results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link&amp;anchor=H9#H9\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\", section on 'Buspirone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Flibanserin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pharmacologic treatment for hypoactive sexual desire disorder (HSDD) is under investigation, but was",
"    <strong>",
"     not",
"    </strong>",
"    approved by the US Food and Drug Administration in 2010 due to concerns about insufficient efficacy data and about the risk of adverse effects, and drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/47\">",
"     47",
"    </a>",
"    ]. Flibanserin, which was initially studied as a possible antidepressant, has central effects on serotonin, dopamine and norepinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/48\">",
"     48",
"    </a>",
"    ]. Preliminary data from several large, multicenter randomized trials in premenopausal women with HSDD noted improvement in sexual desire (flibanserin versus placebo: 21 versus 10 percent of women reported desire was much or very much improved) and satisfying sexual events (0.7 per month) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Herbal supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women are interested in trying over-the-counter herbal supplements, which are advertised widely and claim to increase sexual desire and pleasure. Women should be informed that the safety and efficacy of these products are unproven, there is minimal regulatory oversight, and they are often costly. Nonetheless, given a 30 percent predicted placebo response and few reported side effects, women may elect a trial of these alternatives.",
"   </p>",
"   <p>",
"    One such product is a proprietary blend of herbal supplements (Avlimil&trade;). Many of the components of Avlimil&trade; are estrogenic, and animal study data suggest that the product may stimulate growth of estrogen-dependent breast tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another product, a botanical feminine massage oil (Zestra&trade;), is applied to the clitoris, labia and vagina. A randomized double-blind crossover trial in 20 women reported increased sexual arousal, orgasm, and pleasure compared with a placebo oil; the only adverse effect reported was mild genital burning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34985/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initiating therapy for sexual dysfunction, patients should be seen for regular follow-up visits, approximately every three months, until effective interventions are identified and the sexual problem has improved. Patients may then be seen every 6 to 12 months, depending on the potential risks of the treatments selected. Patients using pharmacologic therapies will need to be monitored for drug-related risks and side effects at these visits. Treatment efficacy is best assessed by patient self-report of improvement of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     RESOURCES FOR CLINICIANS AND PATIENTS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Books",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Becoming Orgasmic: A Sexual and Personal Growth Program for Women, by Julia Heiman &amp; Joseph Lopiccolo",
"     </li>",
"     <li>",
"      For Women Only: A Revolutionary Guide to Overcoming Sexual Dysfunction and Reclaiming Your Sex Life, by Berman JR, Berman, LA.",
"     </li>",
"     <li>",
"      Getting the Sex You Want: A Woman's Guide to Becoming Proud, Passionate and Pleased in Bed, by Sandra Leiblum &amp; Judith Sachs",
"     </li>",
"     <li>",
"      Illustrated Manual of Sex Therapy, by Helen Singer Kaplan",
"     </li>",
"     <li>",
"      Making Love the Way We Used to or Better: Secrets to Satisfying Midlife Sexuality, by Alan Altman and Laurie Asher",
"     </li>",
"     <li>",
"      My Secret Garden, by Nancy Friday",
"     </li>",
"     <li>",
"      The New Love and Sex After 60, by Robert Butler &amp; Myrna Lewis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Websites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      American Association of Sex Educators, Counselors, and Therapists:",
"      <a class=\"external\" href=\"file://www.aasect.org/\">",
"       www.aasect.org",
"      </a>",
"     </li>",
"     <li>",
"      American College of Obstetricians and Gynecologists:",
"      <a class=\"external\" href=\"file://www.acog.org/\">",
"       www.acog.org",
"      </a>",
"     </li>",
"     <li>",
"      American Urological Association:",
"      <a class=\"external\" href=\"file://www.auanet.org/\">",
"       www.auanet.org",
"      </a>",
"     </li>",
"     <li>",
"      Female Sexual Dysfunction Online:",
"      <a class=\"external\" href=\"file://www.femalesexualdysfunctiononline.org/\">",
"       www.femalesexualdysfunctiononline.org",
"      </a>",
"     </li>",
"     <li>",
"      Kinsey Institute:",
"      <a class=\"external\" href=\"file://www.kinseyinstitute.org/\">",
"       www.kinseyinstitute.org",
"      </a>",
"     </li>",
"     <li>",
"      North American Menopause Society:",
"      <a class=\"external\" href=\"file://www.menopause.org/\">",
"       www.menopause.org",
"      </a>",
"      ; module on &ldquo;Sexual Health and Menopause&rdquo;",
"     </li>",
"     <li>",
"      Nurture Your Nature:",
"      <a class=\"external\" href=\"file://www.nurtureyournature.org/\">",
"       www.nurtureyournature.org",
"      </a>",
"     </li>",
"     <li>",
"      Sexuality Information and Education Council of the United States:",
"      <a class=\"external\" href=\"file://www.siecus.org/\">",
"       www.siecus.org",
"      </a>",
"     </li>",
"     <li>",
"      Society for Sex Therapy and Research:",
"      <a class=\"external\" href=\"file://www.sstarnet.org/\">",
"       www.sstarnet.org",
"      </a>",
"     </li>",
"     <li>",
"      Society for the Scientific Study of Sexuality:",
"      <a class=\"external\" href=\"file://www.sexscience.org/\">",
"       www.sexscience.org",
"      </a>",
"     </li>",
"     <li>",
"      The Women's Sexual Health Foundation:",
"      <a class=\"external\" href=\"file://www.twshf.org/\">",
"       www.twshf.org",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/17/11538?source=see_link\">",
"       \"Patient information: Sex problems in women (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/20/16706?source=see_link\">",
"       \"Patient information: Sex as you get older (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/4/12357?source=see_link\">",
"       \"Patient information: Sexual problems in women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of female sexual dysfunction must be tailored to the sexual issue and to underlying physical and psychological, including relationship, factors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conditions that may alter sexual function (eg, depression, vaginal atrophy, sexual issues related to medications) should be assessed for and treated before or during sexual dysfunction therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treat associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Non-pharmacologic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifestyle changes should be advised, including reducing stress and fatigue, increasing quality time with partners, bringing novelty to the sexual repertoire, and improving body image.",
"     </li>",
"     <li>",
"      Referral to a sex therapist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychotherapist is a highly effective intervention for sexual dysfunction. Pelvic physical therapists are often needed to address specific problems, including vaginismus or pelvic pain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Use a team approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacologic therapy should be restricted to women who meet diagnostic criteria for a sexual disorder (a sexual problem with associated personal distress) and for whom non-pharmacologic interventions have proven ineffective. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Approach to management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Hormone therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For postmenopausal women with vaginal dryness or dyspareunia, we recommend low dose vaginal estrogen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For women in whom low dose vaginal estrogen is contraindicated or who decline this therapy, we suggest water-based lubricants during coitus and regular use of vaginal moisturizers (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Estrogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women with sexual problems not associated with vasomotor symptoms, we recommend against using systemic estrogen (with or without progestin, as appropriate) therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Postmenopausal systemic estrogen or",
"      <span class=\"nowrap\">",
"       estrogen/progestin",
"      </span>",
"      therapy is a reasonable option for women with vasomotor symptoms resulting in sexual dysfunction. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Estrogens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Lubricants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest against using tibolone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Tibolone'",
"      </a>",
"      above.)&nbsp;",
"     </li>",
"     <li>",
"      For postmenopausal women with hypoactive sexual desire disorder for whom non-pharmacologic therapy has been unsuccessful, a trial of testosterone may be of benefit in some women. Candidates for therapy must have no contraindications to taking testosterone, be willing to accept androgenic side effects, and be counseled that this therapy is not approved by the United States Food and Drug Association due to a lack of long-term safety data. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Androgens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For premenopausal women with sexual dysfunction, we recommend against androgen therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Androgens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two preparations of testosterone that are most likely to achieve therapeutic levels are: (1) topical compounded 1 percent testosterone cream (0.5 grams daily) applied to the skin of the arms, legs or abdomen, or (2) a 300 mcg testosterone patch applied twice weekly (available in Europe). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Available androgen preparations and limitations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Non-hormonal therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with arousal or orgasm disorders associated with use of a selective serotonin reuptake inhibitor (SSRI) in whom stopping the SSRI or switching to another antidepressant is not advisable, we suggest treatment with a phosphodiesterase inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Phosphodiesterase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      may be an effective treatment for sexual dysfunction in women with or without associated depression. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Psychotropic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no high quality data demonstrating the safety or efficacy of over-the-counter herbal supplements for sexual dysfunction. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Herbal supplements'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/1\">",
"      Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/2\">",
"      Sarwer DB, Durlak JA. A field trial of the effectiveness of behavioral treatment for sexual dysfunctions. J Sex Marital Ther 1997; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/3\">",
"      Billups KL, Berman L, Berman J, et al. A new non-pharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther 2001; 27:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/4\">",
"      North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005; 12:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/5\">",
"      Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005; :CD004509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/6\">",
"      Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol 2003; 188:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/7\">",
"      Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/8\">",
"      Davis SR, van der Mooren MJ, van Lunsen RH, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006; 13:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/9\">",
"      Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006; 13:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/10\">",
"      Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/11\">",
"      Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008; 359:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/12\">",
"      Bl&uuml;mel JE, Del Pino M, Aprikian D, et al. Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecol Endocrinol 2008; 24:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/13\">",
"      Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90:5226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/14\">",
"      El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 2007; 10:335.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.biosantepharma.com/LibiGel.php (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     Basson, R. Int Journal Impotence Research 2008; 20;466.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/17\">",
"      Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/18\">",
"      Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84:3896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/19\">",
"      Davis S, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 2008; 148:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/20\">",
"      Goldstat R, Briganti E, Tran J, et al. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003; 10:390.",
"     </a>",
"    </li>",
"    <li>",
"     Chudakov, B. J Sex Med. 2007 Jan;4(1):204.",
"    </li>",
"    <li>",
"     file://www.redorbit.com/news/health/108270/fda_says_more_study_of_intrinsa_necessary/index.html. (Accessed June 8, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/23\">",
"      Hameed A, Brothwood T, Bouloux P. Delivery of testosterone replacement therapy. Curr Opin Investig Drugs 2003; 4:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/24\">",
"      Parasrampuria J, Schwartz K, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA 1998; 280:1565.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/bbs/topics/NEWS/2009/NEW02011.html (Accessed May 12, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/26\">",
"      Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/27\">",
"      Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004; 108:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/28\">",
"      Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008; 15:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/29\">",
"      Jongen VH, Thijssen JH, Hollema H, et al. Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer? Int J Gynecol Cancer 2005; 15:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/30\">",
"      Gast MJ, Freedman MA, Vieweg AJ, et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 2009; 16:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/31\">",
"      Nijland EA, Weijmar Schultz WC, Nathorst-Bo&ouml;s J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008; 5:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/32\">",
"      Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J Sex Med 2008; 5:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/33\">",
"      Osmanaaolu MA, Atasaral T, Baltaci D, Bozkaya H. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women. Climacteric 2006; 9:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/34\">",
"      Wu MH, Pan HA, Wang ST, et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001; 4:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/35\">",
"      Basson R, McInnes R, Smith MD, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/36\">",
"      Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001; 108:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/37\">",
"      Caruso S, Intelisano G, Farina M, et al. The function of sildenafil on female sexual pathways: a double-blind, cross-over, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2003; 110:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/38\">",
"      Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003; 110:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/39\">",
"      Berman JR, Berman LA, Toler SM, et al. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003; 170:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/40\">",
"      Nurnberg HG, Hensley PL, Heiman JR, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008; 300:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/41\">",
"      Caruso S, Rugolo S, Agnello C, et al. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006; 85:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/42\">",
"      Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004; 171:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/43\">",
"      Sipski ML, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000; 55:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/44\">",
"      Singh A, Kandimala G, Dewey RB Jr, O'Suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 2007; 14:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/45\">",
"      Caruso S, Agnello C, Intelisano G, et al. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology 2004; 63:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/46\">",
"      Segraves RT, Clayton A, Croft H, et al. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004; 24:339.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM248751.pdf (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/48\">",
"      Borsini F, Evans K, Jason K, et al. Pharmacology of flibanserin. CNS Drug Rev 2002; 8:117.",
"     </a>",
"    </li>",
"    <li>",
"     Jolly, EE, Thorp, JM, Clayton, AH, et al. Patients' perspective of efficacy of flibanserin in the treatment of premenopausal women with hypoactive sexual desire disorder (abstract). American College of Obstetricians and Gynecologists, annual clinical meeting, May, 2010. file://www.acog.org/acm/pdf/oralMon.pdf. (Accessed June 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/50\">",
"      Moynihan R. FDA advisers to assess drug for low sexual desire in women. BMJ 2010; 340:c2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/51\">",
"      Ju YH, Doerge DR, Helferich WG. A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice. Food Chem Toxicol 2008; 46:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34985/abstract/52\">",
"      Ferguson DM, Steidle CP, Singh GS, et al. Randomized, placebo-controlled, double blind, crossover design trial of the efficacy and safety of Zestra for Women in women with and without female sexual arousal disorder. J Sex Marital Ther 2003; 29 Suppl 1:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5485 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34985=[""].join("\n");
var outline_f34_10_34985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Complete the evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Assess patient goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treat associated conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Use a team approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CHALLENGES TO EVALUATING TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inconsistent measures to assess efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnoses and therapies are multi-faceted",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MAKING A TREATMENT PLAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NON-PHARMACOLOGIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sex and couples therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pelvic physical therapists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Improving body image",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lubricants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Available androgen preparations and limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Adverse effects and contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Monitoring androgen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Estrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Tibolone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OTHER PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Phosphodiesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Psychotropic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Bupropion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Buspirone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Flibanserin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Herbal supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      RESOURCES FOR CLINICIANS AND PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Non-pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Non-hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43032?source=related_link\">",
"      Approach to the woman with sexual pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23128?source=related_link\">",
"      Differential diagnosis of sexual pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36600?source=related_link\">",
"      Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/20/16706?source=related_link\">",
"      Patient information: Sex as you get older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2824?source=related_link\">",
"      Treatment of female orgasmic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_10_34986="Clinical features and diagnosis of primary hepatocellular carcinoma";
var content_f34_10_34986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of primary hepatocellular carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/10/34986/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34986/contributors\">",
"     Jonathan M Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34986/contributors\">",
"     Robert L Carithers, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/10/34986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34986/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/10/34986/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34986/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/10/34986/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/10/34986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is a primary tumor of the liver, which usually develops in the setting of chronic liver disease, particularly in patients with chronic hepatitis B and C. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of HCC can be difficult and often requires the use of one or more imaging modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Ideally, tumors should be detected when they are approximately 2 cm in size so that all treatment options can be offered. However, HCC is frequently diagnosed late in its course because of the absence of pathognomonic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As a result, many patients have untreatable disease when first diagnosed. The median survival following diagnosis is approximately 6 to 20 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/5\">",
"     5",
"    </a>",
"    ]. Large tumor size, vascular invasion, poor functional status, and nodal metastases are all associated with a poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical and histologic features of HCC, and the various modalities used to diagnose and stage this aggressive tumor. The controversial topic of screening populations at risk for HCC will also be discussed. An overview of treatment for this tumor is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop HCC usually have no symptoms other than those related to their chronic liver disease. Suspicion for HCC should be heightened in patients with previously compensated cirrhosis who develop decompensation such as ascites, encephalopathy, jaundice, or variceal bleeding. These complications are often associated with extension of the tumor into the hepatic or portal veins or arteriovenous shunting induced by the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients may have mild to moderate upper abdominal pain, weight loss, early satiety, or a palpable mass in the upper abdomen. These symptoms often indicate an advanced lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/3\">",
"     3",
"    </a>",
"    ]. Other uncommon presentations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive jaundice caused by invasion of the biliary tree, compression of the intrahepatic duct, or rarely, as a result of hemobilia",
"     </li>",
"     <li>",
"      Diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bone pain or dyspnea due to metastases",
"     </li>",
"     <li>",
"      Intraperitoneal bleeding due to tumor rupture. Tumor rupture is often associated with sudden onset of severe abdominal pain with distension, an acute drop in the hematocrit and hypotension, and is most commonly diagnosed by peritoneal lavage and laparotomy. CT scan typically demonstrates a liver mass and free intraperitoneal blood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/10\">",
"       10",
"      </a>",
"      ]. This is a life-threatening complication, and control of bleeding may require emergent angiography and embolization of the bleeding vessel, or even surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/11\">",
"       11",
"      </a>",
"      ]. Although the risk of peritoneal dissemination is high, delayed resection may be considered, if feasible (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link\">",
"       \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"       \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fever may develop in association with central tumor necrosis",
"     </li>",
"     <li>",
"      Paraneoplastic syndromes (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Paraneoplastic syndromes'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Pyogenic liver abscess (very rare) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical findings in most patients with HCC (splenomegaly, ascites, jaundice, or other manifestations of decompensated cirrhosis) reflect the underlying liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/13\">",
"     13",
"    </a>",
"    ]. Hepatomegaly or a bruit heard over the liver are occasionally present.",
"   </p>",
"   <p>",
"    Laboratory examination is usually nonspecific. The majority of patients who develop HCC have cirrhosis, and may have thrombocytopenia, hypoalbuminemia, hyperbilirubinemia, and hypoprothrombinemia. Patients are often mildly anemic and may have electrolyte disturbances (eg, hyponatremia, hypokalemia, metabolic alkalosis) associated with defective water handling or with diuretic use. Serum aminotransferases, alkaline phosphatase and gamma glutamyl transpeptidase are often abnormal in a nonspecific pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Joint Committee on Cancer TNM (Tumor, Node, Metastasis) staging system is presented in table 1 (",
"    <a class=\"graphic graphic_table graphicRef63333 \" href=\"mobipreview.htm?1/45/1757\">",
"     table 1",
"    </a>",
"    ). Issues related to staging and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25992?source=see_link\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Paraneoplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCC occasionally develop a paraneoplastic syndrome that can manifest as hypoglycemia, erythrocytosis, hypercalcemia, or severe watery diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia, which usually occurs in advanced HCC, is thought to result from the tumor's high metabolic needs. The hypoglycemia is typically mild and produces no symptoms; however, more severe reductions in the plasma glucose can occur, resulting in lethargy and confusion.",
"   </p>",
"   <p>",
"    Less than 5 percent of tumors secrete insulin-like growth factor-II, which can cause severe symptomatic hypoglycemia, sometimes early in the course of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Erythrocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytosis in HCC is probably due to tumor secretion of erythropoietin (EPO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Although raised serum EPO levels may be present in up to 23 percent of patients with HCC, elevations in hemoglobin concentration or packed cell volume are uncommon, and most patients are anemic at diagnosis because of other effects of the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24777?source=see_link\">",
"     \"Diagnostic approach to the patient with polycythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypercalcemia is sometimes associated with osteolytic metastases, it may be present in the absence of bony metastasis due to secretion of parathyroid hormone-related protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Watery diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCC may present with watery diarrhea. In one study, for example, diarrhea was significantly more common among cirrhotic patients with HCC compared to matched cirrhotic controls (48 versus 9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/9\">",
"     9",
"    </a>",
"    ]. Rarely, diarrhea may be severe and intractable, leading to hypokalemia and achlorhydria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/21\">",
"     21",
"    </a>",
"    ]. The mechanism underlying this syndrome is not fully understood but it may be related to secretion of peptides that cause intestinal secretion. These include vasoactive intestinal polypeptide, gastrin, and peptides with prostaglandin-like immunoreactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cutaneous features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cutaneous manifestations have been described in association with HCC; however, none is specific for the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/22\">",
"     22",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatomyositis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link\">",
"       \"Cutaneous manifestations of internal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pemphigus foliaceus, a superficial blistering disease similar to pemphigus vulgaris except it rarely involves the mucous membranes. Blisters often appear as shallow erosions associated with erythema, scale and crust formation, which may resemble severe seborrheic dermatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19146?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The sign of Leser-Trelat, which refers to the sudden appearance of multiple seborrheic keratoses often with an inflammatory base in association with skin tags and acanthosis nigricans. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link\">",
"       \"Cutaneous manifestations of internal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pityriasis rotunda, which is characterized by multiple, round or oval, sharply demarcated scaling patches.",
"     </li>",
"     <li>",
"      Porphyria cutanea tarda (PCT), in which exposure to the sun",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      minor trauma leads to skin erythema and the development of vesicles and bullae that may become hemorrhagic. Although PCT has been recognized in patients with HCC related to a variety of risk factors, PCT in patients with HCC may be a marker for underlying hepatitis C virus infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30421?source=see_link\">",
"       \"Porphyria cutanea tarda and hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patterns of metastatic spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrahepatic spread is present at the time of diagnosis in only about 5 to 15 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Extrahepatic metastases are more common in patients with advanced stage primary tumors (&gt;5 cm, large vessel vascular invasion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Extrahepatic disease spread is also uncommon as a component of disease recurrence after locoregional therapy (5 to 24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. The most common sites are lung, intra-abdominal lymph nodes, bone, and adrenal gland, in that order. Brain metastases are rare overall (0.2 to 2 percent), although a higher rate has been reported in patients with advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H17#H17\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Molecularly targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perihepatic lymphadenopathy should not be assumed to represent extrahepatic spread. In patients with cirrhosis, benign nodal enlargement is frequent and most often involves the porta hepatis and portacaval space. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Determining the extent of tumor involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the approach to diagnosis of HCC outlined in a consensus statement issued by the American Association for the Study of Liver Diseases (",
"    <a class=\"graphic graphic_algorithm graphicRef76105 \" href=\"mobipreview.htm?22/51/23358\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar guidelines have been issued by the European Society for Gastrointestinal Endoscopy, though they differ in the evaluation of patients with nodules between 1 and 2 cm in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'AASLD guidelines'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13798191\">",
"     'EASL guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The only way to effectively diagnose HCC in a timely fashion is to enter patients who are at high risk for development of this tumor in a regular surveillance program using ultrasound imaging every six months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who are not in a routine surveillance program, the diagnosis of HCC may be first entertained in a patient with underlying liver disease (ie, cirrhosis, chronic viral hepatitis) who develops a rising serum alpha-fetoprotein (AFP) level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/6\">",
"     6",
"    </a>",
"    ]. In such patients, a CT scan of the liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI) study is often the initial diagnostic maneuver. In cirrhotic patients, any dominant solid nodule that is not clearly a hemangioma should be considered a HCC unless proven otherwise (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67676 \" href=\"mobipreview.htm?2/53/2898\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/37\">",
"     37",
"    </a>",
"    ]. If the lesion is hypervascular, has increased T2 signal intensity, demonstrates venous invasion, or is associated with an elevated AFP, the diagnosis is almost certain.",
"   </p>",
"   <p>",
"    If the initial diagnostic imaging study is not definitive, an alternative imaging technique or follow-up imaging may clarify the diagnosis; dysplastic nodules typically remain stable, while an enlarging dominant lesion more likely represents a HCC. Even stable nodules require close follow-up, since livers containing dysplastic nodules are at high risk to develop HCC in the future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/38\">",
"     38",
"    </a>",
"    ]. Molecular genetic studies have shown promise in identifying a molecular signature that can differentiate dysplastic nodules from HCC, but more studies are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For non-cirrhotic patients, the diagnosis of HCC should be considered for any hepatic mass that is not clearly a hemangioma or focal nodular hyperplasia, especially if it is hypervascular. In the absence of specific clues to the diagnosis, biopsy may be appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Percutaneous biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous biopsy should only be performed when diagnostic imaging results are uncertain, and the result would directly have an impact on management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .) Guidelines for the role of a biopsy in establishing the diagnosis of HCC have been proposed in a statement issued by the American Association for the study of Liver Diseases. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'AASLD guidelines'",
"    </a>",
"    below.) In addition, clinical criteria have been developed, which can be used for prioritizing patients with suspected HCC for liver transplantation without confirming the diagnosis with a biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link&amp;anchor=H13#H13\">",
"     \"Model for End-stage Liver Disease (MELD)\", section on 'Patients with hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risks of a biopsy include bleeding, and spread of tumor along the needle track. The reported magnitude of the risk ranges from 1.6 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. A meta-analysis of eight studies estimated that the overall risk was 2.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/48\">",
"     48",
"    </a>",
"    ]. However, some reports have not observed an increased risk of needle tract seeding, or any adverse impact of preoperative FNA on long-term outcome in patients undergoing potentially curative resection of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/40,49,50\">",
"     40,49,50",
"    </a>",
"    ]. Nevertheless, the potential risk of spreading tumor along the biopsy tract should always be considered in the decision to perform a biopsy, especially in patients in whom surgical resection or liver transplantation might be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link\">",
"     \"Liver transplantation for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     AASLD guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for diagnosis of HCC (updated in 2010) have been issued in a",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/HCCUpdate2010.pdf\">",
"     guideline",
"    </a>",
"    from the American Association for the Study of Liver Diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/1\">",
"     1",
"    </a>",
"    ]. The guidelines point out that a mass found incidentally or on screening in the setting of a patient with known hepatitis B or cirrhosis of other etiology is likely to be HCC. The sequence of tests used to establish the diagnosis in such patients should be guided by the size of the lesion (",
"    <a class=\"graphic graphic_algorithm graphicRef76105 \" href=\"mobipreview.htm?22/51/23358\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodules found on ultrasound surveillance that are smaller than 1 cm should be followed with ultrasound at intervals of three to six months. If there has been no growth over a period of up to two years, one can revert to routine surveillance.",
"     </li>",
"     <li>",
"      Lesions larger than 1 cm in diameter should be evaluated with dynamic MRI or multidetector CT. If the appearance is typical for HCC, no further investigation is required. If the characteristics are not typical for HCC (and do not suggest hemangioma), one of two strategies is acceptable: either a second study (CT or MRI, whichever was not performed) or a biopsy.",
"     </li>",
"     <li>",
"      Biopsies of small lesions should be evaluated by expert pathologists. Staining for tumor markers including CD34, CK7, glypican 3, HSP-70 and glutamine synthetase can help characterize lesions that are not clearly HCC on microscopy. If the biopsy is negative for HCC patients should be followed by imaging at three to six month intervals until the nodule either disappears, enlarges, or displays diagnostic characteristics of HCC. If the lesion enlarges but remains atypical for HCC a repeat biopsy is recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some have argued that the data are insufficient to support the use of only one imaging modality for diagnosing HCC in patients with nodules between 1 and 2 cm and that in order to diagnose HCC in such patients, there should be concordant results from multidetector CT and MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, one study of 74 patients with nodules between 1 and 2 cm in size found that CT and MRI were 100 percent specific for HCC or high-grade dysplastic nodules if conclusive findings (ie, arterial enhancement and washout) were present on at least one of the imaging studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/53\">",
"     53",
"    </a>",
"    ]. If just HCC was considered, the specificity was 81 percent. We follow the AASLD guidelines since routinely obtaining a second imaging study in patients with findings suggestive of HCC on the first study may lead to unnecessary expense and radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13798191\">",
"    <span class=\"h2\">",
"     EASL guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"external\" href=\"file://www.easl.eu/assets/application/files/d38c7689f123edf_file.pdf\">",
"     Guidelines",
"    </a>",
"    from 2012 issued by the European Association for the Study of the Liver (EASL) are similar to the AASLD guidelines, though they differ with regard to the interval for obtaining follow-up ultrasounds in patients with small nodules and the number of radiographic tests needed to make a diagnosis for nodules between 1 and 2 cm, reflecting the uncertainty regarding the optimal number of tests for patients with lesions of this size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'AASLD guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For nodules seen on ultrasound that are &lt;1 cm, the EASL guidelines recommend:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat ultrasound at four months. If the nodule grows, additional investigation is required and dictated by the size of the nodule. If the nodule is stable, ultrasound is repeated at four-month intervals for one year, after which time it can be performed every six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For nodules between 1 and 2 cm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain a 4-phase CT scan",
"      <span class=\"nowrap\">",
"       <strong>",
"        and/or",
"       </strong>",
"      </span>",
"      dynamic contrast enhanced MRI. Only one imaging study is recommended in centers of excellence with high-end radiologic equipment. Otherwise, both studies should be obtained.",
"     </li>",
"     <li>",
"      If there are radiologic hallmarks of HCC (arterial hypervascularity and",
"      <span class=\"nowrap\">",
"       venous/late",
"      </span>",
"      phase wash out), then a diagnosis of HCC is made.",
"     </li>",
"     <li>",
"      If the radiologic hallmarks of HCC are not seen, a biopsy should be obtained and assessed by an expert pathologist. If the biopsy results are inconclusive a second biopsy is recommended. If the results are still inconclusive, ultrasound should be repeated at four-month intervals to monitor for growth, with a repeat biopsy if there is growth or changes in the nodule's enhancement pattern.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For nodules &gt;2 cm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain a 4-phase CT scan",
"      <strong>",
"       or",
"      </strong>",
"      dynamic contrast enhanced MRI.",
"     </li>",
"     <li>",
"      If there are radiologic hallmarks of HCC (arterial hypervascularity and",
"      <span class=\"nowrap\">",
"       venous/late",
"      </span>",
"      phase wash out), then a diagnosis of HCC is made.",
"     </li>",
"     <li>",
"      If the radiologic hallmarks of HCC are not seen then a biopsy should be obtained to confirm the diagnosis. If the biopsy results are inconclusive, ultrasound should be repeated at four-month intervals to monitor for growth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While not specifically stated in the EASL guidelines, we will obtain a second biopsy in a patient with a nodule &gt;2 cm who has an inconclusive biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SERUM MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used marker for HCC is the serum AFP concentration. Several other serologic markers (such as des-gamma-carboxy prothrombin) may indicate the presence of HCC, and used alone or in combination with the serum AFP may improve the diagnostic accuracy. Although these other markers are not used in routine clinical practice, they continue to be a topic of investigation. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Other serum markers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Alpha-fetoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-fetoprotein is a glycoprotein that is normally produced during gestation by the fetal liver and yolk sac, the serum concentration of which is often elevated in patients with HCC. Serum levels of AFP do not correlate well with other clinical features of HCC, such as size, stage, or prognosis. Elevated serum AFP occurs in pregnancy (",
"    <a class=\"graphic graphic_figure graphicRef65872 \" href=\"mobipreview.htm?4/36/4686\">",
"     figure 1",
"    </a>",
"    ), with tumors of gonadal origin (both germ cell and non-germ cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/54\">",
"     54",
"    </a>",
"    ]) and in a variety of other malignancies, of which gastric cancer is the most common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=see_link&amp;anchor=H8#H8\">",
"     \"Serum tumor markers in testicular germ cell tumors\", section on 'Alpha fetoprotein'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link&amp;anchor=H7#H7\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated serum AFP may also be seen in patients with chronic liver disease without HCC such as acute or chronic viral hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. AFP may be slightly higher in patients with cirrhosis due to hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/58\">",
"     58",
"    </a>",
"    ]. In one report, serum AFP decreased significantly in patients with cirrhosis from hepatitis C, treated with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rise in serum AFP in a patient with cirrhosis should raise concern that HCC has developed. It is generally accepted that serum levels greater than 500",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    (normal in most laboratories is between 10 and 20",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    in a high-risk patient is diagnostic of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/59\">",
"     59",
"    </a>",
"    ]. However, HCC is often diagnosed at a lower AFP level in patients undergoing screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/56,60\">",
"     56,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all tumors secrete AFP, and serum concentrations are normal in up to 40 percent of small HCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/61\">",
"     61",
"    </a>",
"    ]. Furthermore, an elevated AFP may be more likely in patients with HCC due to viral hepatitis compared to alcoholic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/62\">",
"     62",
"    </a>",
"    ]. In a study of 357 patients with hepatitis C and without HCC, 23 percent had an AFP &gt;10.0",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/63\">",
"     63",
"    </a>",
"    ]. Elevated levels were associated with the presence of stage III or IV fibrosis, an elevated international normalized ratio, and an elevated serum aspartate aminotransferase level.",
"   </p>",
"   <p>",
"    AFP levels are normal in the majority of patients with fibrolamellar carcinoma, a variant of HCC (",
"    <a class=\"graphic graphic_picture graphicRef61794 \" href=\"mobipreview.htm?38/43/39606\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/64\">",
"     64",
"    </a>",
"    ]. Cirrhotics with persistently elevated AFP values have an increased risk of developing HCC compared to those with fluctuating or normal levels (29 versus 13 and 2.4 percent, respectively, in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity, specificity, and predictive value for the serum AFP in the diagnosis of HCC depends upon the characteristics of the population under study, the cutoff value chosen for establishing the diagnosis, and the gold-standard used to confirm the diagnosis. A number of studies have described test characteristics in different settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The following estimates were based upon a cutoff value of &gt;20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    in a systematic review that included five studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sensitivity 41 to 65 percent",
"     </li>",
"     <li>",
"      Specificity 80 to 94 percent",
"     </li>",
"     <li>",
"      Positive likelihood ratio 3.1 to 6.8",
"     </li>",
"     <li>",
"      Negative likelihood ratio 0.4 to 0.6",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two examples (one of which was included in the above study) illustrate the range of findings in the individual reports:",
"   </p>",
"   <p>",
"    One study included 1069 patients who were chronic carriers of hepatitis B who underwent regular screening with a serum AFP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/66\">",
"     66",
"    </a>",
"    ]. Serum AFP was greater than 20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    in 9 of 14 patients with HCC compared to 91 of 964 patients without the tumor, giving an overall sensitivity and specificity of 64 and 91 percent, respectively. However, only 9 of the 100 patients with AFP values greater than 20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    had HCC (positive predictive value 9 percent) even in this population of patients with a high prevalence of HCC (",
"    <a class=\"graphic graphic_table graphicRef77832 \" href=\"mobipreview.htm?7/50/7979\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A case-control study evaluated the diagnostic characteristics of the serum AFP in screening for HCC in patients with different types of chronic liver disease. The following sensitivities and specificities were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AFP cutoff 16",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      (sensitivity 62, specificity 89 percent)",
"     </li>",
"     <li>",
"      AFP cutoff 20",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      (sensitivity 60, specificity 91 percent)",
"     </li>",
"     <li>",
"      AFP cutoff 100",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      (sensitivity 31, specificity 99 percent)",
"     </li>",
"     <li>",
"      AFP cutoff 200",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      (sensitivity 22, specificity 99 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At a prevalence of HCC of 5 percent, a serum AFP of &ge;20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    (the cutoff value the authors considered to be best) had a positive and negative predictive value of 25 and 98 percent, respectively. At a prevalence of 20 percent, these numbers were 61 and 90 percent, respectively. The low positive predictive values observed in both of these studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] (and the test characteristics described in the systematic review above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/68\">",
"     68",
"    </a>",
"    ]) underscore the limitation of using the serum AFP as a screening test for HCC.",
"   </p>",
"   <p>",
"    Despite the issues inherent in using AFP for the diagnosis of HCC, it has emerged as an important prognostic marker, especially in patients undergoing resection and those being considered for liver transplantation. Patients with AFP levels &gt;1000 have an extremely high risk of recurrent disease following transplantation, irrespective of the tumor size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H15#H15\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Outcomes and prognostic factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link&amp;anchor=H969401856#H969401856\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\", section on 'Tumor-related prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71555138\">",
"    <span class=\"h2\">",
"     MicroRNAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma microRNA expression has also been studied as a possible marker of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. One study examined 934 participants who were healthy, had chronic HBV, had cirrhosis, or had HBV-related HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/72\">",
"     72",
"    </a>",
"    ]. A microRNA panel that included miR-122, miR-192, miR-21, miR-223, miR-26a, and miR-801 accurately identified patients with HCC, regardless of the stage of HCC (AUC 0.89 with a sensitivity of 82 percent and a specificity of 84 percent for the validation set). The panel also accurately differentiated patients with HCC from those who were healthy, had chronic HBV, or had cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link&amp;anchor=H5280328#H5280328\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\", section on 'MicroRNA profiling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other serum markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the limitations of serum AFP measurements, several other serum markers of HCC used alone or in combination with the serum AFP have been evaluated for diagnosis or determining prognosis in patients with HCC.",
"   </p>",
"   <p>",
"    As an example, the specific sugar-chain structure of circulating alpha-fetoprotein may be useful for discriminating elevated levels of AFP associated with HCC from those seen in relatively benign liver conditions. One study evaluating this approach compared lectin-reactive profiles (a way of measuring the abnormal AFP) in 33 patients with HCC with 32 cirrhotics without HCC who had elevated serum levels of AFP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/74\">",
"     74",
"    </a>",
"    ]. Lectin-reactive profiles were significantly higher in 73 percent of the patients who had HCC compared to those with cirrhosis alone. Another AFP isoform (the Lens culinaris agglutinin-reactive AFP) has also been studied for diagnosis of HCC but is role remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lens culinaris agglutinin-reactive AFP (AFP-L3) is a fucosylated fraction of AFP that may be a helpful diagnostic and prognostic maker of HCC, particularly in patients with low serum AFP levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. In a study with 270 patients with newly diagnosed HCC and 396 patients with chronic liver disease, all of whom had AFP levels &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    the sensitivity and specificity of a highly sensitive AFP-L3 assay (using a cutoff of &ge;5 percent) for HCC were 42 and 85 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/76\">",
"     76",
"    </a>",
"    ]. In addition, patients with high AFP-L3 levels using the highly sensitive assay had lower survival rates than patients with AFP-L3 levels of less than 5 percent.",
"   </p>",
"   <p>",
"    Des-gamma-carboxy prothrombin (also known as \"prothrombin produced by vitamin K absence or antagonism II\" [PIVKA II]) has also shown promise in the diagnosis of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/82-86\">",
"     82-86",
"    </a>",
"    ]. In one series of 76 patients with HCC, this marker was elevated in 69 with a mean serum concentration of 900",
"    <span class=\"nowrap\">",
"     mcg/L;",
"    </span>",
"    much lower mean values were seen in patients with chronic active hepatitis, metastatic disease to the liver, and normal subjects (10 and 42",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    and undetectable, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/82\">",
"     82",
"    </a>",
"    ]. Elevations in des-gamma-carboxy prothrombin are less frequent in tumors less than 3 cm in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/85,87\">",
"     85,87",
"    </a>",
"    ]. Abnormal prothrombin levels do not correlate well with serum AFP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other markers of HCC that have also been studied include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor-associated isoenzymes of gammaglutamyl transpeptidase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Urinary transforming growth factor-beta-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/89\">",
"       89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Serum levels of circulating intercellular adhesion molecule-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/90\">",
"       90",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Serum alpha-L-fucosidase activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/91\">",
"       91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Glypican-3 (a cell-surface heparan sulfate proteoglycan) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/92\">",
"       92",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dickkopf-1 (DKK1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/93\">",
"       93",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these serum markers is currently recommended for surveillance or diagnosis, although some may be useful for diagnosis of HCC on pathologic specimens such as glypican-3, heat shock protein 70, and glutamine synthetase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The imaging tests most commonly used for the diagnosis of HCC are ultrasound, computed tomography, magnetic resonance imaging, and angiography. Ultrasonography is traditionally used as an imaging study (in conjunction with AFP determination) for screening. A classic appearance on one of these imaging modalities combined with an elevated serum AFP concentration in the appropriate clinical setting is usually sufficient for establishing the diagnosis of HCC.",
"   </p>",
"   <p>",
"    The radiographic appearance of HCC may in part be related to the underlying cause. One study suggested that a nodular appearance was more common in HCC arising in patients with cirrhosis while an infiltrative pattern was more common in patients with chronic hepatitis B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ultrasound cannot distinguish HCC from other solid tumors in the liver, it is widely available, noninvasive, and commonly used for screening patients for HCC. Ultrasonography has the added benefit of assessing patency of the hepatic blood supply and the presence of vascular invasion by the tumor. In addition, ultrasound can be used intraoperatively to detect small tumor nodules during hepatic resection.",
"   </p>",
"   <p>",
"    Sonographic characteristics of a hepatic lesion that are suggestive of HCC include poorly-defined margins and coarse, irregular internal echoes. Small tumors are often hypoechoic. As the tumor grows, the echo pattern tends to become isoechoic or hyperechoic, and HCC can be difficult to distinguish from the surrounding liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/95\">",
"     95",
"    </a>",
"    ]. Visualization may be difficult with lesions under the right hemidiaphragm, with overlying bowel gas, and in obese patients.",
"   </p>",
"   <p>",
"    The accuracy of ultrasound for detecting HCC has been evaluated in several reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/62,66,96-98\">",
"     62,66,96-98",
"    </a>",
"    ]. A systematic review estimated that the sensitivity was 60 percent (95% CI 44-76%) and specificity was 97 percent (95% CI 95-98%) compared with pathologic examination of an explanted or resected liver as the reference standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensitivity is improved when combined with AFP determination. In a large prospective study of noncirrhotic hepatitis B carriers, the sensitivity, specificity, and positive predictive value of ultrasound were 71, 93, and 15 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/66\">",
"     66",
"    </a>",
"    ]. When combined with AFP determination, sensitivity increased to 79 percent. Sensitivity values in other studies have ranged from 78 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/98\">",
"     98",
"    </a>",
"    ] to much lower values of 40 to 50 percent, particularly when the diagnosis is confirmed by examination of autopsy specimens or the resected liver after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New ultrasound technologies, especially the use of ultrasound contrast agents, may improve the accuracy of this modality in the diagnosis of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. However, given the low positive predictive value, a suspicious lesion observed on ultrasound requires additional studies to confirm the diagnosis and stage the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Endoscopic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound with fine needle aspiration biopsy can establish the diagnosis of HCC and has the potential to improve accuracy of staging compared with CT and MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/102\">",
"     102",
"    </a>",
"    ]. Its role in evaluation of patients with suspected HCC is still being determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Abdominal CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) of the liver is often performed to evaluate an abnormality detected on ultrasound (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67676 \" href=\"mobipreview.htm?2/53/2898\">",
"     image 1",
"    </a>",
"    ). In some centers, CT scan is also used a primary screening modality for HCC in patients with cirrhosis. New CT technology has substantially increased its accuracy compared to conventional scanning.",
"   </p>",
"   <p>",
"    Several studies have evaluated test characteristics of CT for diagnosis of HCC. A systematic review estimated that the sensitivity was 68 percent (95% CI 55-80%) and specificity was 93 percent (95% CI 89-96%) compared with pathologic examination of an explanted or resected liver as the reference standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability of CT to detect HCCs has improved with the development of helical CT technology. This technique involves the rapid administration of contrast material in combination with extremely fast imaging. The arterial phase of enhancement allows for detection of hypervascular HCCs as small as 3 mm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73767 \" href=\"mobipreview.htm?29/15/29936\">",
"     image 2",
"    </a>",
"    ). The sensitivity of helical CT for detecting HCC may be as high as 90 percent; however its accuracy has not been confirmed with autopsy studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/103\">",
"     103",
"    </a>",
"    ]. One study found that the degree of vascularity may not be a sufficiently sensitive criterion for accurate diagnosis of small (1 to 2 cm) tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some tumors are isoattenuating on both arterial and portal phase imaging, and may be missed. The addition of delayed phase imaging (triple phase helical CT) may improve detection of these tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/105\">",
"     105",
"    </a>",
"    ]. Greater sensitivity can also be achieved using intra-arterial lipoidal, a contrast agent (sensitivity between 93 and 97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/106\">",
"     106",
"    </a>",
"    ]). However, this technique is not commonly used given the need for intra-arterial injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has the advantage of achieving high resolution images of the liver without the use of nephrotoxic contrast agents or ionizing radiation. MRI has a similar sensitivity for the diagnosis of HCC as helical CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. On MRI, HCC appears as a high intensity pattern on T2-weighted images, and a low intensity pattern on T1-weighted images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75007 \" href=\"mobipreview.htm?35/50/36643\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/95\">",
"     95",
"    </a>",
"    ]. However, MRI has better sensitivity and specificity compared to CT and US in cirrhotic patients in whom it can be difficult to distinguish an HCC from regenerative nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/109\">",
"     109",
"    </a>",
"    ]. A systematic review estimated that the sensitivity was 81 percent (95% CI 70-91%) and specificity was 85 percent (95% CI 77-93%) compared with pathologic examination of an explanted or resected liver as the reference standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/99\">",
"     99",
"    </a>",
"    ]. The sensitivity may be higher when used in conjunction with ultrasound. In a study of patients with known HCC, the combination of MRI and ultrasound detected 85 of 87 HCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/110\">",
"     110",
"    </a>",
"    ]. The sensitivity also appears to be increased when gadoxetic acid-enhanced and diffusion-weighted imaging are combined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. In a study of 130 patients with small (&le;2.0 cm) HCCs and 130 patients with cirrhosis without HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/111\">",
"     111",
"    </a>",
"    ], the sensitivity of the combined approach was 91 to 93 percent, compared with 81 to 82 percent for gadoxetic acid-enhanced imaging and 78 to 80 percent for diffusion-weighted imaging alone. The specificity did not differ among the groups.",
"   </p>",
"   <p>",
"    Certain contrast agents used for MRI (such as gadolinium) can cause nephrogenic systemic",
"    <span class=\"nowrap\">",
"     fibrosis/nephrogenic",
"    </span>",
"    fibrosing dermopathy in individuals with advanced renal failure and thus alternatives should be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28054?source=see_link\">",
"     \"Magnetic resonance imaging of the hepatobiliary tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A newer technique (MRI angiography) permits acquisition of a three-dimensional data set within a single breath-hold, incorporating arterial, portal venous and late venous phases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/113\">",
"     113",
"    </a>",
"    ]. A study comparing this technique to triphasic CT (in which pathologic examination of the explanted liver represented the gold standard) found that it had higher sensitivity for HCC nodules that were &ge;10 mm (76 versus 61 percent).",
"   </p>",
"   <p>",
"    Helical CT scanning remains the favored technique by most radiologists because of the high cost of MRI, and the long duration required to obtain standard MRI images. The role of MRI angiography is still being determined. MRI may be useful in patients with renal insufficiency or those with an allergy to CT contrast dye (agents). MRI may also be beneficial in cases in which CT results are ambiguous, particularly when the liver is extremely nodular since MRI can differentiate dysplastic nodules from HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/109,114\">",
"     109,114",
"    </a>",
"    ]. MRI may also be superior to CT scan in distinguishing vascular lesions (such as a hemangioma) and focal fat from HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The less invasive techniques discussed above have replaced conventional angiography for the diagnosis of HCC. However, angiography continues to be used during chemoembolization of tumors and to control bleeding from ruptured HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     CT hepatic arteriography and arterial portography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography can be combined with CT or MRI scanning to improve the detection and characterization of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/115-119\">",
"     115-119",
"    </a>",
"    ]. The technique involves injection of contrast dye intra-arterially (usually in the superior mesenteric, hepatic, or splenic artery) immediately prior to CT or MRI, and obtaining images during the arterial and portal venous phases. This technique has been used for preoperative evaluation of HCC, although it is uncommonly used in the United States. The benefit of CT hepatic arteriography and arterial portography compared to MRI is unclear since it is invasive and does not appear to be more accurate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Experimental imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited experience with a technetium-99m (99mTc)-labeled anti-alpha-fetoprotein (AFP) Fab' imaging kit suggests that it may have a role in the detection of HCC. A study evaluating the accuracy of the kit in 25 patients with suspected HCC demonstrated detection of the tumor in 20 patients, exclusion in four (confirmed by CT and biopsy), and a false negative result in one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET scanning) has been suggested for detection of primary HCCs, tumor staging, assessing response to therapy, and for predicting prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/27,122-125\">",
"     27,122-125",
"    </a>",
"    ]. However, the place of PET in the diagnostic and staging evaluation of HCC remains uncertain.",
"   </p>",
"   <p>",
"    HCCs accumulate FDG to varying degrees, limiting the sensitivity of PET for primary tumors. Only 55 to 65 percent of tumors are positive by PET scanning, with high grade tumors generally having greater FDG avidity (as assessed by higher standardized uptake values, SUV) than lower grade lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/126-128\">",
"     126-128",
"    </a>",
"    ]. This variability limits the utility of PET scanning for diagnostic purposes.",
"   </p>",
"   <p>",
"    The ability of PET to distinguish benign from malignant liver lesions is also limited by false negative and false positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/123,126,129,130\">",
"     123,126,129,130",
"    </a>",
"    ]. A new tracer, [11C] acetate, may improve sensitivity and specificity when used in conjunction with (18)F-FDG PET, but is not yet commercially available in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Detection of extrahepatic metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;As has been observed in other solid tumors, PET has a greater sensitivity for detection of distant metastases than other imaging modalities, including CT scan, bone scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/132\">",
"     132",
"    </a>",
"    ], and MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/27,128\">",
"     27,128",
"    </a>",
"    ]. However, sensitivity is limited for lesions &le;1 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/132,133\">",
"     132,133",
"    </a>",
"    ] and false positive results are also problematic.",
"   </p>",
"   <p>",
"    In the largest series, 87 patients with newly diagnosed HCC underwent CT or MRI of the abdomen and chest x-ray followed by whole body PET scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/27\">",
"     27",
"    </a>",
"    ]. Extrahepatic metastases were confirmed in 24 patients by subsequent radiologic or clinical follow-up. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 22 patients with a suspicious pulmonary lesion on chest x-ray or abdominal CT, 19 had positive FDG uptake, 7 of which were false positives. Of the 65 patients who were not suspected of having lung metastases by conventional imaging, five had false-positive FDG uptake. The sensitivity and specificity of FDG for detection of lung metastases were 100 and 84 percent, respectively.",
"     </li>",
"     <li>",
"      Sixteen patients were suspected of having lymph node metastases based upon CT-defined size criteria; 15 were positive on PET (all true-positives), and one FDG-negative cases was a true negative. In addition, eight of the 71 patients with negative lymph nodes by CT had positive FDG uptake; four were true-positives. The sensitivity and specificity of PET for detection of lymph node metastases were 100 and 94 percent, respectively.",
"     </li>",
"     <li>",
"      Bone metastases were confirmed in 11 patients, all of whom had positive PET scans. However, the use of abdominal CT alone as the conventional imaging modality to detect bone metastases (rather than whole body radionuclide bone scan) limits the interpretation of the sensitivity and specificity data.",
"     </li>",
"     <li>",
"      As a result of adding PET to the initial staging evaluation, the initial TNM stage was increased in only 4 of 87 patients (4.6 percent), three because of the detection of distant lymph node or bone metastases. In contrast, 12 patients were falsely believed to have lung metastases, and four were thought to harbor lymph node metastases, which probably represented reactive adenopathy (although histologic confirmation was not reported).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until further data are available, the role of PET scanning in the evaluation of patients with HCC remains uncertain. Guidelines from the National Comprehensive Cancer Network do not endorse the use of PET for initial staging or restaging at the time of a suspected recurrence of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/134\">",
"     134",
"    </a>",
"    ]. In addition, HCC is not a reimbursable diagnosis for PET scanning in the United States Medicare program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15959347\">",
"    <span class=\"h2\">",
"     Chest CT and bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent sites of extrahepatic disease spread are the lungs, abdominal lymph nodes, and bones, in that order. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Patterns of metastatic spread'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, the rate of extrahepatic spread is low overall (with the possible exception of tumors &gt;5 cm), and the yield of routine chest CT and bone scan for detecting extrahepatic disease is also low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/135-137\">",
"     135-137",
"    </a>",
"    ]. The value of chest CT and bone scan in the staging workup of HCC was addressed in a prospective cohort of 381 patients newly diagnosed with HCC at a single Korean institution over a three-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/137\">",
"     137",
"    </a>",
"    ]. All patients underwent liver-dynamic CT and chest x-ray followed by chest CT and radionuclide bone scan. Abnormal findings on chest CT and bone scan were observed in 60 and 53 percent of the 381 patients, respectively. However, 19 of the 30, and 7 of the 8 patients with documented metastatic disease in the chest or bones, respectively, had the same lesions detected on CT or chest x-ray. Only three patients showed a shift in Barcelona Clinic Liver Cancer (BCLC) stage (from B [localized disease] to C [extrahepatic disease spread],",
"    <span class=\"nowrap\">",
"     3/61",
"    </span>",
"    patients or 5 percent of those with BCLC stage B disease), and additional metastases were revealed in only 1.1, 14, and 5.6 percent of patients with AJCC stage T2, T3a, and T3b (",
"    <a class=\"graphic graphic_table graphicRef63333 \" href=\"mobipreview.htm?1/45/1757\">",
"     table 1",
"    </a>",
"    ) disease, respectively. These data support the view that staging chest CT and bone scans do not provide additional information on metastases in patients who have localized HCC, especially those who fulfill the Milan criteria for transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H9#H9\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Requirements for listing and management while on the wait list'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, revised 2010 guidelines from the",
"    <a class=\"external\" href=\"file://www.unos.org/\">",
"     United Network for Organ Sharing (UNOS)",
"    </a>",
"    still recommend chest CT (but not bone scan, a change from the 1998 recommendation) to detect metastases in patients being considered for liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H713421#H713421\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'United States'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, a biopsy under ultrasound or CT guidance can be helpful in patients with a focal liver lesion in whom the diagnosis is uncertain when the results would influence management. Directed core biopsies are more useful than fine needle biopsy because of the increased amount of tissue obtained and the ability to obtain uninvolved hepatic parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/138\">",
"     138",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histologic appearance of HCC can range from well-differentiated (with individual hepatocytes appearing nearly identical to normal hepatocytes) to poorly differentiated lesions consisting of large multinucleate anaplastic tumor giant cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/92\">",
"     92",
"    </a>",
"    ]. Central necrosis of large tumors is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/10/34986/abstract/139\">",
"     139",
"    </a>",
"    ]. Bile globules and acidophilic inclusions are occasionally present.",
"   </p>",
"   <p>",
"    In some cases, dysplasia rather than carcinoma is diagnosed. There is an ongoing debate about the usefulness of various grades of dysplasia in predicting the ultimate development of HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SCREENING AND SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to surveillance for HCC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recall policies in patients with lesions detected during surveillance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Evaluation of nodules discovered on ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=see_link\">",
"       \"Patient information: Liver cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17359244\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who develop hepatocellular carcinoma (HCC) usually have no symptoms other than those related to their chronic liver disease. Suspicion for HCC should be heightened in patients with previously compensated cirrhosis who develop decompensation such as ascites, encephalopathy, jaundice, or variceal bleeding. Some patients may have mild to moderate upper abdominal pain, weight loss, early satiety, or a palpable mass in the upper abdomen, symptoms that often indicate an advanced lesion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with HCC occasionally develop a paraneoplastic syndrome that can manifest as hypoglycemia, erythrocytosis, hypercalcemia, or severe watery diarrhea. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Paraneoplastic syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical findings in most patients with HCC (splenomegaly, ascites, jaundice, or other manifestations of decompensated cirrhosis) reflect the underlying liver disease. Hepatomegaly or a bruit heard over the liver are occasionally present. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory examination is usually nonspecific. The majority of patients who develop HCC have cirrhosis and may have thrombocytopenia, hypoalbuminemia, hyperbilirubinemia, and hypoprothrombinemia. Patients are often mildly anemic and may have electrolyte disturbances (eg, hyponatremia, hypokalemia, metabolic alkalosis) associated with defective water handling or with diuretic use. Serum aminotransferases, alkaline phosphatase and gamma glutamyl transpeptidase are often abnormal in a nonspecific pattern. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only way to effectively diagnose HCC in a timely fashion is to enter patients who are at high risk for development of this tumor in a regular surveillance program using ultrasound imaging every six months. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=see_link\">",
"       \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are not in a routine surveillance program, the diagnosis of HCC may be first entertained in a patient with underlying liver disease who develops a rising serum alpha-fetoprotein (AFP) level. In such patients, a computed tomographic scan of the liver",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      magnetic resonance imaging (MRI) study is often the initial diagnostic maneuver. In cirrhotic patients, any dominant solid nodule that is not clearly a hemangioma should be considered a HCC unless proven otherwise (",
"      <a class=\"graphic graphic_algorithm graphicRef76105 \" href=\"mobipreview.htm?22/51/23358\">",
"       algorithm 1",
"      </a>",
"      ). If the lesion is hypervascular, has increased T2 signal intensity, demonstrates venous invasion, or is associated with an elevated AFP, the diagnosis is almost certain. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the initial diagnostic imaging study is not definitive, an alternative imaging technique or follow-up imaging may clarify the diagnosis; dysplastic nodules typically remain stable, while an enlarging dominant lesion more likely represents a HCC. Even stable nodules require close follow-up since livers containing dysplastic nodules are at high risk to develop HCC in the future. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For non-cirrhotic patients, the diagnosis of HCC should be considered for any hepatic mass that is not clearly a hemangioma or focal nodular hyperplasia, especially if it is hypervascular. In the absence of specific clues to the diagnosis, biopsy may be appropriate. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/1\">",
"      Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/2\">",
"      Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/3\">",
"      Kew MC, Dos Santos HA, Sherlock S. Diagnosis of primary cancer of the liver. Br Med J 1971; 4:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/4\">",
"      Schwartz JM, Larson AM, Gold PJ, et al. Hepatocellular carcinoma: A one year experience at a tertiary referral center in the United States (abstract). Hepatology 1999; 30:278A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/5\">",
"      A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/6\">",
"      Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/7\">",
"      Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/8\">",
"      Sugano S, Miyoshi K, Suzuki T, et al. Intrahepatic arteriovenous shunting due to hepatocellular carcinoma and cirrhosis, and its change by transcatheter arterial embolization. Am J Gastroenterol 1994; 89:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/9\">",
"      Bruix J, Castells A, Calvet X, et al. Diarrhea as a presenting symptom of hepatocellular carcinoma. Dig Dis Sci 1990; 35:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/10\">",
"      Choi BG, Park SH, Byun JY, et al. The findings of ruptured hepatocellular carcinoma on helical CT. Br J Radiol 2001; 74:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/11\">",
"      Chearanai O, Plengvanit U, Asavanich C, et al. Spontaneous rupture of primary hepatoma: report of 63 cases with particular reference to the pathogenesis and rationale treatment by hepatic artery ligation. Cancer 1983; 51:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/12\">",
"      Lin YT, Liu CJ, Chen TJ, et al. Pyogenic liver abscess as the initial manifestation of underlying hepatocellular carcinoma. Am J Med 2011; 124:1158.",
"     </a>",
"    </li>",
"    <li>",
"     Kew MC. Tumors of the liver. In: Hepatology: A textbook of liver disease, Zakim D, Boyer T (Eds), WB Saunders Company, Philadelphia 1996. p.1513.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/14\">",
"      Lai CL, Ng RP, Lok AS. The diagnostic value of the ratio of serum gamma-glutamyl transpeptidase to alkaline phosphatase in alcoholic liver disease. Scand J Gastroenterol 1982; 17:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/15\">",
"      Eastman RC, Carson RE, Orloff DG, et al. Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. J Clin Invest 1992; 89:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/16\">",
"      Tietge UJ, Sch&ouml;fl C, Ocran KW, et al. Hepatoma with severe non-islet cell tumor hypoglycemia. Am J Gastroenterol 1998; 93:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/17\">",
"      Kew MC, Fisher JW. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 1986; 58:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/18\">",
"      Sakisaka S, Watanabe M, Tateishi H, et al. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology 1993; 18:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/19\">",
"      Knill-Jones RP, Buckle RM, Parsons V, et al. Hypercalcemia and increased parathyroid-hormone activity in a primary hepatoma. Studies before and after hepatic transplantation. N Engl J Med 1970; 282:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/20\">",
"      Yen TC, Hwang SJ, Wang CC, et al. Hypercalcemia and parathyroid hormone-related protein in hepatocellular carcinoma. Liver 1993; 13:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/21\">",
"      Steiner E, Velt P, Gutierrez O, et al. Hepatocellular carcinoma presenting with intractable diarrhea. A radiologic-pathologic correlation. Arch Surg 1986; 121:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/22\">",
"      Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992; 26:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/23\">",
"      Lim HW, Mascaro JM. The porphyrias and hepatocellular carcinoma. Dermatol Clin 1995; 13:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/24\">",
"      Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/25\">",
"      Yoo DJ, Kim KM, Jin YJ, et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol 2011; 26:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/26\">",
"      Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000; 216:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/27\">",
"      Yoon KT, Kim JK, Kim do Y, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007; 72 Suppl 1:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/28\">",
"      Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990; 66:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/29\">",
"      Yi J, Gwak GY, Sinn DH, et al. Screening for Extrahepatic Metastases by Additional Staging Modalities is Required for Hepatocellular Carcinoma Patients Beyond Modified UICC Stage T1. Hepatogastroenterology 2012; 60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/30\">",
"      Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007; 141:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/31\">",
"      Aramaki M, Kawano K, Kai T, et al. Treatment for extrahepatic metastasis of hepatocellular carcinoma following successful hepatic resection. Hepatogastroenterology 1999; 46:2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/32\">",
"      Tonolini M, Solbiati L, Ierace T, et al. Extrahepatic recurrence and second malignancies after treatment of hepatocellular carcinoma: spectrum of imaging findings. Radiol Med 2002; 103:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/33\">",
"      Senthilnathan S, Memon K, Lewandowski RJ, et al. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology 2012; 55:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/34\">",
"      Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2009; 91:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/35\">",
"      Shao YY, Lu LC, Cheng AL, Hsu CH. Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. Oncologist 2011; 16:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/36\">",
"      European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/37\">",
"      Gogel BM, Goldstein RM, Kuhn JA, et al. Diagnostic evaluation of hepatocellular carcinoma in a cirrhotic liver. Oncology (Williston Park) 2000; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/38\">",
"      Borzio M, Fargion S, Borzio F, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/39\">",
"      Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/40\">",
"      Bialecki ES, Ezenekwe AM, Brunt EM, et al. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/41\">",
"      Crippin JS. Biopsy of suspicious liver nodules: does it change management? Clin Gastroenterol Hepatol 2006; 4:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/42\">",
"      Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/43\">",
"      John TG, Garden OJ. Needle track seeding of primary and secondary liver carcinoma after percutaneous liver biopsy. HPB Surg 1993; 6:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/44\">",
"      Durand F, Regimbeau JM, Belghiti J, et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001; 35:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/45\">",
"      Huang GT, Sheu JC, Yang PM, et al. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma--a study based on 420 patients. J Hepatol 1996; 25:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/46\">",
"      Kim SH, Lim HK, Lee WJ, et al. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging 2000; 25:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/47\">",
"      Ohlsson B, Nilsson J, Stenram U, et al. Percutaneous fine-needle aspiration cytology in the diagnosis and management of liver tumours. Br J Surg 2002; 89:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/48\">",
"      Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/49\">",
"      Ng KK, Poon RT, Lo CM, et al. Impact of preoperative fine-needle aspiration cytologic examination on clinical outcome in patients with hepatocellular carcinoma in a tertiary referral center. Arch Surg 2004; 139:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/50\">",
"      Liu YW, Chen CL, Chen YS, et al. Needle tract implantation of hepatocellular carcinoma after fine needle biopsy. Dig Dis Sci 2007; 52:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/51\">",
"      El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/52\">",
"      Yeh JJ, Uemura M. Hepatocellular carcinoma. N Engl J Med 2012; 366:92; author reply 92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/53\">",
"      Serst&eacute; T, Barrau V, Ozenne V, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology 2012; 55:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/54\">",
"      El-Bahrawy M. Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract. Eur J Cancer 2010; 46:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/55\">",
"      Liu X, Cheng Y, Sheng W, et al. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol 2010; 102:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/56\">",
"      Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/57\">",
"      Sterling RK, Wright EC, Morgan TR, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/58\">",
"      Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/59\">",
"      Wu JT. Serum alpha-fetoprotein and its lectin reactivity in liver diseases: a review. Ann Clin Lab Sci 1990; 20:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/60\">",
"      Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/61\">",
"      Chen DS, Sung JL, Sheu JC, et al. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/62\">",
"      Fasani P, Sangiovanni A, De Fazio C, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999; 29:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/63\">",
"      Hu KQ, Kyulo NL, Lim N, et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004; 99:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/64\">",
"      Soreide O, Czerniak A, Bradpiece H, et al. Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. Am J Surg 1986; 151:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/65\">",
"      Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/66\">",
"      Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/67\">",
"      Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/68\">",
"      Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/69\">",
"      Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/70\">",
"      Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/71\">",
"      Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/72\">",
"      Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29:4781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/73\">",
"      Li L, Guo Z, Wang J, et al. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 2012; 57:2910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/74\">",
"      Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993; 328:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/75\">",
"      Leerapun A, Suravarapu SV, Bida JP, et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007; 5:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/76\">",
"      Toyoda H, Kumada T, Tada T, et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein &lt;20 ng/mL. Cancer Sci 2011; 102:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/77\">",
"      Oda K, Ido A, Tamai T, et al. Highly sensitive lens culinaris agglutinin-reactive &alpha;-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease. Oncol Rep 2011; 26:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/78\">",
"      Morimoto M, Numata K, Nozaki A, et al. Novel Lens culinaris agglutinin-reactive fraction of &alpha;-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low &alpha;-fetoprotein concentrations. Int J Clin Oncol 2012; 17:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/79\">",
"      Kumada T, Toyoda H, Kiriyama S, et al. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol 2011; 46:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/80\">",
"      Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010; 45:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/81\">",
"      Sterling RK, Jeffers L, Gordon F, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009; 7:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/82\">",
"      Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/83\">",
"      Nomura F, Ishijima M, Horikoshi A, et al. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996; 91:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/84\">",
"      Aoyagi Y, Oguro M, Yanagi M, et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/85\">",
"      Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/86\">",
"      Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/87\">",
"      Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/88\">",
"      Kew MC, Wolf P, Whittaker D, Rowe P. Tumour-associated isoenzymes of gamma-glutamyl transferase in the serum of patients with hepatocellular carcinoma. Br J Cancer 1984; 50:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/89\">",
"      Tsai JF, Jeng JE, Chuang LY, et al. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer 1997; 75:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/90\">",
"      Hamazaki K, Gochi A, Shimamura H, et al. Serum levels of circulating intercellular adhesion molecule 1 in hepatocellular carcinoma. Hepatogastroenterology 1996; 43:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/91\">",
"      Takahashi H, Saibara T, Iwamura S, et al. Serum alpha-L-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology 1994; 19:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/92\">",
"      International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/93\">",
"      Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012; 13:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/94\">",
"      Benvegn&ugrave; L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/95\">",
"      Ishiguchi T, Shimamoto K, Fukatsu H, et al. Radiologic diagnosis of hepatocellular carcinoma. Semin Surg Oncol 1996; 12:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/96\">",
"      Larcos G, Sorokopud H, Berry G, Farrell GC. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol 1998; 171:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/97\">",
"      Dodd GD 3rd, Miller WJ, Baron RL, et al. Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. AJR Am J Roentgenol 1992; 159:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/98\">",
"      Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/99\">",
"      Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/100\">",
"      Whittingham TA. New and future developments in ultrasonic imaging. Br J Radiol 1997; 70 Spec No:S119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/101\">",
"      Hayakawa S, Goto H, Hirooka Y, et al. A new ultrasound imaging method in the abdominal area: Harmonic imaging without an enhancing agent (abstract). Gastroenterology 1998; 114:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/102\">",
"      Singh P, Erickson RA, Mukhopadhyay P, et al. EUS for detection of the hepatocellular carcinoma: results of a prospective study. Gastrointest Endosc 2007; 66:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/103\">",
"      Hollett MD, Jeffrey RB Jr, Nino-Murcia M, et al. Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (&lt; or = 1.5 cm) malignant hepatic neoplasms. AJR Am J Roentgenol 1995; 164:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/104\">",
"      Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/105\">",
"      Lim JH, Choi D, Kim SH, et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol 2002; 179:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/106\">",
"      Ngan H. Lipiodol computerized tomography: how sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? Br J Radiol 1990; 63:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/107\">",
"      Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. AJR Am J Roentgenol 2003; 180:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/108\">",
"      Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/109\">",
"      Libbrecht L, Bielen D, Verslype C, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/110\">",
"      Kunishi Y, Numata K, Morimoto M, et al. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol 2012; 198:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/111\">",
"      Park MJ, Kim YK, Lee MW, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012; 264:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/112\">",
"      Granito A, Galassi M, Piscaglia F, et al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2013; 37:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/113\">",
"      Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/114\">",
"      Lencioni R, Mascalchi M, Caramella D, Bartolozzi C. Small hepatocellular carcinoma: differentiation from adenomatous hyperplasia with color Doppler US and dynamic Gd-DTPA-enhanced MR imaging. Abdom Imaging 1996; 21:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/115\">",
"      Heiken JP, Weyman PJ, Lee JK, et al. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989; 171:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/116\">",
"      Yu JS, Kim KW, Lee JT, Yoo HS. MR imaging during arterial portography for assessment of hepatocellular carcinoma: comparison with CT during arterial portography. AJR Am J Roentgenol 1998; 170:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/117\">",
"      Kanematsu M, Hoshi H, Murakami T, et al. Detection of hepatocellular carcinoma in patients with cirrhosis: MR imaging versus angiographically assisted helical CT. AJR Am J Roentgenol 1997; 169:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/118\">",
"      Murakami T, Oi H, Hori M, et al. Helical CT during arterial portography and hepatic arteriography for detecting hypervascular hepatocellular carcinoma. AJR Am J Roentgenol 1997; 169:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/119\">",
"      Kanematsu M, Hoshi H, Imaeda T, et al. Detection and characterization of hepatic tumors: value of combined helical CT hepatic arteriography and CT during arterial portography. AJR Am J Roentgenol 1997; 168:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/120\">",
"      Choi D, Kim S, Lim J, et al. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced mr imaging versus combined helical CT during arterial portography and CT hepatic arteriography. AJR Am J Roentgenol 2001; 176:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/121\">",
"      Dresel S, Kirsch CM, Tatsch K, et al. Detection of hepatocellular carcinoma with a new alpha-fetoprotein antibody imaging kit. J Clin Oncol 1997; 15:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/122\">",
"      Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001; 96:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/123\">",
"      Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000; 14:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/124\">",
"      Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007; 13:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/125\">",
"      Yang SH, Suh KS, Lee HW, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006; 12:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/126\">",
"      Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/127\">",
"      Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94:3314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/128\">",
"      Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/129\">",
"      Jeng LB, Changlai SP, Shen YY, et al. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology 2003; 50:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/130\">",
"      Schr&ouml;der O, Trojan J, Zeuzem S, Baum RP. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998; 37:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/131\">",
"      Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/132\">",
"      Kim YK, Lee KW, Cho SY, et al. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 2010; 16:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/133\">",
"      Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004; 39:961.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/135\">",
"      Koneru B, Teperman LW, Manzarbeitia C, et al. A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma. Ann Surg 2005; 241:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/136\">",
"      Sheth H, Javed SS, Hilson AJ, et al. Radioisotope bone scans in the preoperative staging of hepatopancreatobiliary cancer. Br J Surg 2005; 92:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/137\">",
"      Jin YJ, Lee HC, Lee D, et al. Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma. J Hepatol 2012; 56:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/10/34986/abstract/138\">",
"      Bru C, Maroto A, Bruix J, et al. Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. Dig Dis Sci 1989; 34:1765.",
"     </a>",
"    </li>",
"    <li>",
"     Robbins S, Kumar V. Basic Pathology, 4th, WB Saunders, Philadelphia 1987. p.598.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3597 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34986=[""].join("\n");
var outline_f34_10_34986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17359244\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Erythrocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Watery diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cutaneous features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patterns of metastatic spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Percutaneous biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      AASLD guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13798191\">",
"      EASL guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SERUM MARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Alpha-fetoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71555138\">",
"      MicroRNAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other serum markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Endoscopic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Abdominal CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CT hepatic arteriography and arterial portography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Experimental imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PET scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Detection of extrahepatic metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15959347\">",
"      Chest CT and bone scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SCREENING AND SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17359244\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3597|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/51/23358\" title=\"algorithm 1\">",
"      Diagnostic algorithm for HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3597|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/53/2898\" title=\"diagnostic image 1\">",
"      Hepatoma in cirrhosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/15/29936\" title=\"diagnostic image 2\">",
"      Triple phase CT HCC diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/50/36643\" title=\"diagnostic image 3\">",
"      MRI hepatocellular CA diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3597|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/36/4686\" title=\"figure 1\">",
"      MSAFP by gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3597|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/43/39606\" title=\"picture 1\">",
"      Fibrolamellar carcinoma Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/45/1757\" title=\"table 1\">",
"      TNM staging HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/50/7979\" title=\"table 2\">",
"      Sensitivity specificity PPV NPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36888?source=related_link\">",
"      Approach to the patient with a focal liver lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24777?source=related_link\">",
"      Diagnostic approach to the patient with polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28054?source=related_link\">",
"      Magnetic resonance imaging of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=related_link\">",
"      Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=related_link\">",
"      Overview of treatment approaches for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30421?source=related_link\">",
"      Porphyria cutanea tarda and hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25992?source=related_link\">",
"      Staging and prognostic factors in hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_10_34987="TEE aortic rupture v dissection";
var content_f34_10_34987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography criteria for distinguishing aortic rupture and dissection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aortic rupture",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aortic Dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Size/contour",
"       </td>",
"       <td>",
"        &rarr; or &uarr; / asymmetric",
"       </td>",
"       <td>",
"        &uarr; / symmetric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraluminal flap",
"       </td>",
"       <td>",
"        Thick (\"medial flap\")",
"       </td>",
"       <td>",
"        Thin (\"intimal flap\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Entry tear",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Frequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombus",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes (false lumen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Blood flow velocity (color Doppler)",
"       </td>",
"       <td>",
"        Similar",
"       </td>",
"       <td>",
"        Different (slower in the false lumen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aliasing (mosaic of colors)",
"       </td>",
"       <td>",
"        Yes (surrounding the torn aortic wall)",
"       </td>",
"       <td>",
"        Unusual (near an intimal tear)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spatial extension",
"       </td>",
"       <td>",
"        Limited (aortic isthmus)",
"       </td>",
"       <td>",
"        Variable (anatomical type)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemomediastinum",
"       </td>",
"       <td>",
"        Frequent (large)",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34987=[""].join("\n");
var outline_f34_10_34987=null;
var title_f34_10_34988="Summary ACIP recs IV";
var content_f34_10_34988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of ACIP recommendations on use of immune globulins in immune compromised persons",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Immune globulin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Not immunocompromised",
"       </td>",
"       <td class=\"subtitle1\">",
"        HIV infected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severely immunocompromised*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Immune globulin",
"       </td>",
"       <td rowspan=\"2\">",
"        Recommended for infants and adults with contraindication to measles vaccine exposed to measles",
"       </td>",
"       <td>",
"        Recommended for symptomatic patients regardless of immunization status",
"       </td>",
"       <td rowspan=\"2\">",
"        Recommended for patients exposed to measles regardless of immunization status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recommended for persons with exposure to hepatitis A or who will travel to HAV-endemic areas",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Varicella zoster immune globulin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Recommended for newborns of mothers who develop chicken pox within 5 days before and 48 hours after delivery",
"       </td>",
"       <td rowspan=\"4\">",
"        Recommended for susceptible infants and adults after significant exposure to V-Z",
"       </td>",
"       <td rowspan=\"4\">",
"        Recommended for susceptible infants and adults after significant exposure to V-Z",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recommended for exposed newborns (&lt;28 weeks gestation of susceptible mothers)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recommended for exposed pre-term infants &lt;28 weeks or &lt;1000 gm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May be used for exposed, susceptible adults, exposed pregnant women and infants &lt;28 days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Tetanus IG",
"       </td>",
"       <td>",
"        Recommended for those with serious wounds and &lt;3 doses of tetanus toxoid",
"       </td>",
"       <td>",
"        Same as for non-immunocompromised",
"       </td>",
"       <td>",
"        Same as for non-immunocompromised",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hepatitis B IG",
"       </td>",
"       <td>",
"        Recommended for prophylaxis of infants born to HBsAg+ mothers and persons with percutaneous, sexual, or mucosal exposure to HB virus",
"       </td>",
"       <td>",
"        Same as for non-immunocompromised",
"       </td>",
"       <td>",
"        Same as for non-immunocompromised",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Rabies IG",
"       </td>",
"       <td>",
"        Recommended for post- exposure prophylaxis of persons not previously vaccinated against rabies",
"       </td>",
"       <td>",
"        Same as for non-immunocompromised",
"       </td>",
"       <td>",
"        Same as for non-immunocompromised",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Severe immunosuppression can be the result of congenital immunodeficiency, HIV infection, leukemia, lymphoma, aplastic anemia, generalized malignancy or therapy with alkylating agents, antimetabolites, radiation, or large amounts of corticosteroids.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     VZIG is no longer available. VariZIG became available in 2006.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: CDC. Recommendations of the advisory committee on immunization practices (ACIP): use of vaccines and immune globulins for persons with altered immune competence. MMWR 2006; 55RR15:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34988=[""].join("\n");
var outline_f34_10_34988=null;
var title_f34_10_34989="Duke Treadmill Score and survival";
var content_f34_10_34989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Duke treadmill score predicts survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a group of 2758 consecutive patients undergoing ECG exercise testing (70 percent male), the prognosis was related to the risk category which was established by Duke treadmill score based upon exercise duration, the degree of ST segment depression, and the presence and severity of angina. The five year survival was 65 percent in high risk patients with a score of &le;-11 compared with a survival of 90 percent in moderate risk patients with a score of -10 to +4 and over 97 percent in low risk patients with a score of &ge;+5 (p&lt;0.00001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Shaw, LJ, Peterson, ED, Shaw, LK, et al. Circulation 1998; 98:1622.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34989=[""].join("\n");
var outline_f34_10_34989=null;
var title_f34_10_34990="Treatment of ascites refractory to first-line treatment";
var content_f34_10_34990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for treatment of ascites that seems refractory to first-line treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARB: angiotensin II receptor blockers; ACEi: Angiotensin converting enzyme inhibitors; NSAIDs: nonsteroidal anti-inflammatory drugs; TIPS: transjugular intrahepatic porto-systemic shunt.",
"     <br>",
"      * Initiate midodrine at 5 mg orally three times per day. Increase the dose, by increments of 2.5 mg each dose, as needed every 24 hours to a maximum of&nbsp;17.5 mg three times per day to achieve an increase in standing systolic blood pressure of approximately 10 to 15 mmHg, one to two hours after a dose.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34990=[""].join("\n");
var outline_f34_10_34990=null;
var title_f34_10_34991="Fusion of sacroiliac joints AS";
var content_f34_10_34991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusion of sacroiliac joints in AS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADpAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5k/75/HinY/Clx9MUbfQnHrQAg56c/WlA6Dil9OeKUDPWgBMfX6UoGaeFzwKmjiJIwPxoAiSPPJFWreHLLwSc1ctLAz7QF5PNalrZxo4R8EkjBoAtaTbqykttk9CV6H0rVtrSQyYKKcg49xjvU2l2o3YX5OcLx3ro4rPAA6MAcgD2/wD10wOG+yBWZSpVQQQyjp9a1YrOG4gNvdKZLbOCT1X3HoasPCdxIHyg4HvWtY2reUvy9sg+lAHIah4Vmsv3to4lgP3W/ofeqtrI+4xyKBIg/iGMV6UtvNGu3CshHzK3p3rJ1DQIXmBPcZimAz+B9RRYRj2qKQoJ5xViZVTaTz05xT1tZbKURXMLKe3PB+h70k4LSBFicn86Bm/oMJup1js4i8/U7j8ijufrXe6Ho92J8NwuQQwGc1i/Du1SOUxkDeQSxJ68dK9U062aGFSo5bvTEWtOsYBCGaItIO5Xv9Kq39rGQ2xeWPPbP4VtQI5TIzvA7nqKgdfmIcBccnPpSA56SC5jhCwqAuMcdqx5rCQNId37w++Sa6DU51yERup5wccVj3F7BZnMgLNjCrn9TTAi0vTXe4Ej7hjqT0qTVkMO5V4JbPA5PvUlnrQn2rOojVuMA9KuSosj/vXIjXBLY60AVdZlBa2lkTfuhXcMc5rOZ4rqGRI1MZOOR1+lalzHFc8jbIi4GM8inRWFsvMasGIzuODQBh2dgWuQHJc5x9a7GLS4p4FXIDqMA+lZCW/lSmRdx56elakMshCjJI/nQByHirSL2KJhZxr5Kfect96uOuNNuvsQkuRFcIoOY2xlfoetezXke+Ab0Xnk5ritetyLO7MaFto3UAeMarZwkERxgJk4wcmsX+y1UqykKPTHX611d80ryB1VFP8AGu3pVeexlun8qMEE9VUDH/6qQzmrayjtrmPzGy+Rtx39q3DbtI5WbAXsoHH/ANetew8PJaYuL5gZlGVQdR7mug0PSklC3c6KUQ/ICMUCMTS/DEar500eO4jI/U1rmw3Mu5cjoBjAFdNBGCSxRsn8aPsxYsxXnPX0pgY66fFbxjI3cZ5H54qje2wEZYDhvbpXVCBmjB2gjkBjxVS9sxtQnHIzzQBwl5pzHcQDxzWBfadvxuIz+tegXNqCHwpPqemKyp7PjCgH6CgDzW+0kqGIUHjtwSa5y6tfLmZSpBPOAOleo6jZKqliVXA/H8q5DWLULKGCHJ7npSGck0WGINRFO1ak0JLfKOnYVTki25z+tICmRwfWipHxjj9DRQAz604AZ44pPyp3qB1oAAD0wT/KpETcadHHk1YjjyC3AxwKAGJGQOBg1dtYMHJY4zgii3iYDeCcDv7+1atjamQp8j4DYoAW2tWa5RImVPl3EZzmumtLFJIwroPMGCSBz6flT9OsI1kDbRuxjIP511Oj6azvhhlGGRt9PSmBBpNlsKKEzkgZxXUxaZ5aSPtHBO7d1J7VraToykocEei+laniDTZI7VUt1J3nc3cmmI82l08KTsXAB5GBV+zs9g2suSuOldFZ6DcSThjFti7k1ujSIYx8uOOpHNAHIrpjyshUNsBNXToJmtXiB2h/mUn+Fsd66SCzjV8LHx7jt61qwWykqPKzGevNAHm1tYRyIYb1fOVcgq3Wmz+H7GCIyW2WbGQmc7R6V6Fr+lxwhbmNQQ33gnr71yslqXm/dblx8zcGgCPwfBJHOH2Bc8gdK9Ms5g8ajgED0rl9Ks9ib9oV14yBXR2sbSbARtPYjoTQBrRSg4BPIHbtVS+YmCRi4wBgDvVo6dMWyh3KffkUS2zmJlMbltvccUgOI1FgrYTBl6DvtrFlsWKl2JZicktzmuplWaOQnZ7DC4qo90VYqTjPqKYGP9kdgPLQ7jjGO9XNTjuIkjiDuwPGMcZrU0yRmu8OwCgE5AxinazdJDLGokyccgDODQByzw3ME3mQOyN7ZwT71o2dxJIiZUpKp6YOGqZrp5OFZs98Gk8q5KblG0D1FAGpZyEyLlQefmAPXNbK2v2cgqvyHkHrxWNp5uMosqrJtPBxzXWSWszovlhtpHftSAybzDLtDDJOa5/UYwIZ1xkEYIrqbuxESCRiN4zgCsTUl+TBAww6e1MDzl9G025kk88SwnPBjb+dSw6db2cfl2YHqXP3s1o3du5n+Q8g5YjqBUsNm0mxMd8gqODQBzS6dNdXwUK7Akbmx0H1rrorIRqqKFQdAo4wa6HS9LW3hOY/mPzMR1q6bRSxfYrHHSgDlzZ7SGx69B0NV57fknlcjAxzXUG2R3JU8k4OTVaewPTAwOlAGTFa4jAUnGc/Wob2zZ40wvIBPT9K2LaEggbeR61eurcFU4zxn04oA4K5tB5bMfrwKy7izCnzGyrFRkdvWu1u7dkBI/QdKw9RhDR/OdpNAHC6jbgAnGck9q5XWIFKAADr+dd3rFuwOVHH8q4zWI3CEknr3pMDhb8osjYx16Z6VkzsGJ/zxWtqFufNOf4snIwazZI9uepwKQylJkKeo+nFFSsuQc56UUAQflzUiJu9fSmAe9WYcA8igC1b24KFiD9BVqG28wbVGQG6jmpLWMTRgAEntW7pGnrFGSUO48ncaAIbLTlHzuhKk8KegresrZ2dhGuQBzxzUlpbvNLtCkDHUdBXU6NYRx8hN0nQlu1MCvp2nHzAG+WM8Y25Oa7fSbDysJCMjGdxGSKrWFoqHPJY9xXU6fAC3GRx0piL2l22HQsc4FdNDFFImXUNmsuwi2oCOCT6VpIwCjqAP50gK17ZSN9w/L14GKrx2Bx8wJxWosu4kE/LQv3SDk5NAGatusbDchJHY1ZRCUxkkdcAYqfaMkk5HqalRCMFSMigCEQpcQSWswADjge9c6ulRwyMkiEbTnHIrqj8rDgH0+lS6haC4QuozKB0/vCgDBtBDEME/KDnA6fjV6B4vNBjyvb5Tx+VUQPJyoA680quNytxtz196AOqtHJxuyAOzDA/OtAgHrzWbpySMi7/ALuOAa0VjAAGOlIZRu7KBudoDfSsG/0yF5Q0kakfTrXUzJ1I9KoyxPtLE8+lMDEg02BJ0lxjGRj1GKbPpFvI6ylgOMYIzmtK5YKqgYyvJquZSvHYnoRyKBFVdNhHAjG3vjirlvpcBPK8H1H9afbsZuFfnnAbvWlbROBg5PuaAI7bSrZGV8fMOcZzVy4k8sYUHOKfEjDhqcyBs5GSOmaQzntRZmckAlfQetZNzbxMMzF947L2rpdUhVY29T2rnZQ46gg5496YjKuNPhZ1YO6ZGMBPvYq/pGmxxMHUYboCR/SpYIpXZCGJXdwDXQpbeWgLHntigDPeMRkDPXv0FIyAfd71fMeeOcfTNQPGAOckdeO9AFVUyQWwR6gU9bRXIGOM96nRcDKirHQbgDzQBRlsIk5X05OaiubZfLHsK0SNwJHINQScgqRxQBz13Cu1j0z3xWHf26OrAjk/jXU3qHJ65H8qwrxMKTg5zwaYHE6zZ74zjqBXCa5alVIwcd8969Uvo8RMT6fkK4nXkUqT1OKAPMb+yJAIXBHPHFYVzbALuyMH8xXd3aAgnBOPXisK5swVPyq3XipGct5WI2IXIweaK27iyb7O5VT0PBNFAHIqvSrUS5IHaool444rQsoXkYAAY9T2oA1NFjUyqr8jPArutMt12ZbIGPrWDoVgiyghMkdz612elWoEYAUcnuM5poC7Z2UZCuBtI649a19NtzkjBGD1FR2oK4WQ8etaenDLgkDrwegpiNKwhB6KcjjNb9gmH7EduKzbUhR1xxWzaENyODjigDXiX5RntUpPBHJA6c9famQ/MmVIx396m2kgHHToKQERJA989hVpWyqkoOlNRAp+YZqYKdoOMmgBVVTzkj6mpAoA6jj0pmcYKqSR2Henb+MMMMeSPT8aAHqucZVDk8ZqzAeTjO5em45qOBiThwVHTPrVy3VCRu5PUUDMbVdPyzuoz3wOgqjZRAybHyPeurdRkt054qCWxtpTyCjdSV4z+FAh1pIAuAvzeo6VbUg/WqsdoscYCtuA6Gp4uvPX2pDJeo+tVbyMmIKo49PWrW35wdx6Y29vr9aUgcZFAGBPBwCc5zwexpLmEGcooHatyaJWGKqi1BJ5I/WmIzYoW8whBjBAz61swLgYIFPihCcgc1Jj060hh2pp4p2OKjPU4oAr3ZQod2QexrDmgO/AGeeucmt68gadAFZQM85pkNpHHjPzH1oAq2lptwT1PJJFXDtJx+FPlb5CB0A79KrqxHUGgBsoG4ckA1E6j+7n61M+cAnOOlQycgnoTTAiyAx5xntUrYUe9QkHbgkZFSNwvbI4FADASGwR061DIMngfpUx+bIAyKZtwvGRQIz7sDH16Vh3qkk8c/yroLsAr05J4rHvF5zgdevtQBzV+MROOoPH0riNbTcMgd8AYrv9UQGPk9R0rjNXjAUr6UwOHvYDyVBx+dZU0BVgCK6i6jJJCAY6gmsya2wzE5JA6UgOW1GYhHQLjKnn1oq5qlmHDELuJBHWikM4VYGLAYI9K6DRYWD5HQ8Y9aSG044DYx6d62tPhwVKjAxz25oA2dPjYlCBgd/Sun01Rjpzng1hWIZlOVGB6VvWGQRtw3YDNUI24E5XGN3TpWnbQlWViSRis20528Y/Gt22DSIAO3OM0AXoEDDg8CtGBWUL79P8KzYCVIGCQK2bKMZz3x9aANO0bagHPuauxnHAHHWqkSgEH3qzgL8wJOPWkBMcckZ59aehYYBHJ7mmkfKOaliGAN3T3oAQkYyfTkioHYkcqSPX0qW6kKjCAH+lQOhdVZn2jPr1oAsQMBgA59v61pWoON7ZJ7VjQMNxVclu9XLa6LEp6H8zQBenfO1QRyfXoKoyXB81snAB61Pc3EFtHmZ8ytztXmsHUtTk2boIAFA+YHk0Ablvdh8AHBzxnjNaUeFUFgATXAWuryySANChUnAGTwa6i1vlmVd7bSDg7jRYDcWnZzUSFTGpU7h2NODZ6H3pDH/Sm4HcClFKeaAGKSemOKcaaODxwKCeOT9aABjwRUHmZboOOKbe3H2eMHPJPX0rEn1dIiQSXYdwBjH1oA6AOGU5xjpz604DPWuftNTLyhhECRgZJ6CteG+ifGcjPftQBLKCtQN2x65NXGIKZGCpqFo1b5lwT70AVmXoP5U1lA5z171Z8oZOAQfrRsHH60wKfl984X36VHIwJ2g9OatSDkjHHTFV3G3vyKAGqDnPoKbISGGKeDgjHTtxTW5GPwxmgChckdOMGsq6OFOMHsfetSc4BOMjuKxbzJBI6+1AjE1RhgnblsdcVyGrLklSe9dhqA3KScFh+hrj9X35IXKDrzTAxriPaQSdxzjpgVnXIVmOAOvUcAVqGMyBsnvyCM1nTRsGbIG3t6igDDmhJRz3HJPairl5GADuDZ5AH944opDOdhg2N8pJBHQmrUEZVhgVKkSng56Z5HWrEER3rkbjnoDQBpWAwoLfeGASRW3aptYkYPY8VkWRwcqo3A/XNb1opwGkDMOvHemI19Oj34IGXHtmugto/mzkk/yrM0xQq56c9B0rTil+bPQk0AaCxKRuzkdee9XrR8DAGPaqEL7u3vk1ftUOQOncYoA1IiSMAkD6VdjTkD0qnbp93jnHWr8WFyeppATRjg5FI20N9aduwMEdaif5vudemQKAIm+YgR/jgVKIQwbzTlQCS3pTogu4BiM9jjmp5NqRyseBtOfrQBgzSuR5aHameSO9WLS7WBB5Yy/949BWLPNOZCCwC59ODWjpyNMD5CE9mPpQAy7leWUpnIbndnNVeZ8AdFHHPWtSWCBOJJYw3cjkn8qpTXNpBgYnfHooAFAAqYQcDI4Bx09quQA5UAZyenpVOHUoJAypayHDdNwz9a0Le5Qxh3jaEf7Y5oA3LGKONiwyAOcE9DWghXAweMcViwSfvGDMCv6H3q1Pc7YVUMQ3tSAvu4U8sAO9OR1b7pBrDkuEwY85PXB71NZSiNwXwCaBmq5G07jiql1KI0LZbjqRUlxMAvJAqnIwmiZcnoSDQBkajcGWQB3JVegJ6/WstpNzfOAU7Yqa9ms48iWZEPIxycGorU2c7EJexZHrkY/SmI0LSDchKkgkdKswBhJtz9eKlsbXcm2FkkH+y9XvIKphVKEdgMDFAENrM8EhXJZT1GK0opFcfL09KzDGzcDK4Pc1dt4zGeOh/SgZbJ4qJ+2OP61J1NNekBC2DmqzR84I49xVsjFRvyOfpQBWbjr+lRSHC5PerDqAODnFV5CSp9qYGZdMOTzWXNt5LN9RWpd459qxrvgnH3vXNAjF1Fwh+6SOnAzkVzl3EGUZYsTn8PSukvRsGZAT14FYMjBw7hSvYj196YGHcJyuQQ2fXP51l3RMajaSOfxJrpLqMMA45Lnoeax9QhDAOV+dT0A6UAYl2r8YAVccnuaKs3SPLhhwCCM+9FIColqQMhfl20kMOACyNjOMg1u21srRJwWbAJz9KWW2EZyVww6D098UwKdnFDGQzgjsAR1NblhtdwQSCPu44ArOgt1MnzP7/StTS4y8uQmV9MdaAN+CI+UwVgM9far8Fr5SqBnd3zzimWtsQFOPc5NasUR2jpjHcUAJbRD5T6+1aVvGcr61XiCgHAIFXbcYIJFAFyBSOTirMecZz+FRREcYBqxGM0gEJzwacqnI/u47024uLazhMl1KkaerGsWTxppqSlIoZ5MdGwAKAOjSEDhR+NJKqPERKQp+vNc+PEkN02PMMS9x6VcYlol8tsgDPB60AV5hawSqEjWSR87RIcBsDJwO+BVeS5uJk27ysXTy0G1fyFeU/H/UHhuvC8FrcTW93E092ksLbXjICoCpHI7+x7+lbXwy8dDxPFJY6lBIms2yBpJ4oj9nnHrkcRuRyUOB3XPQAHd4CjGOvYd6bLboyFpANxGVXP8AOoJb4wgiNUTg8nOaz31FjNhn6+nApgTySNG+N+xCc/LxV62vI5mwQ/Tr1rBnkFyDGz4Ocgg1FZG580Jktg4+v1FAHpGneTLHtXlsYAY4xSXe0cEbV6ZHequiQRnThJcSEOn8APQdsk1T1y53RZhk57AH+VIBJpQWILEbOcAZOBUkUhDgBi3ORxya5GW9nidj5hVh1796jgu5mlG+YtyOM9fenYD0hJC8UbYzzzyOB6msfUr6NAyRSbwQcsnf/wCtVjTgZ4njV+SAAc9+9YmqJHZOwEwds5Hp6UgMqe4lnQxFRs6gMoNWdJhjeRg6mE469ifTFUrqQk7kxn9MVLb3JUqVPTqKYHTWcDLINuUBHDDvXQ28k4UjzN2Om4Zrl9M1PewDruAHPaultJUkRSrY9j2pAWROrHEiDPqtTptIyrAiqcmM5VuBT4QSQSRgc0DLnQc1nx6vp8utz6PFeRSapbwi4mtlbLRIxwpb0J9OuOfSuI+N3ijxL4Y8JyT+F9LllLIxuNUyjJYIOrbCcs2OhxtHU56V4l+zJrUn/C37uK4na4n1Oxn8+SRy0jyKyybmPcnnk/hSA+sSO1Mx6d6cHVzhWGfTvQwIoArSA5PFU5c5PvV+X3qlPgNx2pgZd4pxgEfSsTUpTEhHVuw61vXXCE9+1cxe7izEnPtmmIx7mQTLiXcN3XAqv9mMcf7olkxg7s9a09gcnOCh6g0ycEHao3DGNuP1oAxriNl+YgkDgisa9iDOQPlPuOtdNMhiU793P3vcVlzKsu4YXAPDHtQBzEsRDMedpyB/9aitmZQS3ygn1xRQA+K3VYo9pJwq9PoKleEOOFGccc8/WlsJvPgiC5OY1P1GKvJCFwSnHfOeaAKEdkqMTIDtI5IFaFpDjaf4RyFqUKSfnxgDOM4xUlqRk4xu6/jQBqacA3L8qT39a1olOMqMj1FYcDYPyc9Mitm0nC4DEkntQBZjQnBboOoIq3EmG4AB7UwLgb1zz+lPjyWz6CkBejzjiqeu6rFpFiZpCDIRiNM9TV2IdM8CvIvGGpSanrUx8w+ShKRr6Ad6AHalq9zfXDTXMhcn7oHRfoKr27eY5wee/tWaXK4AYk1NZy9ckA9qYHRoQsQC8CtLTdRktyqsxZCclc9BXPWsmQpLYAq35xKgL94dcUATeJvDejeLbg3d5D510tq1rBI0pUW5Y53BR/FuwcnPSuS+BGpzwrrXhnUSRc28jXSRnjDA+XMAOpwwVvYMK6+xyjltxy3X0Nef+OJV8E/FDRvFAbbp9+4Nz2GcCOZffKMr49VJ60gPTL4SyyFYzhRWVOZCSP4vXtXX3UESFl3bwTwwHbtWNdKkYwFFMCnGmwKS3J/h962dM2BXcgMyDNYO4SbVQsDnH1ro9KhSKHMjK3+ye/vQBM+sMIJIY0ZmblpB6VwevajeQXYkWV0OMqR0rsdSuRFbTRxYVm7gVx2oBpxhlJIHGfX1oAl0zUZ76Ly7xNrE43qMZq7EJrWYjOVODzyfzrNtYktR5jMRkZ2A96nXVVlYDyH3A46/pQB22gakY5HD4B9zz0rO1SRJoVBPzo5YHvk9qoWdzCs6RzLtlceuc1bv7FyoZMnzOQc96AKPmMmVY8cnI7VLb7ZBlOnXI7U02ziFt43N0GO5qeytXBG04HfPIoAtWm8Ou3dkdun4V0WnXDFApyDisqCIg8LwPXitm1XZECMbRx1oAsNeMDgjHb3NXba9iRN0nTHPrWRPPHGpPVsY4rFkmea6UsevQHoKQHFftP8AjNo/CFt4esQftGqy73RTlmhjIO3H+05VcfXrW54W0K18PaHoFgbW2e90iH93cmJd8czD96yv1GSSDg8jrXmp0698XftBPPqthd22maWvmRLcQsivFBjyyCeCGlfdxmvVZZQHyWy2eT70IDSn1Gc/emNNsPFFxZToty5lgY8qxyR9Kwp7lsEjoPU9axNRunZiFK49TTA9utbuC9t0mgcOjDjmoZkO4nPFeY+C9cewvUikfMErBWB7Hsa9PdSSDk9M0gKl7BvjwDgiufntACxZtwPTiurccYx16VSuLYPjsPpQBzSW2SpC5weoHIp13AiDexUsP4cYrWl2QKUQ/N0LYrC1GTIKkEnryaYGXdtuRmU/MOcZ61jXETEnCnYecZ5FX5GUSZHIB6dqhuW38x8P2GSP/wBVAGQwAOMcjgHNFW7u3kniDRyNDMrAuVA+cDqMEdD045ooAzNFkxDA3GTGmPpgfrXVRgSxh1OBjNcppVufs1uScDy0xnqflFdDaT7FEeT/ALXPA+lABMC3zEc5z1HNQ7wZMNwc81O4DMwOCD0wMGqjJs5bBAPC460Aa1tIuAqnJ6nPGatrJ2Z8HsKy7VPNJzwMfeORmtDyXjHz8+hz0oA39LvPMIjkOR0DVppFtbIPHuOtctbZbLqeen0rp9NnE8QVj+8UcigCxOxjs5pB1CGvEtTx57Dn1r2+4Tfayr/eGK8S8SRmC7dehDEdOlAGe74BPGR68U2O42sgDcZ9etUZpTjGe9RxS/vQDz34oA7C2fIzkfnV6BBkgj3JFc5aXAZvvBQOpIxWvbanaoQGYFiemec0AbtuiomWPIHJNammNBKY3lghlkhYtC7oGMbYxuUnocEjI7Vhi7inQ7cEDnPvU+k3G2456Y6UAal5dnnJ5J7GsK6vgDlmwpPXPT8KtapOEc9wOwHQVyep3Aab7hwO470AbAuFnuw1oR5fUAnmtqwu8TeQSVZuCx6E1wlteFD+6B3cds11mmMzxrI3OOOeM+1AG/qdr5O1gVfcucgZzXPENJPgplQPvEdPYVu6lOy2MKpjCrjJP6VnWsiSKQVZT1FAFCW2JMjKoKg88feqWwMRfEiIrZBXbwfpST3EVuZMM/HQY61W88TXETr8oPUeooA200sTE3S85OT7VtQ3USIluY1ZQNvP8VFpMx0s+WwyrAY7YrF1K9FvOAhQMeS2P5UAaq26EtJGCoHQP1/CoRKY5gq59cY5rFgv5JZAzMRz8uWyaklvWeQAlTg8kHrQBvveKwwQc9NorQW6DWRQYJz1yK5BbrBJOOefpVz7YVtQwxlv50AaE0pd9ucrT0RRjPJrNikYxgk4JwcEj9auI+Y1JPJoAtzSbowuSVHTPasa9X5gRkA9frV2SQKTg96zLuRiuBlvf0oAy7o7ZGHGD0zWDqUpAUA4Gf8A9da99Pzk8e4rF1LEsfA5PTigC3pUgYglu4OQK9w0ib7VpFnP3aMZ+o4rw3R4/mQAYwM4Fe4+HU2aBYLg8R5/WkwLRU//AFqpXswhU4OT35q1ezC3iLcZ7c1zl5K0jHB5z3oAp39z8hI5xWFPKSpycpjrWneDnnO3tzjNYl2xSQqerckZpgV2PbcpB5I6H/69REgnaGAU9Pf602aQ5LPhQecngVWMxWQlHJzxknOaAJ+HU5wSRzg0VHEcb+vTNFAFbQ4g1taszMcQRnJ7/KK1oofmZhnB6duKrWSmPT9PcHKvaREH/gAq7ZqwYZ3Y9/60ALgsMHGV6f8A66pyoxfcCXGcfLzW/b2LSOSTwfripZbHy1OwBmzx7flQBQsI2DRFTHuJyQRitm3uEL48sgHseR+VU47SSFwzL16961kKcb4R6bguCKAIXgjkIaMYcdVpbIva3IZic9OfSm+RskLWsm0sfuk5pVMjAb2/eDt6UAdGGWS3LZ4K5zXmnivRJ7/WEhtfLV58ld5wvA55Aru9GlLeZA/UDgGobuAG9t5MAGNj+AIIpAeXP8O9bYfLLpw+szf/ABFEHw411XJefTPwmf8A+Ir1hetSICSABknoKAPJZ/hx4gcKIrrSgo5O6aTr/wB8VEnwx8SeZu+3aR+Msh/9kr1aHUrGXS31GK9tn05Fd3ullBiVUJDkt0wu1s+mDVk3EKxRStNH5UpQRvuG19+NmD3zkY9c0Aed6b4E1y1YF73Tm+jv/wDE1or4Q1gSApeWKLnOAz/4V2ZvLVbSS5a4jFvG7RvLu4Vg+wr9Qw249eKcLy1NpBdLcRG3n8sRShsrIZCAgU9yxIA9c0AcjceENSm/5fbReMfxH+lZdx8OdUmdSupWCqDkgo5NejwXEM1sLmKWNrcoX83dhdozls9hweaq2mtabdTwww3YMkxAh3I6LMSM4RmADnH90mgDh7X4b3cbEyajZsDxhUfpW/beFby3tzGl3a5POSjYz61utq1gmorYvcAXLMI8bGKByAVjZ8bFcgghCQxByBUlvqVrcXRt4GmklErQnbby7A6nDAvt28EEdetAHNr4V1FsibUrRv8Adib/ABqc+Fpwo2XsAf18s1sR63pr7CLkpG7GNZZYZI4mYNtIEjKEPIxwa0J5Y7aKaW5dIYoVZ5XkO1UUDJJJ6ADmgDjbjwRLcZL6hDu9fKbj9aji8C3Ebf8AIVhKf3fIP+NdbpupWupGRbUzCWIgPFPbyQSKCSFbZIqttODhsYODinabf2uqQvNp8wmiSaS3YhWXDo21hggHg9+h6gkc0AYth4amtIWja+V1JyMRkEfrVW/8Gvdyqw1FIwDwvkk/1raXXtPbLLJcm3Gc3Qs5vs3B5PnbdmP9rOPelude0+3vLi2ka7eW1CNM0NlPNHEHGVLSIhUDHJ54HJwKLgc8ngeRQB/aikDt5J/xp3/CEN21NB9IT/jXT6jqVlptkl3eXAW2d0RJEUyBi/3SNoPHfPQAEkgAmrE00cV5HayMVuJFdkXGchNobnpxuX86AOSj8FFD82oqw9PJ/wDr1cm8MmSFIze4285EfX9a2pb+1iuHheQiVHgjYbTw0zFY+fcgj271I88a3SW5Y+dIjSKuONqkA8/VhQBixeHUjXH2jd77P/r059BU/cuWX/gP/wBetGy1C2vrq+trV2eaylEEylGXDHP3SR8wyrDIyMqw6g1VXWbaZ5PsdvqF7DHI0T3FrbGSJWX7wDZy+D8p8sNggjqCAAVG8PA5zeNg/wDTP/69V38LowIa9fn0jH+NdBBPFc28c9tIssMg3I69GFRyXUSXsdo7FZZIZJwTwoSMoGJbtjzF/U9qAOYfwVC/3tQm/wC/Q/xqv/wgVrkn+0bjpjAhXH863Rr0LRidbDVW08qXF+LYeTtz94Lu80qeoYR7cc5xzT9T1qz0+3uZpfOljgtEvSbePzd8TuUUpg/MSRwB1GMZzQBjWvg21tvu3s7fWNR/WuxhvzDbxxJEu1FCj5vSs24vYIorWUMZY7qWOGFogGDNIcKeo4Pr2rLj8QRt9q+0aXq9otqVSQzJA2ZG27IlEcrFnbeuMDHqRQBuXczXDZb5fYc1Qe2U5O85PtTdOvzeidZbK7sbqBgsttdeWXXIypDRsyMCAeQx7g4NWWxQBk39u4CiLe5IzkAcVj31rIrecwX5hgoOprp2VDMpfd0OAO9U9VcRx+Xax7CTy55OaYHG3qsG3EOFI/iXoKzI4zkcHOTniugKyySky5bB6EmnvZBudueM7dvSgDDbKKN2QTyO9FW7mMxRtlOgOOeaKAJ/B9r9s8NaWWbn7LF+PyCujtNPt7QBsb2/vEV5d4P8dW82haZb24Mc0NvFE6secqoHHtxXdWupSXUYYsULY7UAdC11GiZUc/lUQ1CJ32mM59qqw+WxGRkjsxzVyIKpzge2BQA/7VCCAysP1q1C8Eo4bBPrUB+cYIyp9aEiiI+6F7DbxSAg1C3eBhJF0J6A1FbXDyyZIxgcE1YmWSMYiG9e61lO7LIWxjn05HtTA6G02w3aS5I8zgg1avUK3GccN3rDspRKBGT15X2NdBc/NCjnuB+dICAdeRms7xHdT22kulkkr312y2lssRUPvfgsu4gDau5uSPu1oLS7VLo7IpdCSrEcrkYOPTg4oA5a9lFlaeItPj0+fT7K40uW5tFlMe3fHFslVdjMB8oifnrlsdDV/WHj02KztGKx2lxfWrWmTgK5lQtCPryyj03D+EVtvFFKAJYo5MAgb1BxkYPX1BIPqDUjKjgB0VwCGAZQQCOQR7jsaAOZ0eWaPUTNqi266YupXkVgyuT5dybqUb5cjALZ2J2Ug5OXGNPSLJ08Wtau6HTrN11C2gxys0zOrAjH3VO9lHYyHptWtQpG0bRtHGY3zuQqCrZOTkd8nn681KAA5cAbzwW7nHTmgDl7WSJvBmil2jmtYJYpbyJSHPkLI24lRyQrbGYY5VSO9a/iW9t7jw/eW5uo7uW7iMdvHDMHeaYjMewA5yGwwIxjGcjGavW9ta285nt7W1hmPWWKFEc55PzAZNLBbW1vK8tvaWsMrAhpIoURmB6gkAE5oAxLm9+xyzvY31tdOdRhiv8ATpkALzsY1ZocfMrcrKNwZTjgoORb8NvP9tuEXVbLyBqt0v2XyAZT+/bjf5nXPP3P8a1fLh89ZzDCZ1XasxjUyKvoGxkDk8ZpBa2v2jz/ALJafaM7vO8hPMz67sZz75oAxtF1DToPCMa39zbm3/fxSwlwxkzM48vZ1YnOAuOSRVkotv4MSLXfP2R2CpeYYtKgCjdlhyWUdWHdSea044LeOYzxW1tHcHOZUhRXOevzAZ5+tSq21gVJBHIIPSgDl73Vb+FtSs7S9ttVuXghjsbpNiSLLKWUJKyjYxGGlDAKMZyo4LQX8F/D9p06CwitIdSsfskCx3glLzQpwmdo2l4Q6bicfIO5rrUWOJNkUcUaAltsaBRk9Tgd/elyOhAPOeaAM86/pC2YuRe28MGNgib5ZFP3fK8r727+HZjOeMVjyXN/Z3/i250lI45omsZCskJZo4/I+cqgIy6rkhc4O3FdSD+983C+bjHmbRux/vdaXdjGOMc5FAHM28H+k2Wnadbx6jpGl6etuXmuPK81pUCg8IcnygemMeYePSCx1Nba+0SLWZ4be6soL2yuHkkARmXyChDHAO6Pa34n0NdZnt0HoKNxA4NAHLatcQxajf3TzItqJ9Fk84n5Nv2lvmz0xjnNWNT1eGK7t9S0+SO98uzukiELBw8u6IImRxksVH410QdgQQSD2xSGR853HPrmgDlUtdQ0n+yvtAtIolhOmXVxBM8jFpfuS4KjgTd+o3+man03WtM0vSrCw1K6g027tII7Z7Wd9rhkAXKDq6sRlWXO7d68V0OSORkdqcs06rtSSRV9ASBQBVjuGltRcC3uVLKZBC8e2Y98bc8MewODyM4OQOR1G4t/FwePQpUulfSLmOTf8qI7yW7LbzA8oziORWUjIAbPv2ZB9D+VLI8sgHmNI2Om4k4oAxv+Eq0r7QrNcTJelg32Awv9sDZ+55QG4n3GV75281y02nXOn6LdWs6nzhpER2JhhETfO4iUqMEIGCjHZc+9egmSfy9m+TZ/dycY+lQ7mXoSOcjtQBz/AIgV7PVdOhijd7K51i3mQopIgk8wtIG9EYZcHoG3D+IZr6h5KxeJft1jc3lm09v5kdureZs8tA0ibfmJT73yfN8vHOK6XcRnaSMjBwe1NJbjrx09qAMPQbmWe61JI726v9LjaP7NcXKncHKnzEVyAZUHyneckElSzY41WOakdnc5YsT6mom4oAltUD7z6YqG8txJnt9KY0kiqVj4z1qpLDI3LSDHsKAImszwAMjvk1L5KAbW4JGOvWqv2Yq5/fNk0x45QP8AWA0wIdS0pZI2ZAMjn60U95pIgSxwMd+lFAHy54bIgihlVv3m0MBjpXp3h7WHcoA7D1AryDTZv9GhA5woHJrq9JuHjmUozA/zpIZ7hpd8zqCZMk+ordgmzjOMY65rzvw1fGUDaxI9fQ129k+7B6gdc0xG2p4+lSEjHI+lVFlK8dqnidTjuKQDmbr7VXvLVbiJ3UYlHTH8VWjjbkUkJPmBQuBQBgQyvbyjfng56YrsLGUXem8feXtWDe7EnBePcD1PpWxooUNmNyUYdKYFaSVwDh9vvgHFeeeJ/EfibSbx44r9AnVGNtEeP++a9F1OMpOwHGec1y2tWUGo2csFwoZwDtY4yPSgDy+4+J3i5Jti6pCAP+nKE/8AstQt8UfGKtzq0OP+vKHj/wAdrF1ixeymaKaP5wcfX6Vg7NlxgnjsKQzuv+Fn+MvLU/2uu7viyh/+Jq9afEXxe5HmauGB7i1iA/8AQa4+0jRsLgZ9quLEeoXAzkAUAdrF478UnltWYjv/AKPEMf8AjtW4/GviVhn+1WI9RDH/APE1yEJwo3HvzirYcKvB5Ppx+dAjtLbxhrjjDai5x1O1OP0qte/EW+tQyC/kaUeqj/CuF1m5ljSONXKK3LEZrmNU1NmnClT5fHfJNAHol38TfEbZNvqUqD/ZVf8ACs8/EzxTFta4167APYBcfyrg7e7Dq+Cdq9B1NaX2BrmHMke9hz7D8aBnVN8R/FcyM8XiG+UDjClf8Kgj+JHi4QsZfEOoB1OTuZeRn6VzlvYssgbzItu3G3eByPxpGRovNZmTCqCRuB4oA9a8L+OtT1GEC51G68/OOJOvv9a35df1QRA/b7lfffzXi3hp2NyjQnA3DvxXqFwQIozyxxnHWmI0v+Eg1Qn/AJCd57DzKkOu6ntB/tG72kcYkNc8ZThccE9RThcbVADdT1xQBtvrupf9BO6+hkqs+vaqSCNSvAP+uhrOVxnnHA/CoJ5z93gY6jNAE154h1cD5NYvVOOR5xzXL6j4n8SvLtg1/VY1H924NT6lJ5zBEIwPTjP0rFnbYeOD60AW7PxT4kST99rmqSp6vcE1qad4g1p7kCXVr9lP964Y4rmlBwA+eDnNbOgQ/abrGzPPU8d6QHoGkXN7MwL3l244+9Kxr0nQbZ0td85LO3945/nXMeEtHzIssoxGnTPeu9hHzKMYUc0wM7WZBCihVG4DqOOa5eeeR5STKc/3Qa2taMktywxhV4B9axIYk+0lQAXJ6nsKQEttbzTENvcDGSSxxWhHEkQ4Zmz3JqVjsAUKAB0poGV78UAMYE9ajZcnAqQnp2/rUbnBJHWgCtIFAz3qhLOqZOQCOhzS3tzs4/melcnrV6BE5Z8HP5UwJ9a1uK1ik3SJjHPzCivMdduWldzkhdpxRRcDzfS0jNujSH5tvY445rqdKmjDqVjAI6EjNclpat9mic52beCR7102l4ZcDnHGakZ33h69Cy/N909hxmvSNKdGPru7E14/pdxtYnHTuea7Xw/qjRTEMxCHHfpVCO9kIUHggCnRXHPHA71Xt7pZABkEH8RUjeS5LL64DA8UAaEUobgAn3q1CMnoelZiHbjAzVq1n2sDzjPPNAEd+n7wZXI61e0QBQuwYx680t3CZYty8gjoaNPj8scKFxyPpQBb1hMhWwOR1rgtUlaKYuFJbocd69GvQslorEEjjp2rgtWjLl8EnB6EUIDjvEGjLrlgGGxLiPJX3ry+7s2tpnili2yR8EY6V64ZGtgBk8H1rC8S6bb63bmSHbHeoOD03exoYHFWDBWXDVqCdNuRgEnnJrk7iSW0uWR1aNkYhgwxitKwvhIB0J6Uhm/DJHuA5J5P0q/EVCYJB74rHWUcEAbgO3pTxdN0GB6CgRL4heNUyFB+XI9a87u5CZXBGFc5Fdbrdw6bHcEqRgnsDmuS1Jorj/Vkg5z6UMZLYz+WjlDhlH3e55q7Z6hJIZGffszkgnNc3H50b5QMGFXbYSSIoDuHJBIXuKQGs86lpBJINoxtVTwTQpbltxCOcjB6j8ax3EglDD74/SrkJuJGUKu5s5Lg8Y9KYHUeH5fJl7HB5/OvTEkL6chJO4r0x1rzzw3pNw0odgQrHJ9PwrvJ5RFCkYx0wKaENRwCd7EZyeakMw6bt3GeB1qoGQqC5JPal84o2Fx60AWM7n+UNgdsdqhuHUAgt068Zpv2p1BAKnI71lX1zkliAAaAI7ww88kEdx1NZTBQMqXC/XrUk0u5gCQKq3T5lWOMZ/pSAkZvnSKMZ9ye9ekfD/Q2ublZGQi3XGT6n2rlvDOjS6pcLAkRc4yzjgKPU17dYQQ2VrDbWoARAOR34oA27RUGIox8o4OK0yAkTEdf6Vn6Wu5sYHB7jpVy4bKuFPAOKBnOawzksVPzP+lUtEhJkfeOeuT1rVu4AF4BYepqGxUAyHAGTjFAh0pAJXP6VCZR1OcUt0dr8Yz61QkkAOc9OtAFhpjzkY/rVaWfI5zkeveomdyMqCT/ACqrO3lo3mMAR2B5pgZ2qXATGOTn0rkNYZZMo74XqTurc1W6QqwRjgdeetcbqlwpycfMODmgDnNaVMOxfHBxgZNFU9XkYo5Ge/eikM4zSXBs4ARnapHA9z1re09iFC85xzntXMaVIfs8aqCTzwPrXR28qpCoGQ27GB1P4UgOisiwOVxxjHfIrbtLpkIyRg81y9tJzkN8mPTFWVuSRkNyT+lMD0DStbMbeWzDkfKCetdLBqKyQLnG3vgd68dN8wXh9p/lXQaNq+4xq8hHHSmI9esJzKgwRyMZFa0MaEf0Nc14Tk2WRdz8u7jPaunR1YDaecUAXoVwMY4ohHy8KC3aqktyIonI64wOcVWsr5mmAK7gOMr3pAdLGu62K8ivO/Ec4tZGiBxI7fkK9IhxtH0rzTxtG0esyu2NhUUwMRYYWJ3nDHk+9Z17bAO5Xr14rRgO9Rg444zVe+54BJ45GKAOV1vw/ba8o2sIL5BiOVujf7J9a89a2vNL1B7S7hMNxGcMp7j1HqPcV64WAcpgF1GRnmi+t7TVrF7XVYElUfckX70ZPcHqKLAec2s4kUHvj171O8p2qR19aXVvDl9obmRA91pxPy3CjkezDtWe10DGdpBb2PekMuzlbi2dXwG7EnvXIXCAXRVRjnofWtua6Eci554wcGoLi0SaQXETZI+8Dzz6igDMdUhKqBvVx1ratLKK5hC24feR8y+ntmqE8OYiyjDAdMYwKv2MjRQLuAUHt3zSAtXOmG5ePdiMgYwB19609G0ZIMKx3AZJNQQagGAX7xx/H2rX0+cjcQPvHsKYjegAtoFQE88ZFV55nZuCRjiqt3clEzwPpVeKYtzkbuwzTAuo5DYDYB71MjCTqB9OlZvmk/MCMZ5qR7kKvQZ+maALUsnl55wDxknNZN3cgqdx5PXFRXd/gPg/NzisGO9eSfBHzZC529z2FIDRDlpAC3Hb3NdB4V8P3et3wjgi+QY3ytyqD/Guh8E+A5r1Y77WS1takZCE4eT8Owr0kT29nbrZafFHFAvChe/vQBWsrK20ezFtYgkj7znksfUmrOlzEsY5OecqapTlpfunPH50un/u7uPap4bDd6YHoOlqVti5GCaU5ELHnkk81PENtsgHTAqvMdsDZOKQzOmztIJB9M0yOPZEdpwTVZ5cytz+NTRMGiJPIz1oEZ92GLdOveqTqFbLn/gI71r3ILbuAMDrXPanciFSfXnrTAZqN8IIgNyr3rltU1guSqkkeorG8R6wWkKo3AyMVzaX6tlQTyeBngUAbF9eE9GHp1rEvG3q/wA3zjtnrQZgcK3JHFVbl8EnJyRzjikBlahkwvu+7g9v8aKj1KQLby7jldpPAzRSGcLph/cqCeMnP51t2v71lIIx9cD3rnLH/Vj6t/Otiy7/AO6KAOkiBXYFPBBwc9qSS5jjUFyACcZI6++KpW/+om+h/kar6h0j/wCuX+FMC1NqUUgyqHCggZPX8KsaLqBe7QI/GeR1rlE/1P8AwKrGj/8AH8n+9QB9XeFYQ+hW+1s5XPTitYubWJix2qvft+dZXgT/AJAFt/uVP4s/5BLf7opiMi+1z7XcCKNxhSQGzjJq3oVxK04w7kg5Irz2+/4/U/367HSPufl/SgD1K0u4tqK8qiVv4c81wHxD1WztdTWOZ/nzjB9Kn0n/AJCa/wDXQfyFcP8AF7/kZF+ooAsxajYyZdJVGOcButXkSK5XY3IYfK46qa8ml6H/AD2ruPCX8P8Au0AX761MRQdJE6/7QqtAzZYHbj1xW3q3+th/3v6ViWn+uf6H+VADkuntGZOTGeSH5yPfNYGt+G9K1MtNbuNPuuuYjmNj9K1dS+5+BrD7N9aAOI1rQNTsj/q1uIR0ltjn816j9apWV2VTyndg4OCGGCD9K9Cs/wDj7H0FY+v/AOrk/wA96QzDufLliyhALcfKcUlqgB43FSRgY6H1qE/cb/rrV2H/AFS/UUATeYVBMe1iT06fXmtPTZzxu4PWsNvvf981c0n7g+p/maAOilkD4OeDz9ajSRVyUOQODVcdE+v9aY33zQIutOuD0AXrmsy4vDI+yIO8hOAiKSTn6VJJ0T8P513fw8/4+P8AgQoA4qx8HeIdUdWeJLG1ON0tw238QvU/pXpPgrwhpHh9fNhVry9/iurgZA/3FHArS1T/AI/z9Ks2P+pH+7TA07m5klQngg9MHpVaENJ8sZ75J9Kjl/1MtXNO/wCPQ/SgBxUdVPOcZqSzT/SEJBYbhn25qEfeb6Vbt/8AXQ/UfzoA7xnAVV9Kz9VkK252qGz2qxff6xfoapt/qH+lIDnJJSo3HjnFWbC8DMyAZzwOelUdU/1J+tQaP/WmB0EzhUJI4x7V5t4rvyDLGgwQcE16XP8A6r8K8i8VdZ6EB53qV8zysh5we9UYZG84FcKO3OKS4/4/G+tZ2o/66L/fNIZ0TsSMqc5HOKieYFAeCeh5zUNl/qn+lV5/9S34fzoAj1BgLadcjIU9vais7Xf+PaT/AK4t/wCgmikB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ankylosis of the sacroiliac joint in advanced ankylosing spondylitis with complete obliteration of the joint space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_10_34991=[""].join("\n");
var outline_f34_10_34991=null;
